form10-k.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM 10-K
|
x ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE
|
SECURITIES
EXCHANGE ACT OF 1934
For
the fiscal year ended December 31, 2008
|
o TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE
|
SECURITIES
EXCHANGE ACT OF 1934
Commission
File Number 0-20540
ON
ASSIGNMENT, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
95-4023433
|
(State
or other jurisdiction of
|
|
(I.R.S.
Employer
|
incorporation
or organization)
|
|
Identification
No.)
|
26651
West Agoura Road
Calabasas, California 91302
(Address
of Principal Executive Offices)
Registrant’s
telephone number, including area code: (818)
878-7900
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.01 par value
|
|
The
NASDAQ Stock Market,
LLC
|
Securities
registered pursuant to Section 12(g) of the Act:
None
(Title of
Class)
Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in
Rule 405 of the Securities Act. Yes o No x
Indicate
by check mark if the registrant is not required to file reports pursuant to
Section 13 or Section 15(d) of the Act. Yes o No x
Indicate
by check mark whether the registrant (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements of the past 90 days. Yes x No o
Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of
Regulation S-K is not contained herein, and will not be contained, to the best
of registrant’s knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. o
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer or a smaller reporting company. See
the definitions of “large accelerated filer,” “accelerated filer” and
“smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer o
|
Accelerated
filer x
|
Non-accelerated
filer o
|
Smaller
reporting company
o
|
Indicate
by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes o No x
As of
June 30, 2008, the aggregate market value of our common stock held by
non-affiliates of the registrant was approximately $188,926,875.
As of
March 10, 2009, the registrant had outstanding 36,381,626 shares of Common
Stock, $0.01 par value.
DOCUMENTS
INCORPORATED BY REFERENCE
Portions
of the registrant’s proxy statement for the 2009 Annual Meeting of Stockholders,
to be filed within 120 days of the close of the registrant’s fiscal year 2008,
are incorporated by reference into Part III of this Annual Report on
Form 10-K.
SPECIAL
NOTE ON FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K
contains forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. Such statements are based upon current expectations, as
well as management’s beliefs and assumptions, and involve a high degree of risk
and uncertainty. Any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. Statements that
include the words “believes,” “anticipates,” “plans,” “expects,” “intends,” and
similar expressions that convey uncertainty of future events or outcomes are
forward-looking statements. Forward-looking statements include statements
regarding our anticipated financial and operating performance for future
periods. Our actual results could differ materially from those discussed or
suggested in the forward-looking statements herein. Factors that could
cause or contribute to these differences or prove our forward-looking
statements, by hindsight, to be overly optimistic or unachievable include, but
are not limited to actual demand for our services, our ability to attract,
train, and retain qualified staffing consultants, our ability to remain
competitive in obtaining and retaining temporary staffing clients, the
availability of qualified temporary nurses and other qualified contract
professionals, our ability to manage our growth efficiently and effectively,
continued performance of our information systems and the factors described in
Item 1A of this Annual Report on Form 10-K under the Section titled ”Risk
Factors.” Other factors also may contribute to the differences between our
forward-looking statements and our actual results. In addition, as a result of
these and other factors, our past financial performance should not be relied on
as an indication of future performance. All forward-looking statements in this
document are based on information available to us as of the date we file this
Annual Report on Form 10-K, and we assume no obligation to update any
forward-looking statement or the reasons why our actual results may
differ.
On
Assignment, Inc. is a diversified professional staffing firm providing
flexible and permanent staffing solutions in specialty skills including
Laboratory/Scientific, Healthcare/Nursing, Physician, Medical Financial,
Information Technology and Engineering. We provide clients in these markets with
short-term or long-term assignments of contract
professionals, contract-to-permanent placement and direct placement of
these professionals. As of December 31, 2008, our business consists of four
operating segments: Life Sciences, Healthcare, Physician and Information
Technology (IT) and Engineering.
The Life
Sciences (formerly Lab Support) segment includes our domestic and international
life science staffing businesses. Life Sciences segment revenues for 2008 were
$129.5 million and represented 20.9 percent of our total revenues. We provide
locally-based contract life science professionals to clients in the
biotechnology, pharmaceutical, food and beverage, medical device, personal care,
chemical, automotive, educational and environmental industries. Our contract
professionals include chemists, clinical research associates, clinical lab
assistants, engineers, biologists, biochemists, microbiologists, molecular
biologists, food scientists, regulatory affairs specialists, lab assistants and
other skilled scientific professionals.
The
Healthcare segment includes our Nurse Travel and Allied Healthcare (formerly
Medical Financial and Allied, or MF&A) lines of business. Healthcare segment
revenues for 2008 were $180.7 million and represented 29.2 percent of our total
revenues. We offer our healthcare clients locally-based and traveling contract
professionals, from more than ten healthcare and medical financial and allied
occupations. Our contract professionals include nurses, specialty nurses, health
information management professionals, dialysis technicians, surgical
technicians, imaging technicians, x-ray technicians, medical technologists,
phlebotomists, coders, billers, claims processors and collections
staff.
Our
Physician segment consists of VISTA Staffing Solutions, Inc. (VISTA), which we
acquired on January 3, 2007. The Physician segment revenues for 2008 were
$89.2 million and represented 14.4 percent of our total revenues. VISTA is a
leading provider of physician staffing, known as locum tenens, and permanent
physician search services based in Salt Lake City, Utah. We provide short and
long-term locum tenens services and full-service physician search and consulting
services, primarily in the United States, with some locum tenens placements in
Australia and New Zealand. We work with physicians in a wide range of
specialties, placing them in hospitals, community-based practices and federal,
state and local facilities.
Our IT
and Engineering segment consists of Oxford Global Resources, Inc. (Oxford) which
we acquired on January 31, 2007. The IT and Engineering segment revenues for
2008 were $218.7 million and represented 35.4 percent of our total revenues.
Oxford, based in Beverly, Massachusetts, delivers high-end consultants with
expertise in specialized information technology, hardware and software
engineering and mechanical, electrical, validation and telecommunications
engineering fields. We combine international reach with local depth, serving
clients through a network of Oxford International recruiting centers in the
United States and Europe, and Oxford & Associates branch offices in major
metropolitan markets across the United States.
We were
incorporated on December 30, 1985, and thereafter commenced operation of
our Lab Support line of business (now included in our Life Sciences operating
segment), our first contract staffing line of business. Utilizing our experience
and unique approach in servicing our clients and contract professionals, we
expanded our operations into other industries requiring specialty staffing. In
1994, through our acquisition of 1st Choice
Personnel, Inc. and Sklar Resource Group, Inc., we established our
Healthcare Financial Staffing service line of business (now a part of our
Healthcare operating segment). Originally named Finance Support, this service
line of business changed its name in 1997 and shifted in its business
development focus to medical billing and collections for hospitals, HMO’s and
physician groups. In 1996, we acquired Enviro Staff, and began providing
contract professionals to the environmental services industry. In 1998, we
acquired LabStaffers, Inc. to enhance our Life Sciences business. In 1999,
we expanded our Life Sciences operations into Europe. Also in 1999, we formed
our Clinical Lab Staff service line of business, and in 2001, we formed our
Diagnostic Imaging Staff service line of business. Both of these service lines
of business provide scientific and medical professionals to hospitals,
physicians’ offices, clinics, reference laboratories and managed care
organizations and are currently included as a part of our Healthcare segment. In
2002, we acquired Health Personnel Options Corporation, and established our
Nurse Travel line of business, which provides registered nurses to hospitals and
managed healthcare organizations. In 2003, we expanded our service offerings for
our Life Sciences operating segment to include clinical research and
engineering. Our clinical research line of business provides life science
professionals in medical and clinical trial research, and engineering line of
business provides contract professionals in manufacturing, packaging, research
and development and quality control positions. In 2004, we expanded our service
offerings in our Healthcare operating segment to include local nursing and
health information management, which provides health information professionals
to healthcare clients to process insurance claims and manage patient data. On
January 3, 2007, we acquired VISTA, and established our Physician operating
segment, a company that provides short and long-term physician staffing (locum
tenens) solutions to healthcare providers. VISTA was founded in 1990 and its
headquarters are located in Salt Lake City, Utah. On January 31, 2007, we
acquired Oxford, and established our IT and Engineering operating segment, a
company that provides high-end consultants with expertise in specialized
information technology, software and hardware engineering, and
mechanical, electrical, validation and telecommunications engineering fields.
Oxford was founded in 1984 and is headquartered in Beverly,
Massachusetts.
Financial
information regarding our operating segments and our domestic and international
revenues are included under “Financial Statements and Supplementary Data” in
Part II, Item 8 of this Annual Report.
Our
principal executive office is located at 26651 West Agoura Road, Calabasas,
California 91302, and our telephone number is (818) 878-7900. We have
approximately 79 branch offices in 25 states within the United States and in
five foreign countries.
Industry
and Market Dynamics
|
|
Though
the most recent U.S. employment figures indicate a significant contraction in
the job growth rates, from late 2007 through the present, the latest U.S. Bureau
of Labor Statistics estimates that total employment will grow by 15.6 million
jobs, or 10 percent, between 2006 and 2016. By comparison, there were 15.9
million new jobs created in the prior ten-year period. Employment growth will
continue to be concentrated in the service sector with healthcare and social
assistance, and professional and business services providing the strongest
employment growth.
The Staffing Industry Analysts Insight:
Staffing Industry Forecast 2009 (dated January 9, 2009), an independent
staffing industry publication, estimates that total staffing industry revenues
were $127 billion in 2008 and will be $114 billion in 2009, down from $133
billion in 2007. The biggest industry segment, contract help, is forecasted to
contract at an annual rate of 8.2 percent in 2009 with revenues of $86 billion
in 2009, while permanent placement is expected to contract by 25.4 percent.
Within the contract help segment, professional staffing is expected to contract
at an annual rate of 5.1 percent in 2009 to revenues of $52 billion. While the
current economic climate has affected the staffing industry, we believe
healthcare, scientific and IT clients will continue to outsource their labor
needs to professional staffing firms. These end users will benefit
from cost structure advantages, improved flexibility to fluctuating demand in
business and access to greater expertise. Typically, life sciences and
healthcare clients' products directly influence an individual’s health, welfare
and well being, which will also impact our customers’ decision to use our
services.
As of
December 31, 2008, our staffing service offerings were grouped under four
operating segments: Life Sciences, Healthcare, Physician and IT and
Engineering.
The Staffing Industry Analysts Insight:
Staffing Industry Forecast 2009 (dated January 9,
2009), states that the life sciences professional staffing market will contract
2.0 percent in 2009. Demand for staffing in our Life Sciences segment is driven
primarily by clients with research and development projects across a wide array
of industries. However, due to the current economic climate customers are
delaying projects and slowing work on existing projects.
Our Life
Sciences segment includes our domestic and international life science staffing
businesses. We provide locally-based, contract life science professionals to
clients in the biotechnology, pharmaceutical, food and beverage, personal care,
chemical, medical device, automotive, education and environmental industries.
Our Life Sciences segment operates from local branch offices in the United
States, United Kingdom, Netherlands, Belgium, Ireland and Canada.
The Staffing Industry Analysts Insight:
Staffing Industry Forecast 2009 (dated January 9,
2009), estimates that the healthcare staffing market will grow by 1.5 percent in
2009. Despite the forecasted contraction in the broader staffing industry,
healthcare staffing is estimated to have grown by 3.5 percent in 2008. Within
the healthcare staffing industry, allied health and locum tenens continue to be
the strongest areas with estimated 2008 revenue growth of 7.0 percent and 14.5
percent, respectively.
In prior
years, nursing employment levels were affected by cutbacks in the use of agency
workers by hospitals and medical groups and their reluctance to pay market
rates. Today, as a result of the economy, hospitals are seeing fewer admissions
and procedures and are attempting to minimize expenses, which in turn have
impacted the demand for our services. Looking forward, contract
nursing employment growth should be stimulated by various factors including a
limited supply of nurses, more favorable nurse-patient ratios and an aging
population.
The
combination of increased demand for health services and advances in life science
and medical technology is expected to create significant demand for workers with
specialized science and medical skills. Also influencing the demand for these
workers is the departure of mature professionals from the ranks of full-time
employment as they retire, reduce hours worked and pursue other career
opportunities.
Our
Healthcare segment provides locally-based and traveling contract professionals
to healthcare clients, including hospitals, integrated delivery systems, imaging
centers, clinics, physician offices, reference laboratories, universities,
managed care organizations and third-party administrators. These healthcare
clients face shortages of operations-critical staff that limit their ability to
generate revenues.
Physician
The Staffing Industry Analysts Insight:
Staffing Industry Forecast 2009 (dated January 9,
2009), states that the physician staffing market will increase 14.0 percent in
2009. This is one of the fastest growing sectors of the staffing markets. An
ongoing shortage of physicians is fueling this growth.
Our
Physician staffing business places physicians in a wide range of specialties
throughout the United States, as well as Australia and New Zealand, under the
brand VISTA. The physician staffing market requires a high degree of specialized
knowledge about credentialing and qualifications, as well as unique insurance
requirements that make it more difficult to replicate than certain other types
of staffing markets. Our Physician segment operates out of one primary
recruitment center with several branch offices.
IT
and Engineering
The Staffing Industry Analysts Insight:
Staffing Industry Forecast 2009 (dated January 9,
2009), estimates that the IT staffing market will contract 8.0 percent in 2009
to $18.9 billion. Demand in our IT and engineering business segment is driven by
a shortage of highly skilled professionals with specific
expertise. However, due to the lack of capital in this economic
environment, customers are postponing or canceling projects and extending
completion dates.
Our IT
and Engineering segment places only very highly qualified professionals across a
wide range of disciplines. The segment operates out of several large sales and
recruitment centers including one in Cork, Ireland under the brand Oxford
International, and a number of domestic branch offices under the brand Oxford
& Associates. Placements are highly diversified in that we average less than
two contract placements per client.
Our
strategy is to serve the needs of our targeted industries by effectively
understanding and matching client staffing needs with qualified contract
professionals. In contrast to the mass market approach generally used for
contract office/clerical and light industrial personnel, we believe effective
assignments of contract healthcare, life science, physician and IT and
engineering professionals require the people involved in making assignments to
have significant knowledge of the client’s industry and the ability to assess
the specific needs of the client as well as the contract professionals’
qualifications. We believe that face-to-face selling is significantly more
effective than the telephonic solicitation of clients, a tactic favored by many
of our competitors. We believe our strategy of using industry professionals to
develop personal relationships provides us with a competitive advantage in our
industry which is recognized by our clients.
Our
corporate offices are organized to perform many functions that allow staffing
consultants and recruiters to focus more effectively on business development and
the assignment of contract professionals. These functions include the recruiting
and hiring of staffing consultants, recruiters and support staff, as well as
ongoing training, coaching and administrative support. Our corporate offices
also select, open and maintain branch offices.
We have
developed a tailored approach to the assignment-making process that utilizes
staffing consultants. Unlike traditional approaches that tend to be focused on
telephonic solicitation, our Life Sciences staffing consultants are experienced
professionals who work in our branch office network in the United States, United
Kingdom, Netherlands, Belgium, Ireland and Canada to enable face-to-face
meetings with clients and contract professionals. At December 31, 2008, we
had 47 Life Sciences segment branch offices. Most of our staffing consultants
are either focused on sales and business development or on fulfillment. Sales
staffing
consultants meet with clients’ managers to understand client needs, formulate
position descriptions and assess workplace environments. Fulfillment staffing
consultants meet with candidates to assess their qualifications and interests
and place these contract professionals on quality assignments with
clients.
Contract
professionals assigned to clients are generally our employees, although clients
provide on-the-job supervisors for these professionals. Therefore, clients
control and direct the work of contract professionals and approve hours worked,
while we are responsible for many of the activities typically handled by the
client’s human resources department.
The sales
and fulfillment functions of our Nurse Travel line of business are aligned with
more traditional nurse travel companies. We employ regional sales directors and
account managers to identify and sell services to healthcare clients who need
nurses. We employ recruiters to find nurses and place them on assignment as
contract professionals with healthcare providers for periods ranging from three
weeks to thirteen weeks and longer. We serve a diverse collection of healthcare
clients, including hospitals, integrated delivery systems and managed care
organizations on a national basis. We seek to address occupations that represent
“high demand and highly-skilled” staff such as operating room nurses, which are
essential to maintaining the hospital’s ability to care for patients and
maintain business and revenues. The critical nature of these occupations to
drive revenue motivates clients to respond to our ability to rapidly fill open
positions with experienced nurses. The recruitment and placement of nurse travel
assignments are primarily managed at our locations in Cincinnati, Ohio and San
Diego, California.
The
nurses we assign to clients are our employees, although clients provide
on-the-job supervisors for the nurses. Therefore, clients control and direct the
work of nurses and approve hours worked, while we are responsible for many of
the activities typically handled by the client’s human resources
department.
At
December 31, 2008, we had 31 Allied Healthcare branch offices in the
United States, of which 16 share office space with the Life
Sciences segment. We have developed a tailored approach to the
assignment-making process that utilizes staffing consultants. Staffing
consultants are experienced professionals who work in our branch
offices and personally meet with clients and contract professionals. Our
staffing consultants are typically either focused primarily on sales and
business development or on fulfillment. Sales staffing consultants meet
with clients to understand their staffing needs, formulate position
descriptions and assess workplace environments. Fulfillment staffing consultants
meet with candidates to assess their qualifications and interests and place
these contract professionals on quality assignments with clients.
The
contract professionals assigned to our Allied Healthcare clients are usually our
employees, although clients provide on-the-job supervisors for these
professionals. Therefore, clients control and direct the work of contract
professionals and approve hours worked, while we are responsible for many of the
activities typically handled by the client’s human resources
department.
Physician
The sales
and fulfillment functions at our Physician segment are similar to those of our
competitors. Our client sales specialists are organized by geographic
territories so that a single individual can handle a client’s physician staffing
needs for all disciplines. Our recruiters and schedulers are organized by
physician specialty and identify physician candidates with the skills,
experience and availability to meet our clients’ needs. Our Physician business
is headquartered in Salt Lake City, Utah, where the majority of our recruiters
and all back-office functions are located. In addition, we have three branch
locations that also carry out recruiting functions. We supply doctors in a wide
range of specialties throughout the United States, Australia and New Zealand.
Assignments are typically booked up to three months in advance and last six
weeks.
The
physicians we place at clients are independent contractors. Clients assign
shifts and approve hours worked, while we are responsible for issuing payments
to the physicians for services rendered to our clients.
IT
and Engineering
Our IT
and Engineering segment is headquartered outside of Boston, Massachusetts, where
all of the back-office activities are located along with several large
recruiting centers. The segment operates in two separate formats. The first
operating format consists of 11 sales and recruiting hubs that manage client
orders submitted from anywhere in the country and fulfill those orders with
appropriate candidates identified from a nationwide database of skilled IT
and engineering professionals. The right candidates for these assignments
often reside in locations that are remote from the client worksite and will
travel away from their homes to perform the assignments. The second operating
format consists of 10 branch offices that typically receive orders from clients
in their local market and fulfill those orders with professionals from the local
market. In each of these formats, we employ both client-oriented sales people
and recruiters. Because our IT and Engineering segment addresses a wide range of
disciplines within the IT and engineering markets, our sales people and
recruiters generally specialize in a given discipline. We also have sales and
recruiting hubs in Cork, Ireland and Utrecht, Netherlands to service the
European market. Our competitive advantage in this segment comes from our effort
to respond very quickly to a client’s request.
Contract
professionals assigned to clients are generally our employees, although clients
provide on-the-job supervisors for these professionals. Therefore, clients
control and direct the work of contract professionals and approve hours worked,
while we are responsible for many of the activities typically handled by the
client’s human resources department.
During
the year ended December 31, 2008, we provided contract professionals to
approximately 6,313 clients. In 2008, we earned 1.4 percent of our consolidated
revenues from a single contract. The revenues from this contract are included in
Healthcare segment revenues. No other single client or contract accounted
for 1.4 percent or more of total revenues during the 2008
period.
All
contract assignments, regardless of their planned length, may be terminated with
limited notice by the client or the contract professional.
Life
Sciences
Our
clients in the Life Sciences segment include biotechnology and pharmaceutical
companies, along with a broad range of clients in food and beverage, medical
device, personal care, chemical, material sciences, energy, education and
environmental industries. Our primary contacts with our clients are a mix of end
users and process facilitators. End users consist of lab directors, managers and
department heads. Facilitators consist of human resource managers, procurement
departments and administrators. Facilitators are more price sensitive than end
users who typically are more focused on technical capabilities. Assignments in
our Life Sciences segment typically have a term of three to six
months.
Healthcare
In our
Healthcare segment, we serve a diverse collection of healthcare clients,
including hospitals, integrated delivery systems, imaging centers, clinics,
physician offices, reference laboratories, universities, managed care
organizations and third-party administrators. In doing so, we address
occupations that require “high demand and highly-skilled” staff, such as
operating room nurses and health information professionals that are essential to
the hospital’s ability to care for patients and maintain business and revenues.
Today, many clients in our Healthcare segment face shortages of these
operations-critical staff. Assignments in our Healthcare segment typically have
a term of three to thirteen weeks.
Physician
Clients
in our Physician segment include hospitals, doctors’ practice groups, large
healthcare systems and government agencies. We are called on to supply temporary
and permanent doctors because of the difficulty that healthcare providers have
finding qualified practitioners. Assignments in our Physician segment typically
have a term of six weeks.
IT
and Engineering
In our IT
and Engineering segment, we supply services to a very wide range of clients. Our
clients range from very large companies that may, for example, be installing new
enterprise-wide computer systems and have a need for a project manager with a
certain type of experience to a system integrator who is looking for a similar
person. We can also provide a person with a specific type of embedded software
expertise to a smaller company finishing up the development of a new product.
The disciplines in our IT and Engineering segment are quite varied in the
information technology, hardware/software, engineering and telecom markets.
Assignments in our IT and Engineering segment typically have a term of
approximately five months.
The
Contract Professional
|
|
Contract
professionals often work with a number of staffing companies and develop
relationships or loyalty based on a variety of factors, including competitive
salaries and benefits, availability and diversity of assignments, quality and
duration of assignments and responsiveness to requests for placement. Contract
professionals seeking traveling positions are also interested in the quality of
travel and housing accommodations as well as the quality of the clinical
experience while on assignment.
Hourly
wage or contract rates for our contract professionals are established based on
their specific skills and whether or not the assignment involves travel away
from the professional’s primary residence. Our consultants are
our employees or are subcontracted from other corporate entities. For
our consultant employees we pay the related costs of employment including social
security taxes, federal and state unemployment taxes, workers’ compensation
insurance and other similar costs. After achieving minimum service periods and
hours worked, we also provide our contract professional employees with paid
holidays, and allow participation in our 401(k) Retirement Savings
Plan.
Life
Sciences
Our Life
Sciences segment’s professionals include chemists, clinical research associates,
clinical lab assistants, engineers, biologists, biochemists, microbiologists,
molecular biologists, food scientists, regulatory affairs specialists, lab
assistants and other skilled scientific professionals. These contract
professionals range from individuals with bachelor and/or master degrees and
considerable experience, to technicians with limited chemistry or biology
backgrounds and lab experience.
Healthcare
Our
Healthcare segment’s contract professionals include nurses, specialty nurses,
health information management professionals, respiratory therapists, surgical
technicians, imaging technicians, x-ray technicians, medical technologists,
phlebotomists, coders, billers, medical assistants, dental assistants,
hygienists, claims processors and collections staff.
Physician
The
physicians in our Physician segment, come from 33 different specialties
including emergency medicine, psychiatry, anesthesiology, radiology, family
practice, surgical specialties, internal medicine, pediatrics, obstetrics and
gynecology. All of these professionals are independent contractors.
IT
and Engineering
Our IT
and Engineering segment’s professionals come from various information
technology, hardware/software, telecom and engineering disciplines. Typically,
they have a great deal of knowledge and experience in a fairly narrow field
which makes them uniquely qualified to fill a given assignment.
We remain
committed to growing our operations in the life science, healthcare, physician
and IT and engineering markets that we currently serve, primarily through
supporting our core service offerings and growing our newer service lines of
business.
In 2008,
we continued to focus on increasing market share in each of our segments,
increasing our gross margins, and controlling our operating costs. We
have increased interaction between our segments so that each can learn best
practices from the others. Late in the year, we began to feel the
impact of the weakening worldwide economy. Given this change in
market demand, we shifted our focus to the areas that we can control, which not
only includes the management of margins and operating costs, but also the
generation of cash.
In
January 2007, we completed the acquisitions of VISTA and Oxford. Throughout
the balance of 2007, our strategy was in great part focused on assisting the
newly acquired Physician and IT and Engineering segments to continue to perform
while integrating with and operating as a part of On Assignment. In doing this,
we focused on increasing the number of staffing consultants in each segment. We
also focused on diversifying our client mix in the Healthcare segment through
the expansion of our client base. In addition, during 2007, we were successful
maintaining our pricing in all of our segments while controlling operating
costs.
As part
of our initiative to improve our sales capabilities, we completed Phases I, II
and III of the implementation of Vurv Technology (formerly known as RecruitMax),
a front office system, for our domestic Life Sciences and certain Allied
Healthcare service lines of business in 2006 and 2007. Phase IV of the
implementation for our Nurse Travel line of business was completed in the fourth
quarter of 2008. The application interfaces with the existing enterprise-wide
information system, PeopleSoft, used in our Life Sciences, IT and Engineering,
Nurse Travel and Allied Healthcare lines of business and provides additional
functionality, including applicant tracking and search tools, customer and
candidate contact management and sales management tools. Phase V of the
implementation, which will support our IT and Engineering segment, is
expected to be completed in 2010. We believe these improvements should continue
to increase the productivity of our staffing consultants and streamline
corporate operations.
In 2009,
we anticipate that we will continue to review acquisition opportunities that may
enable us to leverage our current infrastructure and capabilities, increase our
service offerings and expand our geographic reach. We periodically engage in
discussions with possible acquisition candidates but have no formal commitments
at this time.
Many of
our competitors are larger and have substantially greater financial and
marketing resources than we do. We also compete with privately-owned
temporary staffing companies on a regional and local basis. Frequently, the
strongest competition in a particular market is a privately-held local company
with established relationships. These companies oftentimes are extremely
competitive on pricing. While their pricing strategies are not necessarily
sustainable, they can be problematic in the short-term.
The
principal competitive factors in attracting qualified candidates for temporary
employment or engagements are salaries, contract rates and benefits,
availability and variety of assignments, quality and duration of assignments and
responsiveness to requests for placement. We believe that many people seeking
temporary employment or engagements through us are also pursuing employment
through other means, including other temporary staffing or locum tenens
companies. Therefore, the speed at which we place prospective contract
professionals and the availability of appropriate assignments are important
factors in our ability to complete assignments of qualified candidates. In
addition to having high quality contract professionals to assign in a timely
manner, the principal competitive factors in obtaining and retaining clients in
the temporary staffing industry are properly assessing the clients’ specific job
requirements, the appropriateness of the contract professional assigned to the
client, the price of services and the monitoring of client satisfaction.
Although we believe we compete favorably with respect to these factors, we
expect competition to continue to increase.
Life
Sciences
Our Life
Sciences segment competes in the biotechnology, pharmaceutical, food and
beverage, medical device, personal care, chemical, material sciences, energy,
education and environmental markets. We believe our Life Sciences segment is one
of the few nationwide temporary staffing providers specializing exclusively in
the placement of life science professionals. Although other nationwide temporary
staffing companies compete with us with respect to scientific, clinical
laboratory, medical billing and collection personnel, many of these companies
focus on office/clerical and light and heavy industrial personnel, which account
for a significant portion of the overall contract staffing market. These
competitors include Manpower, Inc., Kelly Services, Inc., Adecco SA
and the scientific division of the Yoh Company.
Healthcare
Our
Healthcare segment competes in the healthcare market, serving hospitals,
integrated delivery systems, imaging centers, clinics, physician offices,
reference laboratories, universities, managed care organizations and third-party
administrators. In the Nurse Travel line of business, our competitors include
AMN Healthcare Services, Inc., Cross Country, Inc. and several
privately-held companies. In the Allied Healthcare line of business, our
competitors include Cross Country, Inc., AMN Healthcare Services, Inc. and
Kforce Inc.
Physician
Our
Physician segment also competes in the healthcare market, serving hospitals,
doctors’ practice groups and private healthcare systems and government
administrated healthcare agencies. VISTA’s competitors include the locum tenens
divisions of CHG Healthcare Services, TeamHealth, Inc., Cross Country, Inc. and
AMN Healthcare Services, Inc., along with several other privately-held
companies providing locum tenens.
IT
and Engineering
Our IT
and Engineering segment competes in the higher-end of the market for information
technology and engineering consultants. Our IT specialties include
enterprise resource planning, business intelligence, customer relationship
management, supply chain management, and database administration. Our
engineering specialties include hardware and software, mechanical, electrical,
validation, network, and telecommunications. Oxford’s competition ranges
from local and regional specialty staffing companies to large IT consulting
firms like Accenture, Inc., and international staffing firms such as
Aerotek and Robert Half International, Inc.
Demand
for our staffing services historically has been lower during the first and
fourth quarters due to fewer business days resulting from client shutdowns,
adverse weather conditions and a decline in the number of contract professionals
willing to work during the holidays. As is common in the staffing
industry, we run special incentive programs to keep our contract professionals,
particularly nurses, working through the holidays. Demand for our staffing
services usually increases in the second and third quarters of the year. In addition, our cost of services typically increase in
the first quarter primarily due to the reset of payroll taxes.
At
December 31, 2008, we employed approximately 1,134 full-time regular
employees, including staffing consultants, regional sales directors, account
managers, recruiters and corporate office employees. At December 31, 2008,
we employed approximately 15,149 contract professionals and 1,090 traveling
physicians.
The
healthcare industry is subject to extensive and complex federal and state laws
and regulations related to professional licensure, certification, conduct of
operations, payment for services, payment for referrals and insurance. Our
operations are subject to additional state and local regulations that require
temporary staffing companies placing healthcare personnel to be licensed or
separately registered to an extent beyond that required by temporary staffing
companies that only place non-healthcare personnel. To date, we have not
experienced any material difficulties in complying with such regulations and
obtaining required licensure.
Some
states require state licensure with associated fees for businesses that employ
and/or assign certain healthcare personnel at hospitals and other healthcare
facilities. We are currently licensed in all the states that require such
licenses. In addition, most of the contract healthcare professionals that we
employ are required to be individually licensed and/or certified under
applicable state laws. We take reasonable steps to ensure that our contract
professionals possess all current licenses and certifications required for each
placement. We provide state mandated workers’ compensation insurance,
unemployment insurance and professional liability insurance for our contract
professionals and our regular employees. These expenses have a direct effect on
our cost of services, margins and likelihood of achieving or maintaining
profitability.
For a
further discussion of government regulation associated with our business, see
“Risk Factors” within Item 1A of Part I of this Annual Report.
Executive
Officers of the Company
|
|
The
executive officers of On Assignment, Inc. are as follows:
Name
|
Age
|
Position
|
Peter
T. Dameris
|
49
|
Chief
Executive Officer and President
|
James
L. Brill
|
57
|
Senior
Vice President, Finance and Chief Financial Officer
|
Emmett
B. McGrath
|
47
|
President,
Life Sciences and Allied Divisions
|
Mark
S. Brouse
|
55
|
President,
VISTA Staffing Solutions, Inc.
|
Michael
J. McGowan
|
55
|
President,
Oxford Global Resources,
Inc.
|
Peter T. Dameris joined
the Company in November 2003 as Executive Vice President, Chief Operating
Officer and was promoted to President and Chief Executive Officer
in September 2004. He was appointed to the Board of Directors
of the Company in February 2005. From February 2001 through
October 2002, Mr. Dameris served as Executive Vice President and Chief
Operating Officer of Quanta Services, Inc. (NYSE: PWR), a leading provider
of specialized contracting services for the electric and gas utility, cable and
telecommunications industries. From December 1994 through
September 2000, Mr. Dameris served in a number of different positions
at Metamor Worldwide, Inc. (formerly, NASDAQ: MMWW), an international,
publicly-traded IT consulting/staffing company, including Chairman of the Board,
President and Chief Executive Officer, Executive Vice President, General
Counsel, Senior Vice President and Secretary. In June 2000,
Mr. Dameris successfully negotiated the sale of Metamor for $1.9 billion.
From November 2002 to January 2006, Mr. Dameris was a member of
the Board of Directors of Bindview Corporation (acquired by Symatec Corporation
in January 2006). Mr. Dameris holds a Juris Doctorate from the
University of Texas Law School and a Bachelor’s in Business Administration from
Southern Methodist University.
James L. Brill joined the
Company in January 2007 as Senior Vice President, Finance and Chief
Financial Officer. Mr. Brill was Vice President, Finance and Chief Financial
Officer of Diagnostic Products Corporation, a manufacturer of immuno-diagnostic
kits, from July 1999 until it was acquired by Siemens in July 2006. From
August 1998 to June 1999, Mr. Brill served as Chief Financial Officer of Jafra
Cosmetics International, a marketing and direct-selling company in the skin care
and beauty industry, and as Vice President of Finance and Administration and
Chief Financial Officer of Vertel Corporation, a provider of middleware for the
telecommunications industry, from 1996 to 1998. Mr. Brill also served as Senior
Vice President, Finance and Chief Financial Officer of Merisel, Inc., an
internet commerce service provider, from 1988 to 1996. Mr. Brill has been a
member of the Board of Directors of Onvia Inc. since March 2004. He holds a
Bachelor’s of Science degree from the United States Naval Academy and a Master’s
of Business Administration degree from the University of California Los
Angeles.
Emmett B. McGrath joined
the Company in September 2004 as President, Life Sciences U.S., and in
August 2005, Mr. McGrath was appointed as President of Life Sciences
Europe. Mr. McGrath was appointed as President of Allied Healthcare in November
2007. From February 1985 through August 2004, Mr. McGrath worked
at the Yoh Company, a privately-held technology staffing organization.
During his tenure at Yoh, Mr. McGrath held various staffing positions,
including Technical Recruiter, Account Manager, Branch and District Management,
Vice President and Regional President. As Regional President, Mr. McGrath
was responsible for core lines of businesses, including Scientific, Information
Technology, Engineering, Healthcare, Telecommunications and Vendor on Premise
(VOP) programs. In addition, Mr. McGrath served on Yoh’s Executive
Committee and the Chairman’s Board of the Day & Zimmermann Group, Yoh’s
parent company. Mr. McGrath received a Bachelor’s of Science degree in
Business Administration, with an emphasis in Human Resources, from California
State University, Northridge in 1991.
Mark S. Brouse is President of
VISTA Staffing Solutions, Inc., On Assignment’s Physician segment. Mr. Brouse
joined On Assignment as a result of On Assignment’s January 2007 acquisition of
VISTA, a company he co-founded in 1990. Mr. Brouse began his career in
pharmaceutical sales in 1980, and in 1986 joined CompHealth, a locum tenens
staffing company, where he led specialty teams serving psychiatry and internal
medicine clients before founding VISTA. Mr. Brouse holds a Bachelor’s of Science
degree in Chemistry from California State, Dominguez Hills, and is a member of
the Boards of Directors of the YMCA of Greater Salt Lake and PEHR Technologies,
an electronic medical records company.
Michael J. McGowan is
President of Oxford Global Resources, Inc., On Assignment’s IT and Engineering
segment. He has held this position since 1998. He joined Oxford in May of 1997
as Chief Operating Officer. Formerly, Mr. McGowan was Senior Vice President and
General Manager for Kelly Services’ Middle Markets Division, a provider of
staffing solutions. Prior to that time he was Vice President & General
Manager for The MEDSTAT Group, a healthcare information firm, and held
increasingly senior positions for Automatic Data Processing (ADP), a provider of
human resources, payroll and tax and benefits administration solutions, during a
sixteen year tenure. Mr. McGowan holds a Bachelor’s of Science degree in
Electrical Engineering from Michigan State University and a Master’s of Business
Administration degree from the Eli Broad Graduate School of Management, also at
Michigan State University. Mr. McGowan joined On Assignment as a result of the
Company’s acquisition of Oxford in January 2007.
|
Available
Information and Access to Reports
|
We
electronically file our Annual Report on Form 10-K, Quarterly Reports on
Form 10-Q, Current Reports on Form 8-K, and all amendments to those
reports with the Securities and Exchange Commission (SEC). You may read and copy
any of our reports that are filed with the SEC in the following
manner:
·
|
At
the SEC’s Public Reference Room at 100 F Street NE, Washington, DC
20549. You may obtain information on the operation of the Public Reference
Room by calling the SEC at
(800) SEC-0330;
|
·
|
At
the SEC’s website,
http://www.sec.gov;
|
·
|
At
our website,
http://www.onassignment.com;
or
|
·
|
By
contacting our Investor Relations Department at (818)
878-7900.
|
Our
reports are available through any of the foregoing means and are available free
of charge on our website as soon as practicable after such material is
electronically filed with or furnished to the SEC. Also available on our website
(http://www.onassignment.com), free of charge, are copies
of our Code of Ethics for the Principle Executive Officer and Senior Financial
Officers, Code of Business Conduct and Ethics and the charters for the
committees of our Board of Directors. We intend to disclose any amendment to, or
waiver from, a provision of our Code of Ethics for Principal Executive Officer
and Senior Financial Officers on our website within five business days following
the date of the amendment or waiver.
Item
1A. Risk Factors
Our
business is subject to a number of risks, including the following:
Recent
U.S. economic conditions have been uncertain and challenging.
Recent
global market and economic conditions have been unprecedented and challenging
with tighter credit conditions and recession in most major economies continuing
into 2009. Continued concerns about the systemic impact of potential
long-term and wide-spread recession, energy costs, geopolitical issues, the
availability and cost of credit, and the global housing and mortgage markets
have contributed to increased market volatility and diminished expectations for
western and emerging economies. In the second half of 2008, added
concerns fueled by the U.S. government conservatorship of the Federal Home Loan
Mortgage Corporation and the Federal National Mortgage Association, the declared
bankruptcy of Lehman Brothers Holdings Inc., the U.S. government financial
assistance to American International Group Inc., Citibank, Bank of America and
other federal government interventions in the U.S. financial system lead to
increased market uncertainty and instability in both U.S. and international
capital and credit markets. These conditions, combined with volatile
oil prices, declining business and consumer confidence and increased
unemployment, have contributed to volatility of unprecedented
levels.
As a
result of these market conditions, the cost and availability of credit has been
and may continue to be adversely affected by illiquid credit markets and wider
credit spreads. Concern about the stability of the markets generally
and the strength of counterparties specifically has led many lenders and
institutional investors to reduce, and in some cases, cease to provide credit to
businesses and consumers. These factors have lead to a decrease in
spending by businesses and consumers alike, and a corresponding decrease in
global infrastructure spending. Continued turbulence in the U.S. and
international markets and economies and prolonged declines in business consumer
spending may adversely affect our liquidity and financial condition, and the
liquidity and financial condition of our customers, including our ability to
refinance maturing liabilities and access the capital markets to meet liquidity
needs.
In
addition, our liquidity and our ability to obtain financing may be adversely
impacted if any of the lenders under our credit facilities suffers liquidity
issues. In such an event we may not be able to draw on all, or a
substantial portion, of our credit facilities.
Our
results of operations may vary from quarter to quarter as a result of a number
of factors, which may make it difficult to evaluate our business and could cause
instability in the trading price of our common stock.
Factors
that may cause our quarterly results to fluctuate include:
·
|
the
level of demand for our temporary staffing services and the efficiency
with which we source and assign our contract professionals and support our
staffing consultants in the execution of their
duties;
|
·
|
changes
in our pricing policies or those of our competitors;
and
|
·
|
our
ability to control costs and manage our accounts receivable
balances.
|
In
addition, most temporary staffing companies experience seasonal declines in
demand during the first and fourth quarters as a result of fewer business days
and the reduced number of contract professionals willing to work during the
holidays. Historically, we have experienced variability in the duration and
depth of these seasonal declines, which in turn have materially affected our
quarterly results of operations and made period-to-period comparisons of our
financial and operating performance difficult.
If our
operating results are below the expectations of public market analysts or
investors in a given quarter, the trading price of our common stock could
decline.
Failure
to comply with restrictive covenants under our debt instruments could trigger
prepayment obligations or additional costs.
Our
failure to comply with restrictive covenants under our credit facilities and
other debt instruments could result in an event of default, which, if not cured
or waived, could result in us being required to repay these borrowings before
their due date. The lenders may require fees and expenses to be paid
or other changes to terms in connection with waivers or
amendments. If we are forced to refinance these borrowings on less
favorable terms, our results of operations and financial condition could be
adversely affected by increased costs and rates.
Failure
of internal controls may leave us susceptible to errors and fraud.
Our
management, including our CEO and CFO, does not expect that our disclosure
controls and internal controls will prevent all errors and all fraud. A control
system, no matter how well conceived and operated, can provide only
reasonable assurance that the objectives of the control system are
met. Furthermore, because of the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all
control issues and instances of fraud, if any, would be
detected.
Significant
legal actions could subject us to substantial uninsured
liabilities.
In recent
years, healthcare providers have become subject to an increasing number of legal
actions alleging malpractice, vicarious liability, violation of certain consumer
protection acts, negligent hiring, product liability or related legal theories.
We may be subject to liability in such cases even if the contribution to the
alleged injury was minimal. Many of these actions involve large claims and
significant defense costs. In addition, we may be subject to claims related to
torts or crimes committed by our corporate employees or healthcare
professionals. In most instances, we are required to indemnify clients against
some or all of these risks. A failure of any of our corporate employees or
healthcare professionals to observe our policies and guidelines intended to
reduce these risks; relevant client policies and guidelines or applicable
federal, state or local laws, rules and regulations could result in negative
publicity, payment of fines or other damages.
To
protect ourselves from the cost of these types of claims, we maintain workers ’
compensation and professional malpractice liability insurance and general
liability insurance coverage in amounts and with deductibles that we believe are
appropriate for our operations. Our coverage is, in part, self-insured. However,
our insurance coverage may not cover all claims against us or continue to be
available to us at a reasonable cost. If we are unable to maintain adequate
insurance coverage, we may be exposed to substantial liabilities.
If
we are unable to attract and retain qualified contract professionals for our
Life Sciences, Healthcare, Physician and IT and Engineering segments, our
business could be negatively impacted.
Our
business is substantially dependent upon our ability to attract and retain
contract professionals who possess the skills, experience and, as required,
licenses to meet the specified requirements of our clients. We compete for such
contract professionals with other temporary staffing companies and with our
clients and potential clients. Currently, there is a shortage of qualified
nurses in most areas of the United States. Competition for nursing personnel is
increasing and salaries and benefits have risen. Further, there can be no
assurance that qualified healthcare, life science, IT and engineering
professionals will be available to us in adequate numbers to staff our operating
segments. Moreover, our contract professionals are often hired to become regular
employees of our clients. Attracting and retaining contract professionals
depends on several factors, including our ability to provide contract
professionals with desirable assignments and competitive benefits and wages. The
cost of attracting and retaining contract professionals may be higher than we
anticipate and, as a result, if we are unable to pass these costs on to our
clients, our likelihood of achieving or maintaining profitability could decline.
If we are unable to attract and retain a sufficient number of contract
professionals to meet client demand, we may be required to forgo staffing and
revenue opportunities, which may hurt the growth of our business.
We
may not successfully make or integrate acquisitions, which could harm our
business and growth.
As part
of our growth strategy, we intend to opportunistically pursue selected
acquisitions. We compete with other companies in the professional staffing and
consulting industries for acquisition opportunities, and we cannot assure you
that we will be able to effect future acquisitions on commercially reasonable
terms or at all. In January 2007, we acquired VISTA and Oxford. With these
two acquisitions or to the extent we enter into acquisition transactions in the
future, we may experience:
·
|
delays
in realizing or a failure to realize the benefits, cost savings and
synergies that we anticipate;
|
·
|
difficulties
or higher-than-anticipated costs associated with integrating any acquired
companies into our businesses;
|
·
|
attrition
of key personnel from acquired
businesses;
|
·
|
diversion
of management’s attention from other business
concerns;
|
·
|
inability
to maintain the business relationships and reputation of the acquired
companies;
|
·
|
difficulties
in integrating the acquired companies into our information systems,
controls, policies and procedures;
|
·
|
additional
risks relating to the businesses or industry of the acquired companies
that are different from ours;
|
·
|
unexpected
costs or charges; or
|
·
|
unforeseen
operating difficulties that require significant financial and managerial
resources that would otherwise be available for the ongoing development or
expansion of our existing
operations.
|
We
incurred debt for our recent acquisitions, which increased our interest expense.
To undertake more transactions, we may incur additional debt in the future. We
may face unexpected contingent liabilities arising from these
or future
acquisitions that could harm our business. We may also issue additional equity
in connection with these transactions, which would dilute our existing
shareholders.
If
we cannot attract, develop and retain qualified and skilled staffing
consultants, our business growth will suffer.
A key
component of our ability to grow our lines of business is our ability to
attract, develop and retain qualified and skilled staffing consultants,
particularly persons with industry experience. The available pool of qualified
staffing consultant candidates is limited, and further constrained by the
industry practice of entering into non-compete agreements with these employees,
which may restrict their ability to accept employment with other staffing firms,
including us. We cannot assure that we will be able to recruit, develop and
retain qualified staffing consultants in sufficient numbers or that our staffing
consultants will achieve productivity levels sufficient to enable growth of our
business. Failure to attract and retain productive staffing consultants could
adversely affect our business, financial condition and results of
operations.
Reclassification
of our independent contractors by tax authorities could materially and adversely
affect our business model and could require us to pay significant retroactive
wages, taxes and penalties.
We
consider our locum tenens physicians to be independent contractors rather than
employees. As such, we do not withhold or pay income or other employment related
taxes or provide workers’ compensation insurance for them. Our classification of
locum tenens physicians as independent contractors is consistent with general
industry standard, but can nonetheless be challenged by the contractors
themselves as well as the relevant taxing authorities. If federal or state
taxing authorities determine that locums tenens physicians engaged as
independent contractors are employees, our business model for that segment would
be materially and adversely affected. Although we believe we would qualify for
safe harbor under the provisions of Section 530 of the Revenue Act of 1978, Pub.
L. No. 95−600 (“Section 530”), and any similar applicable state laws, we could
incur significant liability for past wages, taxes, penalties and other
employment benefits if we could not so qualify. In addition, many states have
laws that prohibit non−physician owned companies from employing physicians. If
our independent contractor physicians are classified as employees, we could be
found in violation of such state laws, which could subject us to liability in
those states and thereby negatively impact on our profitability.
If
we lose a major client in our Nurse Travel line of business and are not able to
replace the lost business quickly, our business could be negatively
impacted.
Our top
ten clients in the Nurse Travel line of business accounted for 26.2 percent of
Nurse Travel revenues in 2008. The loss of a major client in Nurse Travel and
the failure to replace the lost business with existing or new clients could
adversely affect our business, financial condition, results of segment operating
income and cash flows. In 2008, we earned 1.4 percent of our consolidated
revenues from a single contract. The revenues from this contract are included in
Healthcare segment revenues. No other single customer or contract accounted for
1.4 percent or more of total revenues during 2008.
If
our information systems do not function in a cost effective manner, our business
will be harmed.
The
operation of our business is dependent on the proper functioning of our
information systems. In 2008, we continued to upgrade our information technology
systems, including PeopleSoft and Vurv Technology, enterprise-wide information
systems. Critical information systems used in daily operations identify and
match staffing resources and client assignments, track regulatory credentialing,
manage scheduling and also perform billing and accounts receivable functions. If
the systems fail to perform reliably or otherwise do not meet our expectations,
or if we fail to successfully complete the implementation of other modules of
the systems, we could experience business interruptions that could result in
deferred or lost sales. Our information systems are vulnerable to fire, storm,
flood, power loss, telecommunications failures, physical or software break-ins
and similar events. Our network infrastructure is currently located at our
facility in Salt Lake City, Utah. As a result, any system failure or service
outage at this primary facility could result in a loss of service for the
duration of the failure of the outage. Our location in Southern California is
susceptible to earthquakes and has, in the past, experienced power shortages and
outages, any of which could result in system failures or outages. If our
information systems fail or are otherwise unavailable, these functions would
have to be accomplished manually, which could impact our ability to respond to
business opportunities quickly, to pay our staff in a timely fashion and to bill
for services efficiently.
If
we are not able to remain competitive in obtaining and retaining temporary
staffing clients, our future growth will suffer.
The
contract staffing industry is highly competitive and fragmented with limited
barriers to entry. We compete in national, regional and local markets with
full-service agencies and in regional and local markets with specialized
contract staffing agencies. Some of our competitors in the Nurse Travel line of
business include AMN Healthcare Services, Inc., Cross Country, Inc.
and several privately-held companies. Some of our competitors in the Life
Sciences segment and Allied Healthcare line of business include Kelly
Services, Inc., Manpower, Inc., Adecco, SA and Yoh Scientific.
Competitors for the Physician segment include the locum tenens divisions of CHG
Healthcare Services, Cross Country, TeamHealth, Inc. and AMN Healthcare
Services, Inc., along with several other privately-held companies specializing
in locum tenens. Competitors of our IT and Engineering segment include Robert
Half International, Accenture, International Business Machines Corporation
(IBM), the Yoh Company and a number of privately held companies. Several of
these companies have significantly greater marketing and financial resources
than we do. Our ability to attract and retain clients is based on the value of
the service we deliver, which in turn depends principally on the speed with
which we fill assignments and the appropriateness of the match based on clients’
requirements and the skills and experience of our contract professionals. Our
ability to attract skilled, experienced contract professionals is based on our
ability to pay competitive wages or contract rates, to provide competitive
benefits and to provide multiple, continuous assignments, thereby increasing the
retention rate of these employees or contractors. To the extent that competitors
seek to gain or retain market share by reducing prices or increasing marketing
expenditures, we could lose revenues and our gross and operating margins could
decline, which could seriously harm our operating results and cause the trading
price of our stock to decline. As we expand into new geographic markets, our
success will depend in part on our ability to gain market share from
competitors. We expect competition for clients to increase in the future, and
the success and growth of our business depend on our ability to remain
competitive.
Our
contract staffing agreements may be terminated by clients and contract
professionals at will and the termination of a significant number of such
agreements would adversely affect our revenues and results of
operations.
Each
contract professional’s employment with us is terminable at will. A locum tenens
physician may generally terminate his or her contract with VISTA for
non-emergency reasons upon 60 days notice. The duration of agreements with
clients are generally dictated by the contract. Usually, contracts with clients
may be terminated with 30 days notice by us or by the clients. We cannot assure
that existing clients will continue to use our services at historical levels, if
at all. If clients terminate a significant number of our staffing agreements and
we are unable to generate new contract staffing orders to replace lost revenues
or a significant number of our contract professionals terminate their employment
with us and we are unable to find suitable replacements, our revenues and
results of operations could be harmed.
We
are subject to business risks associated with international operations, which
could make our international operations significantly more costly.
As of
December 31, 2008, we had international operations in the United Kingdom,
Netherlands, Belgium, Canada and Ireland. We have limited experience in
marketing, selling and, particularly, supporting our services outside of North
America.
Operations
in certain markets are subject to risks inherent in international business
activities, including:
·
|
fluctuations
in currency exchange rates;
|
·
|
complicated
work permit requirements;
|
·
|
varying
economic and political conditions;
|
·
|
seasonal
reductions in business activity during the summer months in Europe and
Asia;
|
·
|
overlapping
or differing tax structures;
|
·
|
difficulties
collecting accounts receivable; and
|
·
|
regulations
concerning pay rates, benefits, vacation, union membership, redundancy
payments and the termination of
employment.
|
Our
inability to effectively manage our international operations could result in
increased costs and adversely affect our results of operations.
Improper
activities of our contract professionals could result in damage to our business
reputation, discontinuation of our client relationships and exposure to
liability.
We may be
subject to possible claims by our clients related to errors and omissions,
misuse of proprietary information, discrimination and harassment, theft and
other criminal activity, malpractice and other claims stemming from the improper
activities or alleged activities of our contract professionals. We cannot assure
that our current liability insurance coverage will be adequate or will continue
to be available in sufficient amounts to cover damages or other costs associated
with such claims. Claims raised by clients stemming from the improper actions of
our contract professionals, even if without merit, could cause us to incur
significant expense associated with the costs or damages related to such claims.
Further, such claims by clients could damage our business reputation and result
in the discontinuation of client relationships.
Claims
against us by our contract professionals for damages resulting from the
negligence or mistreatment by our clients could result in significant costs and
adversely affect our recruitment and retention efforts.
We may be
subject to possible claims by our contract professionals alleging
discrimination, sexual harassment, negligence and other similar activities by
our clients. Our physicians may also be subject to medical malpractice claims.
We cannot assure that our current liability insurance coverage will be adequate
or will continue to be available in sufficient amounts to cover damages or other
costs associated with such claims. Claims raised by our contract professionals,
even if without merit, could cause us to incur significant expense associated
with the costs or damages related to such claims. Further, any associated
negative publicity could adversely affect our ability to attract and retain
qualified contract professionals in the future.
If
we are required to further write down goodwill or identifiable intangible
assets, the related charge could materially impact our reported net income or
loss for the period in which it occurs.
In 2004,
we recorded a charge of $26.4 million related to impairment of goodwill and an
impairment charge of $3.9 million related to our identifiable intangible assets.
We did not record any such charges in 2005, 2006, 2007 or 2008. However, we
continue to have approximately $202.8 million in goodwill on our balance sheet
at December 31, 2008, as well as $31.4 million in identifiable intangible
assets. As part of the analysis of goodwill impairment, SFAS No. 142,
“Goodwill and Other Intangible Assets” (SFAS 142), requires the Company’s
management to estimate the fair value of the reporting units on at least an
annual basis. At December 31, 2008, we performed our annual goodwill and
indefinite lived intangible assets impairment test and concluded that there was
no further impairment of goodwill and intangible assets. In addition, at
December 31, 2008, we determined that there were no events or changes in
circumstances that indicated that the carrying values of other identifiable
intangible assets subject to amortization may not be recoverable. While we
believe that our goodwill was not impaired at December 31, 2008, declines in our
market capitalization subsequent to the balance sheet date could be an early
indication that goodwill may become impaired in the future. Although a
future impairment of goodwill and identifiable intangible assets would not
affect our cash flow, it would negatively impact our operating
results.
If
we are subject to material uninsured liabilities under our partially
self-insured workers’ compensation program and medical malpractice coverage, our
financial results could be adversely affected.
We
maintain a partially self-insured workers’ compensation program and medical
malpractice coverage. In connection with these programs, we pay a base premium
plus actual losses incurred up to certain levels. We are insured for losses
greater than certain levels, both per occurrence and in the aggregate. There can
be no assurance that our loss reserves and insurance coverage will be adequate
in amount to cover all workers’ compensation or medical malpractice claims. If
we become subject to substantial uninsured workers’ compensation or medical
malpractice liabilities, our results of operations and financial condition could
be adversely affected.
Our
costs of providing travel and housing for nurses and other traveling contract
professionals may be higher than we anticipate and, as a result, our margins
could decline.
If our
travel and housing costs, including the costs of airline tickets, rental cars,
apartments and rental furniture for our nurses and other traveling contract
professionals exceed the levels we anticipate, and we are unable to pass such
increases on to our clients, our margins may decline. To the extent the length
of our apartment leases exceed the terms of our staffing contracts, we bear the
risk that we will be obligated to pay rent for housing we do not use. If we
cannot source a sufficient number of appropriate short-term leases in regional
markets, or if, for any reason, we are unable to efficiently utilize the
apartments we do lease, we may be required to pay rent for unutilized or
underutilized housing. As we continue to expand our Nurse Travel line of
business, effective management of travel costs will be necessary to prevent a
decrease in gross profit and gross and operating margins.
Demand
for our services is significantly impacted by changes in the general level of
economic activity and continued periods of reduced economic activity could
negatively impact our business and results of operations.
Demand
for the contract staffing services that we provide is significantly impacted by
changes in the general level of economic activity, particularly any negative
effect on healthcare, research and development and quality control spending. As
economic activity slows, many clients or potential clients for our services
reduce their usage of and reliance upon contract professionals before laying off
their regular, full-time employees. During periods of reduced economic activity,
we may also be subject to increased competition for market share and pricing
pressure. As a result, continued periods of reduced economic activity could harm
our business and results of operations.
We
do not have long-term or exclusive agreements with our temporary staffing
clients and growth of our business depends upon our ability to continually
secure and fill new orders.
We do not
have long-term agreements or exclusive guaranteed order contracts with our
temporary staffing clients. Assignments for our Life Sciences segment typically
have a term of three to six months. Assignments for our
Healthcare segment typically have a term of two to thirteen weeks. Assignments
for our Physician segment typically have a term of six weeks. Assignments for
our IT and Engineering segment typically have a term of approximately five
months. The success of our business depends upon our ability to continually
secure new orders from clients and to fill those orders with our contract
professionals. Our agreements do not provide for exclusive use of our services,
and clients are free to place orders with our competitors. As a result, it is
imperative to our business that we maintain positive relationships with our
clients. If we fail to maintain positive relationships with these clients, we
may be unable to generate new contract staffing orders, and the growth of our
business could be adversely affected.
Fluctuation
in patient occupancy rates at client facilities could adversely affect demand
for services of our Healthcare and Physician segments and our results of
operations.
Client
demand for our Healthcare and Physician segment services is significantly
impacted by changes in patient occupancy rates at our hospital and healthcare
clients’ facilities. Increases in occupancy often result in increased client
need for contract professionals before full-time employees can be hired. During
periods of decreased occupancy, however, hospitals and other healthcare
facilities typically reduce their use of contract professionals before laying
off their regular, full-time employees. During periods of decreased occupancy,
we may experience increased competition to service clients, including pricing
pressure. Occupancy at certain healthcare clients’ facilities also fluctuates
due to the seasonality of some elective procedures. Periods of decreased
occupancy at client healthcare facilities could materially adversely affect our
results of operations.
The
loss of key members of our senior management team could adversely affect the
execution of our business strategy and our financial results.
We
believe that the successful execution of our business strategy and our ability
to build upon the significant recent investments in our business and
acquisitions of new businesses depends on the continued employment of key
members of our senior management team. If any members of our senior management
team become unable or unwilling to continue in their present positions, our
financial results and our business could be materially adversely
affected.
Future
changes in reimbursement trends could hamper our Healthcare and Physician
segments clients’ ability to pay us, which would harm our financial
results.
Many of
our Healthcare and Physician segments’ clients are reimbursed under the federal
Medicare program and state Medicaid programs for the services they provide. In
recent years, federal and state governments have made significant changes in
these programs that have reduced reimbursement rates. In addition, insurance
companies and managed care organizations seek to control costs by requiring that
healthcare providers, such as hospitals, discount their services in exchange for
exclusive or preferred participation in their benefit plans. Future federal and
state legislation or evolving commercial reimbursement trends may further
reduce, or change conditions for, our clients’ reimbursement. Limitations on
reimbursement could reduce our clients’ cash flows, thereby hampering their
ability to pay us.
If
our insurance costs increase significantly, these incremental costs could
negatively affect our financial results.
The costs
related to obtaining and maintaining workers’ compensation insurance, medical
malpractice insurance, professional and general liability insurance and health
insurance for our contract professionals have been increasing. If the cost of
carrying this insurance continues to increase significantly, this may reduce our
gross and operating margins and financial results.
Healthcare
reform could negatively impact our business opportunities, revenues and gross
and operating margins.
The U.S.
and state governments have undertaken efforts to control increasing healthcare
costs through legislation, regulation and voluntary agreements with medical care
providers and drug companies. In the recent past, the U.S. Congress has
considered several comprehensive healthcare reform proposals. The proposals were
generally intended to expand healthcare coverage for the uninsured and reduce
the growth of total healthcare expenditures. While the U.S. Congress did not
adopt any comprehensive reform proposals, members of Congress may raise similar
proposals in the future. If any of these proposals are approved, hospitals and
other healthcare facilities may react by spending less on healthcare staffing,
including nurses and physicians. If this were to occur, we would have fewer
business opportunities, which could seriously harm our business.
Furthermore,
third-party payors, such as health maintenance organizations, increasingly
challenge the prices charged for medical care. Failure by hospitals and other
healthcare facilities to obtain full reimbursement from those third-party payors
could reduce the demand or the price paid for our staffing
services.
We
operate in a regulated industry and changes in regulations or violations of
regulations may result in increased costs or sanctions that could reduce our
revenues and profitability.
Our
organization is subject to extensive and complex federal and state laws and
regulations including but not limited to: professional licensure, payroll tax
regulations, conduct of operations, payment for services and payment for
referrals. If we fail to comply with the laws and regulations that are directly
applicable to our business, we could suffer civil and/or criminal penalties or
be subject to injunctions or cease and desist orders.
Extensive
and complex laws that apply to our hospital and healthcare facility clients,
including laws related to Medicare, Medicaid and other federal and state
healthcare programs, could indirectly affect the demand or the prices paid for
our services. For example, our hospital and healthcare facility clients could
suffer civil and/or criminal penalties and/or be excluded from participating in
Medicare, Medicaid and other healthcare programs if they fail to comply with the
laws and regulations applicable to their businesses. In addition, our hospital
and healthcare facility clients could receive reduced reimbursements or be
excluded from coverage because of a change in the rates or conditions set by
federal or state governments. In turn, violations of or changes to these laws
and regulations that adversely affect our hospital and healthcare facility
clients could also adversely affect the prices that these clients are willing or
able to pay for our services.
The
trading price of our common stock has experienced significant fluctuations,
which could make it difficult for us to access the public markets for financing
or use our common stock as consideration in a strategic
transaction.
In 2008,
the trading price of our common stock experienced significant fluctuations, from
a high of $9.70 to a low of $4.05. The closing price of our common stock on the
NASDAQ Global Market was $2.06 on March 10, 2009. Our common stock may continue
to fluctuate widely as a result of a large number of factors, many of which are
beyond our control, including:
·
|
period
to period fluctuations in our financial results or those of our
competitors;
|
·
|
failure
to meet previously announced guidance or analysts’ expectations of our
quarterly results;
|
·
|
announcements
by us or our competitors of acquisitions, significant contracts,
commercial relationships or capital
commitments;
|
·
|
commencement
of, or involvement in, litigation;
|
·
|
any
major change in our board or
management;
|
·
|
changes
in government regulations, including those related to Medicare and
Medicaid reimbursement policies;
|
·
|
recommendations
by securities analysts or changes in earnings
estimates;
|
·
|
announcements
about our earnings that are not in line with analyst
expectations;
|
·
|
the
volume of shares of common stock available for public
sale;
|
·
|
announcements
by our competitors of their earnings that are not in line with analyst
expectations;
|
·
|
sales
of stock by us or by our
shareholders;
|
·
|
short
sales, hedging and other derivative transactions in shares of our common
stock; and
|
·
|
general economic
conditions, slow or negative growth of unrelated markets and other
external factors.
|
The stock
market has experienced extreme price and volume fluctuations that have affected
the market prices of many companies involved in the temporary staffing industry.
As a result of these fluctuations, we may encounter difficulty should we
determine to access the public markets for financing or use our common stock as
consideration in a strategic transaction.
Future
sales of our common stock and the future exercise of options may cause the
market price of our common stock to decline and may result in substantial
dilution.
We cannot
predict what effect, if any, future sales of our common stock, or the
availability of our common stock for sale will have on the market price of our
common stock. Sales of substantial amounts of our common stock in the public
market by management or us, or the perception that such sales could occur, could
adversely affect the market price of our common stock and may make it more
difficult for you to sell your common stock at a time and price which you may
deem appropriate.
We
have adopted anti-takeover measures that could prevent a change in our
control.
In June
2003, we adopted a shareholder rights plan that has certain anti-takeover
effects and will cause substantial dilution to a person or group that attempts
to acquire us in a manner or on terms that have not been approved by our board
of directors. This plan could delay or impede the removal of incumbent directors
and could make more difficult a merger, tender offer or proxy contest involving
us, even if such events could be beneficial, in the short-
term, to
the interests of our shareholders. In addition, such provisions could limit the
price that some investors might be wiling to pay in the future for shares of our
common stock. Our certificate of incorporation and bylaws contain provisions
that limit liability and provide for indemnification of our directors and
officers, and provide that our stockholders can take action only at a duly
called annual meeting of stockholders. These provisions and others also may have
the affect of deterring hostile takeovers or delaying changes in control or
management.
Provisions
in our corporate documents and Delaware law may delay or prevent a change in
control that our stockholders consider favorable.
Provisions
in our certificate of incorporation and bylaws could have the effect of delaying
or preventing a change of control or changes in our management. These provisions
include the following:
·
|
Our
board of directors has the right to elect directors to fill a vacancy
created by the expansion of the board of directors or the resignation,
death or removal of a director, which prevents stockholders from being
able to fill vacancies on our board of
directors.
|
·
|
Our
stockholders may not act by written consent. In addition, a holder or
holders controlling a majority of our capital stock would not be able to
take certain actions without holding a stockholder’s meeting, and only
stockholders owning at least 50 percent of our entire voting stock must
request in writing in order to call a special meeting of stockholders
(which is in addition to the authority held by our board of directors to
call a special stockholder
meetings).
|
·
|
Stockholders
must provide advance notice to nominate individuals for election to the
board of directors or to propose matters that can be acted upon at a
stockholders’ meeting. These provisions may discourage or deter a
potential acquirer from conducting a solicitation of proxies to elect the
acquirer’s own slate of directors or otherwise attempting to obtain
control of our company.
|
·
|
Our
board of directors may issue, without stockholder approval, up to 1
million shares of undesignated or “blank check” preferred stock. The
ability to issue undesignated or “blank check” preferred stock makes it
possible for our board of directors to issue preferred stock with voting
or other rights or preferences that could impede the success of any
attempt or make it more difficult for a third party to acquire
us.
|
As a
Delaware corporation, we are also subject to certain Delaware anti-takeover
provisions, including Section 203 of the Delaware General Corporation Law. Under
these provisions, a corporation may not engage in a business combination with
any large stockholders who hold 15 percent or more of our outstanding voting
capital stock in a merger or business combination unless the holder has held the
stock for 3 years, the board of directors has expressly approved the merger or
business transaction or at least two-thirds of the outstanding voting capital
stock not owned by such large stockholder approve the merger or the transaction.
These provisions of Delaware law may have the effect of delaying, deferring or
preventing a change of control, and may discourage bids for our common stock at
a premium over its market price. In addition, our board of directors could rely
on these provisions of Delaware law to discourage, prevent or delay an
acquisition of us.
Item
1B. Unresolved Staff Comments
As of
December 31, 2008, we leased approximately 30,500 square feet of office space
through March 2011 for our field support and corporate headquarters in
Calabasas, California. Additionally, we leased 16,600 square
feet of office space for our field support offices in Blue Ash,
Ohio. As of December 31, 2008, we leased approximately 56,000 square
feet of office space through December 2016 at our VISTA headquarters in Salt
Lake City, Utah, and 48,200 square feet of office space through December 2015 at
our Oxford headquarters in Beverly, Massachusetts.
In addition,
we lease approximately 380,000 square feet of office space in
approximately 79 branch office locations in the United States, United
Kingdom, Netherlands, Belgium, Ireland and Canada. A branch office typically
occupies space ranging from approximately 1,000 to 3,000 square feet with lease
terms that typically range from six months to five years.
Item 3. Legal
Proceedings
|
|
Item
4. Submission of Matters to a Vote of Security
Holders
|
|
There were no
matters submitted to a stockholder vote during the fourth quarter of 2008.
Item
5. Market for Registrant’s Common Equity and Related Stockholder
Matters
|
|
Our
common stock trades on the NASDAQ Global Market under the symbol ASGN. The
following table sets forth the range of high and low sales prices as reported on
the NASDAQ Global Market for each quarterly period within the two most recent
fiscal years. At March 10, 2009, we had approximately 44 holders of
record, approximately 3,800 beneficial owners of our common stock
and 36,381,626 shares outstanding.
|
|
Price
Range of
Common
Stock
|
|
|
|
|
|
|
Year
Ended December 31, 2008
|
|
|
|
|
|
First
Quarter
|
|
$ |
6.98 |
|
|
$ |
4.32 |
Second
Quarter
|
|
$ |
8.82 |
|
|
$ |
6.26 |
Third
Quarter
|
|
$ |
9.70 |
|
|
$ |
7.26 |
Fourth
Quarter
|
|
$ |
7.92 |
|
|
$ |
4.05 |
|
|
|
|
|
|
|
|
Year
Ended December 31, 2007
|
|
|
|
|
|
|
|
First
Quarter
|
|
$ |
13.78 |
|
|
$ |
11.35 |
Second
Quarter
|
|
$ |
12.72 |
|
|
$ |
9.63 |
Third
Quarter
|
|
$ |
11.63 |
|
|
$ |
9.00 |
Fourth
Quarter
|
|
$ |
10.13 |
|
|
$ |
5.81 |
|
|
|
|
|
|
|
|
Since
inception, we have not declared or paid any cash dividends on our common stock,
and we currently plan to retain all earnings to support the development and
expansion of our business and we have no present intention of paying any
dividends on our common stock in the foreseeable future. However, the Board of
Directors periodically reviews our dividend policy to determine whether the
declaration of dividends is appropriate. In addition, the terms of the debt
agreement restrict our ability to pay dividends of more than $2.0 million per
year.
On
June 15, 2001, the Company’s Board of Directors authorized the repurchase
of up to 2,940,939 million shares of common stock. As of December 31, 2003,
the Company had repurchased 2,662,500 million shares of its common stock at a
total cost of $23.0 million. The Company did not repurchase any shares pursuant
to this authorization for the years ended December 31, 2004, 2005 or 2006.
In December 2007, the Company repurchased the remaining 278,439 million shares
of its common stock at a total cost of $2.0 million. At December 31, 2008,
the Company has no remaining authorization to repurchase
shares.
Stock
Performance Graph
The
following graph compares the performance of On Assignment’s common stock price
during the period from December 31, 2003 to December 31, 2008 with the composite
prices of companies listed on the NASDAQ Stock Market and of companies included
in the SIC Code No. 736—Personnel Supply Services Companies Index. The
companies listed in the SIC Code No. 736 include peer companies in the same
industry or line of business as On Assignment.
The graph
depicts the results of investing $100 in On Assignment’s common stock, the
NASDAQ Stock Market composite index and an index of the companies listed in the
SIC Code No. 736 on December 31, 2003 and assumes that dividends were reinvested
during the period.
The
comparisons shown in the graph below are based upon historical data, and we
caution stockholders that the stock price performance shown in the graph below
is not indicative of, nor intended to forecast, potential future
performance.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
On
Assignment, Inc.
|
|
$ |
108.83 |
|
|
$ |
134.55 |
|
|
$ |
225.33 |
|
|
$ |
209.41 |
|
|
$ |
99.62 |
|
|
$ |
100.00 |
SIC
Code No. 736 Index—Personnel Supply Services Company Index
|
|
$ |
61.44 |
|
|
$ |
94.15 |
|
|
$ |
127.21 |
|
|
$ |
101.09 |
|
|
$ |
97.70 |
|
|
$ |
100.00 |
NASDAQ
Stock Market Index
|
|
$ |
79.25 |
|
|
$ |
134.29 |
|
|
$ |
122.16 |
|
|
$ |
110.79 |
|
|
$ |
108.41 |
|
|
$ |
100.00 |
Item
6. Selected Financial Data
The
following table presents selected financial data of On Assignment as of, and for
the years ended December 31, 2008, 2007, 2006, 2005 and 2004. This selected
financial data should be read in conjunction with the consolidated financial
statements and notes thereto included under “Financial Statements and
Supplementary Data” in Part II, Item 8 of this report.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in
thousands, except per share data)
|
Income
Statement Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
$ |
618,058 |
|
|
$ |
567,180 |
|
|
$ |
287,566 |
|
|
$ |
237,856 |
|
|
$ |
193,574 |
Cost
of services
|
|
|
418,602 |
|
|
|
387,643 |
|
|
|
209,725 |
|
|
|
174,627 |
|
|
|
143,663 |
Gross
profit
|
|
|
199,456 |
|
|
|
179,537 |
|
|
|
77,841 |
|
|
|
63,229 |
|
|
|
49,911 |
Selling,
general and administrative expenses
|
|
|
155,942 |
|
|
|
151,942 |
|
|
|
67,900 |
|
|
|
64,135 |
|
|
|
66,695 |
Impairment
of intangibles
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
3,907 |
Impairment
of goodwill
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
26,421 |
Operating
income (loss)
|
|
|
43,514 |
|
|
|
27,595 |
|
|
|
9,941 |
|
|
|
(906 |
) |
|
|
(47,112) |
Interest
expense
|
|
|
(9,998 |
) |
|
|
(12,174 |
) |
|
|
(54 |
) |
|
|
— |
|
|
|
(7) |
Interest
income
|
|
|
715 |
|
|
|
1,394 |
|
|
|
1,698 |
|
|
|
681 |
|
|
|
402 |
Income
(loss) before income taxes
|
|
|
34,231 |
|
|
|
16,815 |
|
|
|
11,585 |
|
|
|
(225 |
) |
|
|
(46,717) |
Provision
(benefit) for income taxes
|
|
|
15,261 |
|
|
|
7,493 |
|
|
|
541 |
(2) |
|
|
(129 |
) |
|
|
(4,324) |
Net
income (loss)
|
|
$ |
18,970 |
|
|
$ |
9,322 |
|
|
$ |
11,044 |
|
|
$ |
(96 |
) |
|
$ |
(42,393) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings
(loss) per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$ |
0.53 |
|
|
$ |
0.27 |
|
|
$ |
0.41 |
|
|
$ |
(0.00 |
) |
|
$ |
(1.68) |
Diluted
|
|
$ |
0.53 |
|
|
$ |
0.26 |
|
|
$ |
0.39 |
|
|
$ |
(0.00 |
) |
|
$ |
(1.68) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number of shares used to calculate earnings (loss) per
share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
35,487 |
|
|
|
35,138 |
|
|
|
27,155 |
|
|
|
25,464 |
|
|
|
25,231 |
Diluted
|
|
|
35,858 |
|
|
|
35,771 |
|
|
|
28,052 |
|
|
|
25,464 |
|
|
|
25,231 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
Sheet Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash,
cash equivalents, restricted cash and current portion of marketable
securities
|
|
$ |
46,271 |
|
|
$ |
37,764 |
|
|
$ |
110,161 |
|
|
$ |
25,365 |
|
|
$ |
22,787 |
Working
capital
|
|
|
91,192 |
|
|
|
79,009 |
|
|
|
135,501 |
|
|
|
47,629 |
|
|
|
40,957 |
Total
assets
|
|
|
401,850 |
|
|
|
384,680 |
|
|
|
186,995 |
|
|
|
93,705 |
|
|
|
92,382 |
Long-term
liabilities
|
|
|
129,805 |
|
|
|
140,803 |
|
|
|
627 |
|
|
|
70 |
|
|
|
222 |
Stockholders’
equity
|
|
|
218,514 |
|
|
|
193,034 |
|
|
|
165,944 |
|
|
|
76,637 |
|
|
|
74,471 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)Our
working capital at December 31, 2008 was $91.2 million including $46.3 million
in cash and cash equivalents. On January 3, 2007, we acquired VISTA Staffing
Solutions, Inc., and on January 31, 2007, we acquired Oxford Global
Resources, Inc. The Oxford acquisition was completed by utilizing our
existing cash and the proceeds from a new $165 million senior secured credit
facility. For further discussion regarding our credit facility, see Note 4
to our Consolidated Financial Statements appearing in Part II, Item 8 of this
report.
(2) In
2006, there was a reversal of the valuation allowance of $4.9 million that was
recorded against our net deferred income tax assets in 2004 and 2005. Of
the $4.9 million valuation allowance reversal, $4.3 million resulted in an
income tax benefit and $0.6 million was recorded as an increase to additional
paid-in capital resulting from stock option deductions realized in
2006.
This
discussion contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended. Such statements are based
upon current expectations that involve risks and uncertainties. Any statements
contained herein that are not statements of historical fact may be deemed to be
forward-looking statements. For example, the words “believes,” “anticipates,”
“plans,” “expects,” “intends” and similar expressions that convey uncertainty of
future events or outcomes are forward-looking statements. Forward-looking
statements include statements regarding our anticipated financial and operating
performance for future periods. Our actual results could differ materially from
those discussed or suggested in the forward-looking statements herein. Factors
that could cause or contribute to such differences or prove our forward-looking
statements, by hindsight, to be overly optimistic or unachievable include, but
are not limited to, the following:
·
|
actual
demand for our services;
|
·
|
our
ability to attract, train, and retain qualified staffing
consultants;
|
·
|
our
ability to remain competitive in obtaining and retaining temporary
staffing clients;
|
·
|
the
availability of qualified temporary nurses and other qualified contract
professionals;
|
·
|
our
ability to manage our growth efficiently and effectively;
and
|
·
|
continued
performance of our information
systems.
|
For a
discussion of these and other factors that may impact our realization of our
forward-looking statements, see “Business—Risk Factors” within Item 1A of
Part I of this Annual Report on Form 10-K. Other factors may also
contribute to the differences between our forward-looking statements and our
actual results. In addition, as a result of these and other factors, our past
financial performance should not be relied on as an indication of future
performance. All forward-looking statements in this document are based on
information available to us as of the date we file this Annual Report on Form
10-K, and we assume no obligation to update any forward-looking statement or the
reasons why our actual results may differ.
On
Assignment, Inc. is a diversified professional staffing firm providing flexible
and permanent staffing solutions in specialty skills including
Laboratory/Scientific, Healthcare/Nursing, Physicians, Medical Financial,
Information Technology and Engineering. We provide clients in these markets with
short-term or long-term assignments of contract professionals,
contract-to-permanent placement and direct placement of these professionals. Our
business currently consists of four operating segments: Life Sciences,
Healthcare, Physician, and IT and Engineering.
Consolidated
revenues increased 9.0 percent to $618.1 million in 2008 from $567.2
million in the previous year. Consolidated gross margin improved 62 basis points
to 32.3 percent from 31.7 percent in 2007 and gross profit increased 11.1
percent to $199.5 million from $179.5 million in 2007.
Despite
the weakening of the U.S. economy in the latter end of 2008, we were able
to grow our revenues and expand our gross margin in 2008. However,
key indicators of demand have weakened (i.e. permanent placement and
conversion revenues, number of new assignments and/or terminations, bill/pay
spread, amount of time it takes customers to make a hiring decision on a
qualified candidate and the number of billable hours per
contract professional). We do not expect to see a dramatic improvement in
demand for our services in 2009. However, we do believe our continued focus
on items that are within our control (i.e., certain factors impacting gross
margins, selling, general and administrative (SG&A) expense management
and cash generation) has us well positioned to confront the current economic
environment. We remain cautious going into 2009 given the seasonality
of our business, as discussed below, as well as the challenging economic
environment in which we are currently operating. Our Healthcare,
Physician and IT and Engineering segments experienced increased demand in 2008,
yet demand weakened in the fourth quarter for our Healthcare and IT and
Engineering segments. The demand for services in our Life Sciences
segment, which is perhaps most related to the general economic conditions,
weakened in 2008.
The
initiatives undertaken during the last several years have been key to the growth
in revenues and profitability experienced in 2008. In January of
2007, we acquired VISTA Staffing Solutions, Inc. (VISTA), a privately-owned
leading provider of physician staffing, known as locum tenens, and permanent
physician search services and Oxford Global Resources, Inc. (Oxford), a leading
provider of high-end information technology and engineering staffing services.
In 2008, we focused on assisting the newly acquired Physician and IT and
Engineering segments to continue to perform while integrating with and operating
as a part of On Assignment.
During
the past three years, we focused on diversifying our client mix in the
Healthcare segment through the expansion of our client base. We made
significant progress in
further
strengthening the sales force through the hiring of seasoned professionals with
staffing industry experience and committing more resources to our newer services
lines, local nursing, health information management, clinical research and our
two new acquired segments: Physician and IT and Engineering.
Demand
for our staffing services historically has been lower during the first and
fourth quarters due to fewer business days resulting from client shutdowns,
adverse weather conditions and a decline in the number of contract professionals
willing to work during the holidays. As is common in the staffing industry, we
run special incentive programs to keep our contract professionals, particularly
nurses, working through the holidays. Demand for our staffing services usually
increases in the second and third quarters of the year. In addition, our cost of
services typically increases in the first quarter primarily due to the reset of
payroll taxes.
Results
of Operations
The
following table summarizes, for the periods indicated, selected income statement
data expressed as a percentage of revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
|
100.0 |
% |
|
|
100.0 |
% |
|
|
100.0 |
% |
Cost
of services
|
|
|
67.7 |
|
|
|
68.3 |
|
|
|
72.9 |
|
Gross
profit
|
|
|
32.3 |
|
|
|
31.7 |
|
|
|
27.1 |
|
Selling,
general and administrative expenses
|
|
|
25.2 |
|
|
|
26.8 |
|
|
|
23.6 |
|
Operating
income
|
|
|
7.1 |
|
|
|
4.7 |
|
|
|
3.5 |
|
Interest
expense
|
|
|
(1.6 |
) |
|
|
(1.9 |
) |
|
|
0.0 |
|
Interest
income
|
|
|
0.1 |
|
|
|
0.2 |
|
|
|
0.5 |
|
Income
before income taxes
|
|
|
5.6 |
|
|
|
3.0 |
|
|
|
4.0 |
|
Provision
for income taxes
|
|
|
2.5 |
|
|
|
1.4 |
|
|
|
0.2 |
|
Net
income
|
|
|
3.1 |
% |
|
|
1.6 |
% |
|
|
3.8 |
% |
CHANGES
IN RESULTS OF OPERATIONS FOR THE YEAR ENDED DECEMBER 31, 2008
|
|
COMPARED
WITH THE YEAR ENDED DECEMBER 31, 2007
|
|
Revenues.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
|
|
|
% |
|
Revenues
by segment (in thousands):
|
|
|
|
Life
Sciences
|
|
$ |
129,483 |
|
|
$ |
134,622 |
|
|
$ |
(5,139 |
) |
|
|
(3.8 |
%) |
Healthcare
|
|
|
180,671 |
|
|
|
175,079 |
|
|
|
5,592 |
|
|
|
3.2 |
% |
Physician
|
|
|
89,217 |
|
|
|
74,599 |
|
|
|
14,618 |
|
|
|
19.6 |
% |
IT
and Engineering
|
|
|
218,687 |
|
|
|
182,880 |
|
|
|
35,807 |
|
|
|
19.6 |
% |
Total
Revenues
|
|
$ |
618,058 |
|
|
$ |
567,180 |
|
|
$ |
50,878 |
|
|
|
9.0 |
% |
Revenues
increased $50.9 million, or 9.0 percent as a result of growth in our
Healthcare, Physician, IT and Engineering segments. The growth was due to both
demand in our end markets, as well as an expanded and more experienced sales and
fulfillment team. In the latter
half of 2007, we made management changes and realigned certain geographic
markets in our Healthcare segment in order to generate higher revenue
growth. The 2008 period included twelve months of activity from the IT and
Engineering segment, as opposed to only eleven months in the 2007
period.
Life
Sciences segment revenues decreased $5.1 million, or 3.8 percent.
The decrease in revenues was primarily attributable to a 9.8 percent
decrease in the average number of contract professionals on assignment, a $0.6
million, or 28.3 percent, decrease in conversion fee revenues and the
deteriorating foreign exchange rate for the British Pound and the Euro combined
with a deepening recession in the United Kingdom and the United
States. These decreases were partially offset by a 5.4 percent
increase in the average bill rate and a $0.2 million increase in permanent
placement fees. The year-over-year decrease in revenues is a direct result of
our clients’ decisions to focus more
on cost
containment than on completing projects, developing new products or enhancing
existing product lines during this challenging economic period.
The
overall increase in Healthcare segment revenues, which include our Nurse Travel
and Allied Healthcare lines of business, consisted of an increase in both the
Nurse Travel and Allied Healthcare lines of business revenues. Nurse Travel
revenues increased $5.3 million, or 4.4 percent, to $125.1 million. The increase
in revenues was primarily attributable to a 4.0 percent increase in the average
number of nurses on assignment, as well as a 2.9 percent increase in the average
bill rate. The Nurse Travel revenues in 2008 also included $2.4 million related
to supporting a long standing customer that experienced a labor disruption. The
Nurse Travel results include a decrease in revenues derived from hospitals that
experienced labor disruptions, which for the year ended December 31, 2007 were
$2.8 million. Allied Healthcare revenues increased $0.3 million, or
0.6 percent due to a 4.8 percent increase in the average bill rate and an
increase in billable expenses, partially offset by a 6.7 percent decrease in the
average number of contract professionals on assignment. In addition, direct hire
revenues in the Allied Healthcare line of business decreased $0.2 million, or
13.5 percent.
Physician
segment revenues increased $14.6 million, or 19.6 percent. The increase in
revenues in 2008 was primarily due to an 11.2 percent increase in the
average number of contract professionals on assignment as well as a 7.3 percent
increase in the average bill rate as a result of a strong demand environment as
a result of a growing shortage of physicians.
The IT
and Engineering segment revenues increased $35.8 million, or 19.6 percent. The
increase in revenue was primarily due to a 7.3 percent increase in the average
number of contract professionals on assignment, a 3.5 percent increase in the
average bill rate as well as an increase in conversion and direct hire fee
revenue and billable expenses. In addition, revenues for 2007 only included
eleven months of results because the Company completed its acquisition of Oxford
on January 31, 2007.
Gross
Profit and Gross Margins.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
Profit by segment (in thousands):
|
|
|
|
Life
Sciences
|
|
$ |
43,502 |
|
|
|
33.6 |
% |
|
$ |
45,024 |
|
|
|
33.4 |
% |
Healthcare
|
|
|
46,265 |
|
|
|
25.6 |
% |
|
|
44,269 |
|
|
|
25.3 |
% |
Physician
|
|
|
27,369 |
|
|
|
30.7 |
% |
|
|
21,808 |
|
|
|
29.2 |
% |
IT
and Engineering
|
|
|
82,320 |
|
|
|
37.6 |
% |
|
|
68,436 |
|
|
|
37.4 |
% |
Total
Gross Profit
|
|
$ |
199,456 |
|
|
|
32.3 |
% |
|
$ |
179,537 |
|
|
|
31.7 |
% |
The
year-over-year gross profit increase was due to growth in revenues in the IT and
Engineering, Physician and Healthcare segments and a 62 basis point expansion in
consolidated gross margin. The expansion in gross margin was primarily
attributable to increases in margins in the Physician and Healthcare segments
and to a higher proportion of revenues from the IT and Engineering segment,
which has higher gross margins than the other segments. The 2008
period included twelve months of reportable activity from the IT and Engineering
segment as compared with only eleven months in the 2007 period.
Life
Sciences segment gross profit decreased $1.5 million, or 3.4 percent. The
decrease in gross profit was primarily due to a 3.8 percent decrease in the
segment revenues partially offset by an increase of 16 basis points in gross
margin. The increase in gross margin was predominantly due to a 7.1 percent
increase in bill/pay spread as a result of our continued focus on pricing
policies and increased direct hire revenues.
Healthcare
segment gross profit increased $2.0 million, or 4.5 percent. The increase in
gross profit was due to a 3.2 percent increase in the segment revenues and an
increase in gross margin. Gross margin for the segment increased 32 basis points
due to an increase in the bill/pay spread, partially offset by an increase in
other contract employee expenses. This segment includes gross profit from the
Nurse Travel and Allied Healthcare lines of business. Allied Healthcare gross
profit increased 0.7 percent and gross margin increased 2 basis points while
Nurse Travel gross profit increased 7.0 percent and gross margin increased 57
basis points. Gross margins in the first quarter of a year tend to be lower than
the fourth quarter of the preceding year due to the reset of certain payroll
taxes.
Physician
segment gross profit increased $5.6 million, or 25.5 percent. The increase in
gross profit was primarily attributable to a 19.6 percent increase in revenues
as well as an increase in gross margin. Gross margin for the segment increased
145 basis points primarily due to an increase in bill/pay spread, partially
offset by increased medical malpractice expense. The segment began
adjusting bill rates simultaneously with adjustments in the pay
rates
when possible which positively impacted the bill/pay spread in
2008.
IT and
Engineering segment gross profit increased $13.9 million, or 20.3 percent,
primarily due to a 19.6 percent increase in revenues, as the 2008 period
included twelve months of reportable activity versus eleven months in 2007, as
well as an increase in gross margin for the segment. Gross margin for the
segment increased 22 basis points, primarily due to an increase in bill/pay
spread and a $0.8 million, or 83.7 percent increase in conversion fee revenue,
partially offset by a $3.2 million, or 31.0 percent increase in other contract
employment expenses. As with our other divisions, to the extent we employ
contract professionals, we may see lower gross margins in the first quarter of
2009 due to the reset of certain payroll taxes.
Selling,
General and
Administrative Expenses. SG&A
expenses include field operating expenses, such as costs associated with our
network of staffing consultants and branch offices for our Life Sciences segment
and our Allied Healthcare lines of business, including staffing consultant
compensation, rent and other office expenses, as well as marketing and
recruiting for our contract professionals. Nurse Travel SG&A expenses
include compensation for regional sales directors, account managers and
recruiters, as well as rent and other office expenses and marketing for
traveling nurses. SG&A expenses from our Physician and IT and Engineering
segments include compensation for sales personnel, as well as rent and other
office expenses and marketing for these segments. SG&A expenses also include
our corporate and branch office support expenses, such as the salaries of
corporate operations and support personnel, recruiting and training expenses for
field staff, marketing staff expenses, rent, expenses related to being a
publicly-traded company and other general and administrative
expenses.
SG&A
expenses increased $4.0 million, or 2.6 percent, to $155.9 million from $151.9
million. The increase in SG&A was primarily due to a $10.2 million increase
in compensation and benefits as a result of increased revenues, and SG&A
expenses of the IT and Engineering segment being included for twelve months in
2008 compared to only eleven months in 2007. The increase
in SG&A expense was partially offset by a $7.0 million decrease in
depreciation and amortization expenses, primarily related to a reduction of the
amortization amount for other intangibles in 2008. Total SG&A as a
percentage of revenues decreased to 25.2 percent in the 2008 period from
26.8 percent in the 2007 period, primarily due to decreased depreciation
and amortization expense. Going forward, we will continue to manage our SG&A
closely and do not expect any significant changes.
Interest
expense and interest
income. Interest expense was $10.0 million and $12.2 million for
the years ended December 31, 2008 and 2007, respectively. The decrease
in interest expense was primarily due to lower average debt balances in 2008 due
to $9.7 million principal payments in 2007, and a decrease in average interest
rates during 2008. On December 31, 2008 and 2007, the value of our interest
rate swap was marked-to-market, and we recorded a loss of $0.1 million and $1.2
million, respectively, for the years then ended, which is shown in interest
expense, and the related liability of $1.3 million and $1.2 million,
respectively, is included in the Consolidated Balance Sheets in other current
liabilities.
Interest
income was $0.7 million and $1.4 million for the years ended December 31, 2008
and 2007, respectively. Interest income in the current period was also lower due
to lower average interest rates in 2008.
Provision for
Income Taxes. The provision for income taxes was $15.3 million for the
year ended December 31, 2008 compared to $7.5 million for the
same period in the prior year. The annual effective tax rate was 44.6 percent
for 2008 and 2007.
CHANGES
IN RESULTS OF OPERATIONS FOR THE YEAR ENDED DECEMBER 31, 2007
|
|
COMPARED
WITH THE YEAR ENDED DECEMBER 31, 2006
|
|
Revenues.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
|
|
|
%
|
|
Revenues
by segment (in thousands):
|
|
|
|
Life
Sciences
|
|
$ |
134,622 |
|
|
$ |
117,462 |
|
|
$ |
17,160 |
|
|
|
14.6 |
% |
Healthcare
|
|
|
175,079 |
|
|
|
170,104 |
|
|
|
4,975 |
|
|
|
2.9 |
% |
Physician
(from January 3, 2007)
|
|
|
74,599 |
|
|
|
― |
|
|
|
74,599 |
|
|
|
N/A |
|
IT
and Engineering (from January 31, 2007)
|
|
|
182,880 |
|
|
|
― |
|
|
|
182,880 |
|
|
|
N/A |
|
Total
Revenues
|
|
$ |
567,180 |
|
|
$ |
287,566 |
|
|
$ |
279,614 |
|
|
|
97.2 |
% |
Consolidated year-over-year revenue
growth was primarily attributable to the acquisitions of VISTA and Oxford,
completed on January 3, 2007 and January 31, 2007, respectively, and included
revenues from their respective date of acquisition. We also experienced organic
growth in our Life Sciences and Healthcare segments. These organic results were
due to both demand in our end markets as well as an expanded and more
experienced sales and fulfillment team. Our Healthcare segment revenues began to
slow in the latter half of the year, driven by slower than expected progress in
replacing a large account that closed its acute care facility following its
failure to gain government certification, our reduction in placements at another
large customer due to pricing, as well as a generally lackluster Nurse Travel
end market. We made management changes and realigned certain geographic markets
to facilitate generating a better growth rate in the segment on a go-forward
basis. We continued to focus on the growth of our established product lines as
well as our newer product lines, including Health Information Management,
Clinical Research, Engineering, Local Nursing, Physician, IT and Engineering,
and further development of our direct hire business.
Revenues
increased $279.6 million or 97.2 percent, from $287.6 million to $567.2 million.
This increase was due in great part because of the acquisitions of VISTA and
Oxford, which accounted for $257.5 million of the increase. In addition,
conversion and direct hire fee revenues increased $4.9 million, or
75.2 percent, from $6.6 million, or 2.3 percent of revenue to $11.5
million, or 2.0 percent of revenue. This was a result of more contract
professionals being converted into or hired directly as permanent employees in
our legacy businesses, accounting for $2.0 million of the increase, as well as
from conversion and direct hire fee revenues generated in the newly acquired
Physician and IT and Engineering segments, which accounted for $3.0 million of
the increase. Continued development of the direct hire business had a favorable
impact on our operating results and remained a focus of management.
Life
Sciences segment revenues increased $17.2 million, or 14.6 percent, from $117.5
million to $134.6 million. The increase in revenues was primarily attributable
to a 7.6 percent increase in average bill rates, or approximately $9.0 million,
as well as a 5.0 percent increase in the average number of contract
professionals on assignment, or approximately $5.9 million. In addition,
conversion and direct hire fee revenues increased $1.2 million, or 22.3 percent,
from $5.5 million to $6.7 million. Our newer service line offerings, Clinical
Research and Engineering, continued to grow by generating a larger number of
higher-level, higher-revenue placements during 2007 than 2006, with a 17.7
percent increase in contract professionals placed in 2007 than in
2006.
The
overall increase in Healthcare segment revenues, which included our Nurse Travel
and Allied Healthcare lines of business, resulted from an increase in revenues
generated by the Allied Healthcare line of business while the Nurse Travel line
remained relatively flat for the period. Healthcare
segment revenues increased $5.0 million, or 2.9 percent, from $170.1 million to
$175.1 million. Allied Healthcare revenues increased $4.7 million, or 9.4
percent, from $50.5 million to $55.2 million. The increase in revenues was
primarily attributable to a 13.0 percent increase in the average number of
contract professionals on assignment, or approximately $6.5 million, as well as
a 67.6 percent increase in conversion and direct hire fee revenues from $1.1
million to $1.9 million. The increase was offset by a 6.6 percent decrease in
hours worked per contract professional, or approximately $5.0 million. Nurse
Travel revenues increased $0.2 million, or 0.2 percent, from $119.6 million to
$119.8 million. The slight increase in Nurse Travel revenues was due to a 1.0
percent increase in the average bill rate, offset by a 2.6 percent decrease in
average hours worked per nurse and a 0.4 percent decrease in average contract
professionals on assignment.
Physician
segment revenues, which consisted of the recently acquired VISTA, were $74.6
million for the year ended December 31, 2007. Physician segment revenue was 13.2
percent of total revenue for the year ended December 31, 2007. The Physician
segment had fourth quarter 2007 revenues of $19.4 million, an increase of 14.6
percent over the pro-forma fourth quarter revenue of 2006.
IT and
Engineering segment revenues, which consisted of the recently acquired Oxford,
were $182.9 million for the year ended December 31, 2007. IT and Engineering
segment revenue was 32.2 percent of total revenue for the year ended December
31, 2007. The IT and Engineering segment revenues for the fourth quarter of 2007
were $53.3 million, an increase of 16.1 percent over the pro-forma fourth
quarter of 2006.
Gross Profit and Gross
Margins.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
Profit by segment (in thousands):
|
|
|
Life
Sciences
|
|
$ |
45,024 |
|
|
|
33.4 |
% |
|
$ |
38,143 |
|
|
|
32.5 |
% |
Healthcare
|
|
|
44,269 |
|
|
|
25.3 |
% |
|
|
39,698 |
|
|
|
23.3 |
% |
Physician
(from January 3, 2007)
|
|
|
21,808 |
|
|
|
29.2 |
% |
|
|
― |
|
|
|
N/A |
|
IT
and Engineering (from January 31, 2007)
|
|
|
68,436 |
|
|
|
37.4 |
% |
|
|
― |
|
|
|
N/A |
|
Total
Gross Profit
|
|
$ |
179,537 |
|
|
|
31.7 |
% |
|
$ |
77,841 |
|
|
|
27.1 |
% |
Gross
profit increased $101.7 million from $77.8 million to $179.5 million. Gross
margins increased 460 basis points from 27.1 percent to 31.7 percent. On a
consolidated basis, gross profit and gross margins increased significantly due
the acquisitions of VISTA and Oxford completed on January 3, 2007 and January
31, 2007, respectively, and included gross profit from their respective date of
acquisition. The 460 basis point increase in consolidated gross margin year over
year was largely attributable to the 37.4 percent gross margin earned in the IT
and Engineering segment, which consists entirely of the Oxford acquisition.
Additionally, we experienced margin improvement in both of our historical
segments, Life Sciences and Healthcare.
Life
Sciences segment gross profit increased due to an increase in revenues and
improved gross margin. Gross margins for the segment increased 90 basis points
from 32.5 percent to 33.4 percent. The Life Sciences segment gross margin
increase was primarily related to lower workers’ compensation expense, an
increased bill/pay spread and increased direct hire and conversion fee revenues.
Direct hire and conversion fee revenues increased $1.2 million, or 22.3 percent,
from $5.5 million to $6.7 million. Increases in direct hire and conversion fee
revenues had a positive impact on gross margin as there are no associated costs
of services. Gross margins in the first quarter of a year tend to be lower than
the fourth quarter of the preceding year due to the reset of certain payroll
taxes.
Healthcare
segment gross profit increased due to an increase in revenues and improved gross
margin. This segment includes gross profit from the Nurse Travel and Allied
Healthcare lines of business. Gross margin for the segment increased 200 basis
points from 23.3 percent to 25.3 percent. The increase was primarily
related to an increase in the bill/pay spread, reduced housing and travel costs,
lower workers’ compensation expense and increased direct hire and conversion fee
revenues, partially offset by an increase in temporary employee per diem
expense. Direct hire and conversion fee revenues in the Allied Healthcare line
of business increased $0.7 million, or 67.6 percent, from $1.1 million to $1.9
million. Gross margins in the first quarter of a year tend to be lower than the
fourth quarter of the preceding year due to the reset of certain payroll
taxes.
Gross
margins in our Physician and IT and Engineering segments were 29.2 percent and
37.4 percent, respectively, for the year ended December 31, 2007, and as
with our other divisions to the extent we employ contract professionals we may
see lower gross margins in the first quarter due to the reset of certain payroll
taxes.
Selling, General
and Administrative Expenses. SG&A expenses increased $84.0
million, or 123.8 percent, from $67.9 million to $151.9 million. The primary
reason for the increase was the acquisitions of VISTA and Oxford in the first
quarter of 2007. SG&A expenses for VISTA and Oxford were $19.4 million and
$57.5 million, respectively. In addition to expenses related to increased sales
headcount and corporate support personnel associated with the acquisitions, the
amortization of intangible assets acquired caused an increase in amortization
expense from $1.0 million to $15.3 million. Additionally, stock-based
compensation expense was $3.0 million versus $6.4 million.
Total
SG&A as a percentage of revenues increased from 23.6 percent to 26.8
percent, primarily due to increased amortization expense related to the
acquisition of VISTA and Oxford.
Interest
expense and interest
income.
Interest expense was $54,000 and $12.2 million for the years ended
December 31, 2006 and 2007, respectively. The increase in interest expense was
due to the new $165.0 million senior secured credit facility we entered into on
January 31, 2007. On December 31, 2007, the value of our interest rate swap was
marked-to-market, and we recorded a loss of $1.2 million for the year then
ended, which is shown in interest expense, and the related liability of $1.2
million is included in the Consolidated Balance Sheets in other current
liabilities.
Interest
income was $1.7 million and $1.4 million for the years ended December 31, 2006
and 2007, respectively. Interest income was lower due to a lower average
cash balance in 2007 versus 2006. Average interest rates were marginally higher
in the 2007 period versus the 2006 period.
Provision for Income
Taxes. The provision for income taxes increased from $0.5 million for the
year ended December 31, 2006 to $7.5 million for the year ended December 31,
2007. For the year ended December 31, 2007, we recorded a tax provision based on
an annual effective tax rate of approximately 44.6 percent while our effective
rate was 4.7 percent for the year ended December 31, 2006. The difference in our
effective tax rate for the year ended December 31, 2006 as compared with the
corresponding period in 2007 was primarily due to the reversal in 2006 of the
valuation allowance of $4.9 million that was recorded against our net deferred
income tax assets in 2004 and 2005. Of the $4.9 million valuation allowance
reversal, $4.3 million resulted in an income tax benefit and $0.6 million was
recorded as an increase to additional paid-in capital resulting from stock
option deductions realized in the 2006 period.
Liquidity
and Capital Resources
Our
working capital at December 31, 2008 was $91.2 million, including $46.3 million
in cash and cash equivalents. Our operating cash flows have been our primary
source of liquidity and historically have been sufficient to fund our working
capital and capital expenditure needs. Our working capital requirements consist
primarily of the financing of accounts receivable, payroll expenses and the
required periodic payments of principal and interest on our term loan. We do not
currently pay cash dividends on our outstanding common stock and do not intend
to pay cash dividends for the foreseeable future.
Net cash
provided by operating activities was $35.4 million for the year ended December
31, 2008 compared with $33.7 million in the same period in 2007. The
increase in net cash provided by operating activities was primarily due to the
increase in net income, adjusted to exclude the effect of non-cash charges
including a decrease in depreciation and amortization due to a reduction of the
amortization for other intangibles in 2008, offset by an increase in prepaid
income taxes due to increased operating results and an increase in the medical
malpractice provision due to increased claim activity.
Net cash
used in investing activities decreased to $17.7 million in the year ended
December 31, 2008 from $234.0 million in the same period in 2007, primarily due
to our acquisitions of Oxford and VISTA in 2007. Capital expenditures
related to information technology projects, leasehold improvements and various
property and equipment purchases for the year ended December 31, 2008 totaled
$8.2 million, compared with $5.9 million in the comparable 2007 period. The
increase in capital expenditures in 2008 primarily related to the conversion of
the Nurse Travel line of business to RecruitMax and PeopleSoft in the fourth
quarter of 2008. We expect capital expenditures to be approximately $6.0 million
for 2009.
Net cash
used in financing activities was $8.4 million for the year ended December 31,
2008 compared with net cash provided by financing activities of $132.1 million
for the same period in 2007. The significant source of cash provided
by financing activities in 2007 was due to borrowing activity related to the
proceeds from the $145.0 million term loan facility.
During
2008, we used $10.0 million to pay down our term loan facility to $125.9
million. This payment was sufficient to cover the excess cash flow payment
required by the bank as well as all minimum quarterly payments for the next four
years through 2012. The term loan facility matures on January 13,
2013, at which time we expect the facilities to be renewed. Under terms of the
credit facility, we are required to maintain certain financial covenants,
including a minimum total leverage ratio, a minimum interest coverage ratio and
a limitation on capital expenditures. In addition, the terms of the credit
facility restrict the Company’s ability to pay dividends of more than $2.0
million per year. As of December 31, 2008, we were in compliance with all such
covenants. The maximum total leverage ratio, which measures the ratio of total
debt to trailing twelve months consolidated earnings before interest, taxes,
depreciation and amortization of identifiable intangible assets, as defined in
the agreement, decreases to 1.25 from 2.0 for the twelve months ended
September 30, 2009. Based on our current operating plan, we believe
we will be in compliance with the covenants contained in our term loan
facility. However, such compliance will likely require us to prepay a
portion of our term loan prior to September 30, 2009 depending on our operating
results. If the economy continues to worsen, it may impact our
ability to meet these covenants. In order to avoid possible compliance issues
related to maximum leverage later in 2009, we will seek an amendment to increase
the permitted leverage under our term loan facility.
In April
2008, we paid the earn-outs related to the 2007 operating performance of VISTA
and Oxford acquisitions. As of December 31, 2008, we have accrued
$5.3 million and $4.8 million for the payment of the earn-outs related to the
2008 operating performance of VISTA and Oxford, respectively. We also filed for
claims indemnifiable by the selling shareholders of VISTA for $1.4 million,
which was recorded as a decrease to goodwill and an increase in other current
assets as of December 31, 2008. Payment of these earn-outs and claim
indemnification is tentatively scheduled for April 2009, pending the
agreement of all applicable parties to all terms and provisions related to such
payments.
We continue
to make progress on enhancements to our front-office and back-office information
systems. These
enhancements include the consolidation of back-office systems across all
corporate functions, as well as enhancements to and broader application of our
front-office software across all lines of business. The timing of the full
integration of information systems used by VISTA and Oxford will remain a
consideration of management.
Under our
previously board-approved stock repurchase program, we repurchased 2,940,939
shares of our common stock at a total cost of $25.0 million through 2007. As of
December 31, 2007, we had no remaining authorization to repurchase
shares.
During
2008, certain stock-based awards issued under our approved stock option plan
vested. Under the provisions of this plan, a portion of the vested shares were
withheld by us in order to satisfy minimum payroll tax obligations of the
employee. The vested shares withheld have been recorded as treasury stock, a
reduction to stockholder’s equity, at the fair market value on the date that the
tax obligation was determined, which was also the vesting date of the awards. As
of December 31, 2008, there were 156,425 shares withheld related to stock-based
awards and included in treasury stock at a fair-market value of $1.4
million.
We
believe that our working capital as of December 31, 2008, our credit facility
and positive operating cash flows expected from future activities will be
sufficient to fund future requirements of our debt obligations, accounts payable
and related payroll expenses as well as capital expenditure initiatives for the
next twelve months.
Commitments
and Contingencies
We lease
space for our corporate and branch offices. Rent expense was $9.5 million in
2008, $8.8 million in 2007 and $5.1 million in 2006.
The following
table sets forth, on an aggregate basis, at December 31, 2008, the amounts
of specified contractual cash obligations required to be paid in the periods
shown (in thousands):
Contractual Obligations
|
|
2009
|
|
|
2010
|
|
|
2011
|
|
|
2012
|
|
|
2013
|
|
|
Thereafter
|
|
|
Total
|
Long-term
debt
|
|
$ |
― |
|
|
$ |
― |
|
|
$ |
― |
|
|
$ |
― |
|
|
$ |
125,913 |
|
|
$ |
― |
|
|
$ |
125,913 |
Operating
lease obligations
|
|
|
6,426 |
|
|
|
5,456 |
|
|
|
3,420 |
|
|
|
2,011 |
|
|
|
1,512 |
|
|
|
3,757 |
|
|
|
22,582 |
Accrued
earn-out payments
|
|
|
10,168 |
|
|
|
― |
|
|
|
― |
|
|
|
― |
|
|
|
― |
|
|
|
― |
|
|
|
10,168 |
Total
|
|
$ |
16,594 |
|
|
$ |
5,456 |
|
|
$ |
3,420 |
|
|
$ |
2,011 |
|
|
$ |
127,425 |
|
|
$ |
3,757 |
|
|
$ |
158,663 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For
additional information about these contractual cash obligations, see Note 7
to our Consolidated Financial Statements appearing in Part II, Item 8
of this report. Interest payments related to our bank debt are not set forth in
the table above.
We have
accrued $5.3 million and $4.8 million for the estimated payment of the earn-outs
related to the 2008 operating performance of VISTA and Oxford,
respectively. These costs have been included in the Consolidated
Balance Sheets in Part II, Item 8 of this report in accrued
earn-out payments. We also filed for claims indemnifiable by the selling
shareholders of VISTA for $1.4 million, which was recorded as a decrease to
goodwill and an increase in other current assets as of December 31,
2008. Payment of the earn-outs and claim indemnification is
tentatively scheduled for April 2009, pending the agreement of all applicable
parties to all terms and provisions related to such payments.
We are
partially self-insured for our workers' compensation liability related to the
Life Sciences, Healthcare and IT and Engineering segments as well as its medical
malpractice liability in relation to the Physician segment. In connection with
this program, we pay a base premium plus actual losses incurred up to certain
levels and are insured for losses greater than certain levels per occurrence and
in the aggregate. The self-insurance claim liability is determined based on
claims filed and claims incurred but not yet reported. We account for claims
incurred but not yet reported based on estimates derived from historical claims
experience and current trends of industry data. Changes in estimates,
differences in estimates and actual payments for claims are recognized in the
period that the estimates changed or payments were made. The self-insurance
claim liability was approximately $9.8 million and $8.9 million at
December 31, 2008 and 2007, respectively. Additionally, we
have letters of credit outstanding to secure obligations
for workers’ compensation claims with various insurance
carriers. The letters of credit outstanding at December 31, 2008 and
2007 were $3.5 million and $4.4 million, respectively.
As of
December 31, 2008 and 2007, we have an income tax reserve in other
long-term liabilities related to our uncertain tax positions of $0.3
million.
We are
involved in various other legal proceedings, claims and litigation arising in
the ordinary course of business. However, based on the facts currently
available, we do not believe that the disposition of matters that are pending or
asserted will have a material adverse effect on our financial
position.
Off-Balance
Sheet Arrangements
As of
December 31, 2008, the Company had no significant off-balance sheet
arrangements other than operating leases and letters of credit
outstanding.
Recent
Accounting Pronouncements
|
|
In
September 2006, the Financial Accounting Standards Board (FASB) adopted SFAS No.
157, “Fair Value Measurements” (SFAS 157). SFAS 157 defines fair
value, establishes a framework for measuring fair value in accordance with GAAP
and expands disclosures about fair value measurements. While SFAS 157 did not
impact the Company’s valuation methods, it expanded disclosures of assets and
liabilities that are recorded at fair value. SFAS 157 was effective for
financial statements issued for years beginning after November 15, 2007 and
interim periods within those years. The Company adopted this standard on January
1, 2008, and the adoption did not have a material impact on the results of
operations, financial position or cash flows. See Note 12 to our Consolidated
Financial Statements appearing in Part II, Item 8 of this report for the related
disclosure. We are in the process of evaluating the
previously-deferred provisions of SFAS 157, which was effective on January 1,
2009, for non-financial assets and liabilities recorded at fair value and the
impact on our consolidated financial position or results of
operations.
In
February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for
Financial Assets and Financial Liabilities.” This Statement permits entities to
choose to measure many financial instruments and certain other items at fair
value, with the objective of mitigating volatility in reported earnings caused
by measuring related assets and liabilities differently (without being required
to apply complex hedge accounting provisions). The Company was required to
make an election at the beginning of the year after November 15, 2007
to adopt this standard. The Company did not elect the fair value
option.
In
December 2007, the FASB issued SFAS No. 141(R), “Business Combinations” (SFAS
141R). SFAS 141R expanded the definition of a business, thus increasing the
number of transactions that qualify as business combinations. SFAS 141R requires
the acquirer to recognize 100 percent of an acquired business’ assets and
liabilities, including goodwill and certain contingent assets and liabilities,
at their fair values at the acquisition date. Contingent consideration is
recognized at fair value on the acquisition date, with changes in fair value
recognized in earnings until settled. Likewise, changes in acquired tax
contingencies, including those existing at the date of adoption, are recognized
in earnings if outside the maximum allocation period (generally one year).
Transaction-related expenses and restructuring costs are expensed as incurred,
and any adjustments to finalize the purchase accounting allocations, even within
the allocation period, are shown as revised in the future financial statements
to reflect the adjustments as if they had been recorded on the acquisition date.
Finally, a gain could result in the event of a bargain purchase (acquisition of
a business below the fair market value of the assets and liabilities), or a gain
or loss in the case of a change in the control of an existing investment. SFAS
141R is applied prospectively to business combinations with acquisition dates on
or after January 1, 2009. Adoption did not materially impact the Company’s
consolidated financial position or results of operations directly when it became
effective in 2009, as the only impact that the standard had on recorded amounts
at adoption was that related to disposition of uncertain tax positions
related to prior acquisitions. Following the date of adoption of the standard,
the resolution of such items at values that differ from recorded amounts will be
adjusted through earnings, rather than through goodwill. Adoption of this
statement will have a significant effect on how acquisition transactions
subsequent to January 1, 2009 are reflected in our financial
statements.
In March
2008, the FASB issued SFAS No. 161, “Disclosures about Derivative Instruments
and Hedging Activities, an amendment of FASB Statement No. 133,” (SFAS 161),
which requires additional disclosures about the objectives of the derivative
instruments and hedging activities, the method of accounting for such
instruments under SFAS No. 133 and its related interpretations, and a tabular
disclosure of the effects of such instruments and related hedged items on the
Company’s financial position, financial performance, and cash
flows. SFAS 161 was effective for the Company beginning January 1,
2009. We are currently assessing the potential impact that adoption of SFAS 161
may have on our financial statements.
Critical
Accounting Policies
|
|
Our
accounting policies are described in Note 1 of the Notes to Consolidated
Financial Statements in Part II, Item 8 of this report. We prepare our financial
statements in conformity with accounting principles generally accepted in the
United States, which require us to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosures of contingent
assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the year. Actual results could differ
from those estimates. We consider the following policies to be most critical in
understanding the judgments that are involved in preparing our financial
statements and the uncertainties that could impact our results of operations,
financial condition and cash flows.
Allowance for Doubtful
Accounts and Billing
Adjustments. We
estimate an allowance for doubtful accounts as well as an allowance for
billing adjustments related to trade receivables based on our analysis of
historical collection and adjustment experience. We apply actual collection and
adjustment percentages to the outstanding accounts receivable balances at the
end of the period. If we experience a significant change in collections or
billing adjustment experience, our estimates of the recoverability of accounts
receivable could change by a material amount.
Workers’ Compensation and Medical Malpractice Loss
Reserves. We are partially
self-insured for our workers’ compensation liability related to the Life
Sciences, Healthcare and IT and Engineering segments as well as our medical
malpractice liability in relation to the Physician segment. In connection with
these programs, we pay a base premium plus actual losses incurred, not to exceed
certain stop-loss limits. We are insured for losses above these limits, both per
occurrence and in the aggregate. The self-insurance claim liability is
determined based on claims filed and claims incurred but not reported. We
account for claims incurred but not yet reported based on estimates derived from
historical claims experience and current trends of industry data. Changes in
estimates and differences in estimates and actual payments for claims are
recognized in the period that the estimates changed or the payments were
made.
Contingencies. We account for
contingencies in accordance with Statement of Financial Accounting Standards
(SFAS) No. 5, “Accounting for Contingencies.” SFAS 5 requires that we
record an estimated loss from a loss contingency when information available
prior to issuance of our financial statements indicates it is probable that an
asset has been impaired or a liability has been incurred at the date of the
financial statements, and the amount of the loss can be reasonably estimated.
Accounting for contingencies, such as legal settlements, workers’ compensation
matters and medical malpractice insurance matters, requires us to use our
judgment. While we believe that our accruals for these matters are adequate, if
the actual loss from a loss contingency is significantly different than the
estimated loss, results of operations may be over or understated.
Income taxes. We
account for income taxes under the asset and liability method. Deferred tax
assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of
existing assets and liabilities and their respective tax bases. Deferred tax
assets and liabilities are measured using enacted tax rates expected to apply to
taxable income in the years in which those temporary differences are expected to
be recovered or settled. The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in income in the period that includes the
enactment date. Deferred tax assets are reduced by a valuation
allowance if it is more likely than not that a portion of the deferred tax asset
will not be realized.
In
accordance with the recognition standards established by FASB Interpretation No.
48, “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB
Statement No. 109” (FIN 48 ), we make a comprehensive review of our portfolio of
uncertain tax positions regularly. In this regard, an uncertain tax
position represents our expected treatment of a tax position taken in a filed
tax return, or planned to be taken in a future tax return or claim, that has not
been reflected in measuring income tax expense for financial reporting
purposes. Until these positions are sustained by the taxing
authorities, we have not recognized the tax benefits resulting from such
positions and report the tax effects as a liability for uncertain tax positions
in our consolidated balance sheets.
Goodwill and Identifiable Intangible
Assets. Goodwill and other intangible assets having an indefinite useful
life are not amortized for financial statement purposes. Intangible assets
having finite lives are amortized over their useful lives and are periodically
reviewed to ensure that no conditions exist indicating the recorded amount is
not recoverable from future undiscounted cash flows.
We
perform an annual impairment test in the fourth quarter on goodwill and
intangible assets and in the event that facts and circumstances indicate that
goodwill and other identifiable intangible assets may be impaired, an interim
impairment test would be required. We determine the fair value based upon
discounted cash flows prepared for each reporting unit. Cash flows were
developed for each reporting unit based on assumptions including revenue growth
expectations, gross margins, operating expense projection, working capital and
capital expense requirements and tax rates. The principal factors used in the
discounted cash flow analysis requiring judgment are the projected results of
operations, weighted average cost of capital (WACC), and terminal value
assumptions. The WACC takes into account the relative weights of each component
of the company’s consolidated capital structure (equity and debt) and represents
the expected cost of new capital adjusted as appropriate to consider lower risk
profiles associated with longer term contracts and barriers to market entry. The
terminal value assumptions are applied to the final year of the discounted cash
flow model.
Due to
the many variables inherent in the estimation of a business’s fair value and the
relative size of the company’s recorded goodwill, differences in assumptions may
have a material effect on the results of the company’s impairment
analysis. While we believe that our goodwill was not impaired at
December 31, 2008, declines in our market capitalization subsequent to the
balance sheet date could be an early indication that goodwill may become
impaired in the future which could have a material adverse effect on our
results of operations and financial condition.
Impairment or Disposal of Long-Lived
Assets. We evaluate
long-lived assets, other than goodwill and identifiable intangible assets with
indefinite lives, for impairment whenever events or changes in circumstances
indicate that the carrying value of an asset may not be recoverable. An
impairment loss is recognized when the sum of the undiscounted future cash flows
is less than the carrying amount of the asset, in which case a write-down is
recorded to reduce the related asset to its estimated fair value.
Business Combinations. We record
acquisition transactions in accordance with the purchase method of accounting,
and therefore this requires us to use judgment and estimates related to the
allocation of the purchase price to the intangibles assets of the acquisition
and the remaining amount, net of assets and liabilities assumed, to
goodwill.
Stock-Based
Compensation. As discussed in Note 10 to our Consolidated
Financial Statements in Part II, Item 8 of this report, effective January 1,
2006, we account for stock-based compensation in accordance with SFAS No. 123
(revised 2004), “Share-Based Payment” (SFAS 123R), which requires
recognition of the fair value of equity-based compensation. The fair
value of stock options and ESPP shares is estimated using a Black-Scholes option
valuation model. This methodology requires the use of subjective
assumptions, including expected stock price volatility and the estimated life of
each award. The fair value of equity-based compensation awards less
the estimated forfeitures is amortized over the service period of the
award. The fair value of restricted stock awards and stock units is
calculated based upon the fair market value of our common stock at the date of
grant.
Item
7A. Quantitative and Qualitative Disclosures about Market
Risk
|
|
We are
exposed to certain market risks arising from transactions in the normal course
of business, principally risks associated with foreign currency fluctuations and
interest rates. We are exposed to foreign currency risk from the translation of
foreign operations into U.S. dollars. Based on the relative size and nature of
our foreign operations, we do not believe that a ten percent change in the value
of foreign currencies relative to the U.S. dollar would have a material impact
on our financial statements. Our primary exposure to market risk is interest
rate risk associated with our debt instruments. See “Item 7. Management’s
Discussion and Analysis of Financial Condition and Results of Operations” for
further description of our debt instruments. Excluding the effect of our
interest rate swap agreement, a 1 percent change in interest rates on variable
rate debt would have resulted in interest expense fluctuating approximately $1.4
million during the year ended December 31, 2008. Including the effect of our
interest rate swap agreement, a 1 percent change in interest rates on variable
debt would have resulted in interest expense fluctuating approximately $0.6
million during the year ended December 31, 2008. We have not entered
into any market risk sensitive instruments for trading purposes. See
Note 4 to the Consolidated Financial Statements in Part II, Item 8 of this
report for additional information on the rate swap agreement entered into by the
Company.
Item
8. Financial Statements and Supplementary Data
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the
Board of Directors and Stockholders of On Assignment, Inc.
Calabasas,
California
We have
audited the accompanying consolidated balance sheets of On Assignment, Inc. and
subsidiaries (the "Company") as of December 31, 2008 and 2007, and the related
consolidated statements of operations and comprehensive income, stockholders'
equity, and cash flows for each of the three years in the period ended December
31, 2008. Our audits also included the financial statement schedule listed in
the Index at Item 15. These financial statements and financial statement
schedule are the responsibility of the Company's management. Our responsibility
is to express an opinion on these financial statements and financial statement
schedule based on our audits.
We
conducted our audits in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our
opinion, such consolidated financial statements present fairly, in all material
respects, the financial position of On Assignment, Inc. and subsidiaries as of
December 31, 2008 and 2007, and the results of their operations and their cash
flows for each of the three years in the period ended December 31, 2008, in
conformity with accounting principles generally accepted in the United States of
America. Also, in our opinion, such financial statement schedule, when
considered in relation to the basic consolidated financial statements taken as a
whole, present fairly, in all material respects, the information set forth
therein.
Effective
January 1, 2007, the Company adopted FASB Interpretation No. 48, “Accounting for
Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109,” as
discussed in Note 8 to the consolidated financial statements. As
discussed in Notes 1 and 10 to the consolidated financial statements, the
Company adopted, effective January 1, 2006, Statement of Financial Accounting
Standards No. 123R, “Share-Based Payment.”
We have
also audited, in accordance with the standards of the Public Company Accounting
Oversight Board (United States), the Company's internal control over financial
reporting as of December 31, 2008, based on the criteria established in Internal Control—Integrated
Framework issued by the Committee of Sponsoring Organizations of the
Treadway Commission and our report dated March 16, 2009 expressed an unqualified
opinion on the Company's internal control over financial reporting.
/s/ Deloitte & Touche
LLP
Los
Angeles, California
March 16,
2009
ON
ASSIGNMENT, INC. AND SUBSIDIARIES
CONSOLIDATED
BALANCE SHEETS
(In
thousands, except share and per share data)
|
|
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
Current
Assets:
|
|
|
|
|
|
Cash
and cash equivalents
|
|
$ |
46,271 |
|
|
$ |
37,764 |
Accounts
receivable, net of allowance for doubtful accounts and billing adjustments
of $2,443 and $2,254, respectively
|
|
|
78,370 |
|
|
|
78,840 |
Advances
and deposits
|
|
|
311 |
|
|
|
323 |
Prepaid
expenses
|
|
|
4,503 |
|
|
|
4,143 |
Prepaid
income taxes
|
|
|
3,759 |
|
|
|
13 |
Deferred
income tax assets
|
|
|
9,347 |
|
|
|
8,018 |
Other
|
|
|
2,162 |
|
|
|
751 |
Total
current assets
|
|
|
144,723 |
|
|
|
129,852 |
|
|
|
|
|
|
|
|
Property
and Equipment, net
|
|
|
17,495 |
|
|
|
13,898 |
Goodwill
|
|
|
202,777 |
|
|
|
193,552 |
Identifiable
intangible assets, net
|
|
|
31,428 |
|
|
|
40,964 |
Other
assets
|
|
|
5,427 |
|
|
|
6,414 |
Total
Assets
|
|
$ |
401,850 |
|
|
$ |
384,680 |
|
|
|
|
|
|
|
|
LIABILITIES
AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
Current
Liabilities:
|
|
|
|
|
|
|
|
Accounts
payable
|
|
$ |
5,204 |
|
|
$ |
5,718 |
Accrued
payroll and contract professional pay
|
|
|
19,836 |
|
|
|
19,108 |
Deferred
compensation
|
|
|
1,610 |
|
|
|
2,037 |
Workers’
compensation and medical malpractice loss reserves
|
|
|
9,754 |
|
|
|
8,921 |
Accrued
earn-out payments
|
|
|
10,168 |
|
|
|
8,525 |
Other
|
|
|
6,959 |
|
|
|
6,534 |
Total
current liabilities
|
|
|
53,531 |
|
|
|
50,843 |
|
|
|
|
|
|
|
|
Deferred
income taxes
|
|
|
1,997 |
|
|
|
1,664 |
Long-term
debt
|
|
|
125,913 |
|
|
|
135,913 |
Other
long-term liabilities
|
|
|
1,895 |
|
|
|
3,226 |
Total
liabilities
|
|
|
183,336 |
|
|
|
191,646 |
Commitments
and Contingencies (Note 7)
|
|
|
|
|
|
|
|
Stockholders’
Equity:
|
|
|
|
|
|
|
|
Preferred
Stock, $0.01 par value, 1,000,000 shares authorized, no shares issued or
outstanding
|
|
|
— |
|
|
|
— |
Common
Stock, $0.01 par value, 75,000,000 shares authorized, 38,816,844 and
38,216,421 issued, respectively
|
|
|
388 |
|
|
|
382 |
Paid-in
capital
|
|
|
227,522 |
|
|
|
219,217 |
Retained
earnings (accumulated deficit)
|
|
|
16,215 |
|
|
|
(2,755) |
Accumulated
other comprehensive income
|
|
|
800 |
|
|
|
2,190 |
|
|
|
244,925 |
|
|
|
219,034 |
Less:
Treasury Stock at cost, 3,097,364 and 3,038,938 shares,
respectively
|
|
|
26,411 |
|
|
|
26,000 |
Total
stockholders’ equity
|
|
|
218,514 |
|
|
|
193,034 |
Total
Liabilities and Stockholders’ Equity
|
|
$ |
401,850 |
|
|
$ |
384,680 |
|
|
|
|
|
|
|
|
See notes
to consolidated financial statements.
ON
ASSIGNMENT, INC. AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(In
thousands, except per share data)
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
$ |
618,058 |
|
|
$ |
567,180 |
|
|
$ |
287,566 |
Cost
of services
|
|
|
418,602 |
|
|
|
387,643 |
|
|
|
209,725 |
Gross
profit
|
|
|
199,456 |
|
|
|
179,537 |
|
|
|
77,841 |
Selling,
general and administrative expenses
|
|
|
155,942 |
|
|
|
151,942 |
|
|
|
67,900 |
Operating
income
|
|
|
43,514 |
|
|
|
27,595 |
|
|
|
9,941 |
Interest
expense
|
|
|
(9,998 |
) |
|
|
(12,174 |
) |
|
|
(54) |
Interest
income
|
|
|
715 |
|
|
|
1,394 |
|
|
|
1,698 |
Income
before income taxes
|
|
|
34,231 |
|
|
|
16,815 |
|
|
|
11,585 |
Provision
for income taxes
|
|
|
15,261 |
|
|
|
7,493 |
|
|
|
541 |
Net
income
|
|
$ |
18,970 |
|
|
$ |
9,322 |
|
|
$ |
11,044 |
|
|
|
|
|
|
|
|
|
|
|
|
Earnings
per share:
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$ |
0.53 |
|
|
$ |
0.27 |
|
|
$ |
0.41 |
Diluted
|
|
$ |
0.53 |
|
|
$ |
0.26 |
|
|
$ |
0.39 |
Weighted
average number of shares used to calculate earnings per
share:
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
35,487 |
|
|
|
35,138 |
|
|
|
27,155 |
Diluted
|
|
|
35,858 |
|
|
|
35,771 |
|
|
|
28,052 |
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation
of net income to comprehensive income:
|
|
|
|
|
|
|
|
|
Net
income
|
|
$ |
18,970 |
|
|
$ |
9,322 |
|
|
$ |
11,044 |
Foreign
currency translation adjustment
|
|
|
(1,390 |
) |
|
|
628 |
|
|
|
569 |
Comprehensive
income
|
|
$ |
17,580 |
|
|
$ |
9,950 |
|
|
$ |
11,613 |
See notes
to consolidated financial statements.
ON
ASSIGNMENT, INC. AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF STOCKHOLDERS’ EQUITY
(In
thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated
Other Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
at January 1, 2006
|
|
|
|
28,549,063 |
|
|
$ |
286 |
|
|
$ |
121,232 |
|
|
$ |
(22,904 |
) |
|
$ |
993 |
|
|
|
(2,662,500 |
) |
|
$ |
(22,970 |
) |
|
$ |
76,637 |
Stock
offering proceeds, net
|
|
|
|
7,643,141 |
|
|
|
76 |
|
|
|
71,302 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
71,378 |
Exercise
of common stock options
|
|
|
|
338,858 |
|
|
|
3 |
|
|
|
2,066 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
2,069 |
Employee
Stock Purchase Plan
|
|
|
|
78,632 |
|
|
|
1 |
|
|
|
543 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
544 |
Stock
issued for acquisition
|
|
|
|
13,000 |
|
|
|
— |
|
|
|
154 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
154 |
Stock-based
compensation expense
|
|
|
|
— |
|
|
|
— |
|
|
|
2,953 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
2,953 |
Vesting
of restricted stock units and restricted stock awards
|
|
|
|
147,019 |
|
|
|
1 |
|
|
|
(1 |
) |
|
|
— |
|
|
|
— |
|
|
|
(49,066 |
) |
|
|
(510 |
) |
|
|
(510) |
Excess
tax benefits from stock-based compensation
|
|
|
|
— |
|
|
|
— |
|
|
|
1,106 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,106 |
Translation
adjustments
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
569 |
|
|
|
— |
|
|
|
— |
|
|
|
569 |
Net
income
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
11,044 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
11,044 |
Balance
at December 31, 2006
|
|
|
|
36,769,713 |
|
|
|
367 |
|
|
|
199,355 |
|
|
|
(11,860 |
) |
|
|
1,562 |
|
|
|
(2,711,566 |
) |
|
|
(23,480 |
) |
|
|
165,944 |
Exercise
of common stock options
|
|
|
|
362,394 |
|
|
|
4 |
|
|
|
2,012 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
2,016 |
Employee
Stock Purchase Plan
|
|
|
|
126,484 |
|
|
|
1 |
|
|
|
1,105 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,106 |
Stock
issued for acquisition
|
|
|
|
795,292 |
|
|
|
8 |
|
|
|
9,992 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
10,000 |
Stock
repurchase
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(278,439 |
) |
|
|
(1,997 |
) |
|
|
(1,997) |
Stock-based
compensation expense
|
|
|
|
— |
|
|
|
— |
|
|
|
6,092 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
6,092 |
Vesting
of restricted stock units and restricted stock awards
|
|
|
|
162,538 |
|
|
|
2 |
|
|
|
(2 |
) |
|
|
— |
|
|
|
— |
|
|
|
(48,933 |
) |
|
|
(523 |
) |
|
|
(523) |
Adjustment
for adoption of FIN 48
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(217 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(217) |
Excess
tax benefits from stock-based compensation
|
|
|
|
— |
|
|
|
— |
|
|
|
663 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
663 |
Translation
adjustments
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
628 |
|
|
|
— |
|
|
|
— |
|
|
|
628 |
Net
income
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
9,322 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
9,322 |
Balance
at December 31, 2007
|
|
|
|
38,216,421 |
|
|
|
382 |
|
|
|
219,217 |
|
|
|
(2,755 |
) |
|
|
2,190 |
|
|
|
(3,038,938 |
) |
|
|
(26,000 |
) |
|
|
193,034 |
Exercise
of common stock options
|
|
|
|
98,187 |
|
|
|
1 |
|
|
|
482 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
483 |
Employee
Stock Purchase Plan
|
|
|
|
315,827 |
|
|
|
3 |
|
|
|
1,576 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,579 |
Stock-based
compensation expense
|
|
|
|
— |
|
|
|
— |
|
|
|
6,288 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
6,288 |
Vesting
of restricted stock units and restricted stock awards
|
|
|
|
186,409 |
|
|
|
2 |
|
|
|
(2) |
|
|
|
— |
|
|
|
— |
|
|
|
(58,426 |
) |
|
|
(411 |
) |
|
|
(411) |
Tax
benefit deficiency from stock-based compensation
|
|
|
|
— |
|
|
|
— |
|
|
|
(39 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(39) |
Translation
adjustments
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,390 |
) |
|
|
— |
|
|
|
— |
|
|
|
(1,390) |
Net
income
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
18,970 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
18,970 |
Balance
at December 31, 2008
|
|
|
|
38,816,844 |
|
|
$ |
388 |
|
|
$ |
227,522 |
|
|
$ |
16,215 |
|
|
$ |
800 |
|
|
|
(3,097,364 |
) |
|
$ |
(26,411 |
) |
|
$ |
218,514 |
See notes
to consolidated financial statements.
ON
ASSIGNMENT, INC. AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF CASH FLOWS
(In
thousands)
|
|
|
|
|
|
|
|
|
|
|
|
Cash
Flows from Operating Activities:
|
|
|
|
|
|
|
|
|
Net
income
|
|
$ |
18,970 |
|
|
$ |
9,322 |
|
|
$ |
11,044 |
Adjustments
to reconcile net income to net cash provided by operating
activities:
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation
|
|
|
5,106 |
|
|
|
6,194 |
|
|
|
4,672 |
Amortization
of intangible assets
|
|
|
9,436 |
|
|
|
15,342 |
|
|
|
957 |
Provision
for doubtful accounts and billing adjustments
|
|
|
641 |
|
|
|
680 |
|
|
|
60 |
Deferred
income tax expense (benefit)
|
|
|
9 |
|
|
|
(4,163 |
) |
|
|
(3,906) |
Stock-based
compensation
|
|
|
6,349 |
|
|
|
6,359 |
|
|
|
2,953 |
Amortization
of deferred loan costs
|
|
|
591 |
|
|
|
542 |
|
|
|
— |
Change
in fair value of interest rate swap
|
|
|
139 |
|
|
|
1,206 |
|
|
|
— |
(Gain)
loss on officers’ life insurance policies
|
|
|
851 |
|
|
|
(166 |
) |
|
|
(192) |
Gross
excess tax benefits from stock-based compensation
|
|
|
(327 |
) |
|
|
(860 |
) |
|
|
(1,053) |
Loss
on disposal of property and equipment
|
|
|
112 |
|
|
|
317 |
|
|
|
99 |
Workers’
compensation and medical malpractice provision
|
|
|
5,384 |
|
|
|
4,095 |
|
|
|
2,224 |
Changes
in operating assets and liabilities, net of effect of
acquisitions:
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(1,142 |
) |
|
|
(7,335 |
) |
|
|
(3,557) |
Prepaid expenses
|
|
|
(411 |
) |
|
|
(70 |
) |
|
|
402 |
Prepaid income taxes
|
|
|
(4,802 |
) |
|
|
358 |
|
|
|
(101) |
Income taxes payable
|
|
|
(792 |
) |
|
|
1,743 |
|
|
|
1,973 |
Accounts payable
|
|
|
(809 |
) |
|
|
1,035 |
|
|
|
(97) |
Accrued payroll and contract professional pay
|
|
|
877 |
|
|
|
1,074 |
|
|
|
178 |
Deferred compensation
|
|
|
(427 |
) |
|
|
677 |
|
|
|
677 |
Workers’ compensation and medical malpractice loss
reserves
|
|
|
(4,551 |
) |
|
|
(3,321 |
) |
|
|
(2,161) |
Other
|
|
|
154 |
|
|
|
629 |
|
|
|
130 |
Net
cash provided by operating activities
|
|
|
35,358 |
|
|
|
33,658 |
|
|
|
14,302 |
|
|
|
|
|
|
|
|
|
|
|
|
Cash
Flows from Investing Activities:
|
|
|
|
|
|
|
|
|
|
|
|
Purchase
of property and equipment
|
|
|
(8,201 |
) |
|
|
(5,899 |
) |
|
|
(4,111) |
Increase
in other assets
|
|
|
(499 |
) |
|
|
(530 |
) |
|
|
(292) |
Net
cash paid for acquisitions
|
|
|
(9,013 |
) |
|
|
(232,273 |
) |
|
|
(430) |
Decrease
in restricted cash
|
|
|
— |
|
|
|
4,678 |
|
|
|
200 |
Net
cash used in investing activities
|
|
|
(17,713 |
) |
|
|
(234,024 |
) |
|
|
(4,633) |
|
|
|
|
|
|
|
|
|
|
|
|
Cash Flows from Financing
Activities:
|
|
|
|
|
|
|
|
|
|
|
|
Net
proceeds from stock transactions
|
|
|
1,653 |
|
|
|
2,598 |
|
|
|
2,205 |
Gross
excess tax benefits from stock-based compensation
|
|
|
327 |
|
|
|
860 |
|
|
|
1,053 |
Proceeds
from shelf offering
|
|
|
— |
|
|
|
— |
|
|
|
71,678 |
Shelf
offering costs
|
|
|
— |
|
|
|
(300 |
) |
|
|
— |
Proceeds
from issuance of long-term debt
|
|
|
— |
|
|
|
145,000 |
|
|
|
— |
Debt
issuance costs
|
|
|
— |
|
|
|
(4,153 |
) |
|
|
— |
Repurchase
of common stock
|
|
|
— |
|
|
|
(1,997 |
) |
|
|
— |
Payments
of long-term liabilities
|
|
|
(383 |
) |
|
|
(144 |
) |
|
|
— |
Principal
payments of long-term debt
|
|
|
(10,000 |
) |
|
|
(9,725 |
) |
|
|
— |
Net
cash (used in) provided by financing activities
|
|
|
(8,403 |
) |
|
|
132,139 |
|
|
|
74,936 |
|
|
|
|
|
|
|
|
|
|
|
|
Effect
of exchange rate changes on cash and cash equivalents
|
|
|
(735 |
) |
|
|
508 |
|
|
|
391 |
|
|
|
|
|
|
|
|
|
|
|
|
Net
Increase (Decrease) in Cash and Cash Equivalents
|
|
|
8,507 |
|
|
|
(67,719 |
) |
|
|
84,996 |
Cash
and Cash Equivalents at Beginning of Year
|
|
|
37,764 |
|
|
|
105,483 |
|
|
|
20,487 |
Cash
and Cash Equivalents at End of Year
|
|
$ |
46,271 |
|
|
$ |
37,764 |
|
|
$ |
105,483 |
|
|
|
|
|
|
|
|
|
|
|
|
See notes
to consolidated financial statements.
ON
ASSIGNMENT, INC.
CONSOLIDATED
STATEMENTS OF CASH FLOWS (continued)
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental
Disclosure of Cash Flow Information
|
|
|
|
|
|
|
|
|
Cash
paid for:
|
|
|
|
|
|
|
|
|
Income
taxes, net of refunds
|
|
$ |
20,255 |
|
|
$ |
9,586 |
|
|
$ |
2,571 |
Interest
|
|
$ |
9,370 |
|
|
$ |
10,491 |
|
|
$ |
― |
|
|
|
|
|
|
|
|
|
|
|
|
Acquisitions:
|
|
|
|
|
|
|
|
|
|
|
|
Goodwill
|
|
$ |
9,013 |
|
|
$ |
177,478 |
|
|
$ |
513 |
Intangible
assets acquired
|
|
|
— |
|
|
|
55,640 |
|
|
|
68 |
Net
tangible assets acquired
|
|
|
— |
|
|
|
18,841 |
|
|
|
3 |
Fair
value of assets acquired, net of cash received
|
|
$ |
9,013 |
|
|
$ |
251,959 |
|
|
$ |
584 |
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental
Disclosure of Non-Cash Transactions
|
|
|
|
|
|
|
|
|
|
|
|
Common
stock issued in connection with acquisition
|
|
$ |
— |
|
|
$ |
10,000 |
|
|
$ |
154 |
Shelf
offering costs in accounts payable and other accrued
expenses
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
300 |
Deferred
acquisition costs in accounts payable and other accrued
expenses
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
1,546 |
Accrued
earn-out payments and escrow claim receivable
|
|
$ |
8,766 |
|
|
$ |
8,525 |
|
|
$ |
— |
Acquisition
of property and equipment through accounts payable
|
|
$ |
1,251 |
|
|
$ |
452 |
|
|
$ |
254 |
See notes
to consolidated financial statements.
ON
ASSIGNMENT, INC. AND SUBSIDIARIES
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
1.
Summary of Significant Accounting Policies.
|
|
Principles of Consolidation.
The consolidated financial statements include the accounts of the Company
and its wholly-owned domestic and foreign subsidiaries. All intercompany
accounts and transactions have been eliminated.
Cash and Cash Equivalents.
The Company considers all highly liquid investments with a maturity of three
months or less on the date of purchase to be cash equivalents.
Accounts Receivable. The
Company estimates an allowance for doubtful accounts as well as an allowance for
billing adjustments related to trade receivables based on an analysis of
historical collection and billing adjustment experience. The Company applies
actual collection and adjustment percentages to the outstanding accounts
receivable balances at the end of the period. If the Company experiences a
significant change in collections or billing adjustment experience, the
estimates of the recoverability of accounts receivable could change by a
material amount.
Property and Equipment.
Property and equipment are stated at cost. Depreciation and amortization are
provided using the straight-line method over the estimated useful lives of the
related assets, generally three to five years. Leasehold improvements are
amortized over the shorter of the life of the related asset or the life of the
lease. Costs associated with customized internal-use software systems that have
reached the application stage and meet recoverability tests are capitalized.
Such capitalized costs include external direct costs utilized in developing or
obtaining the applications and payroll and payroll-related expenses for
employees who are directly associated with the applications
Goodwill and Identifiable
Intangibles. Goodwill represents the excess of the purchase price over
the fair value of the net assets acquired. Goodwill and other intangible assets
having an indefinite useful life are not amortized for financial statement
purposes. The Company performs an annual impairment test as of
December 31 and in the event that facts and circumstances indicate that goodwill
and other identifiable intangible assets may be impaired, an interim impairment
test would be required. The Company’s testing approach utilizes a discounted
cash flow analysis to determine the fair value of its reporting units for
comparison to their corresponding book values. If the book value
exceeds the estimated fair value for a reporting unit, a potential impairment is
indicated and Statement of Financial Accounting Standard (SFAS) No. 142,
Goodwill and Other Intangible Assets prescribes the approach for determining the
impairment amount, if any. Intangible assets having finite lives are
amortized over their useful lives and are periodically reviewed to ensure that
no conditions exist indicating the recorded amount is not recoverable from
future undiscounted cash flows. Purchased intangible assets with
finite lives are amortized on a straight-line or accelerated basis for staffing
databases based on estimated customer attrition rates.
Impairment of Long-Lived
Assets. The Company evaluates long-lived assets, other than goodwill and
identifiable intangible assets with indefinite lives, for impairment whenever
events or changes in circumstances indicate that the carrying value of an asset
may not be recoverable. An impairment loss is recognized when the sum of the
undiscounted future cash flows is less than the carrying amount of the asset, in
which case a write-down is recorded to reduce the related asset to its estimated
fair value.
Workers’ Compensation and Medical Malpractice Loss
Reserves. The Company is
partially self-insured for its workers’ compensation and medical
malpractice liabilities. In connection with these programs, the Company pays a
base premium plus actual losses incurred, not to exceed certain stop-loss
limits. The Company is insured for losses above these limits, both per
occurrence and in the aggregate. The self-insurance claim liability is
determined based on claims filed and claims incurred but not
reported.
Contingencies. The Company records an estimated loss
from a loss contingency when information available prior to issuance of its
financial statements indicates it is probable that an asset has been impaired or
a liability has been incurred at the date of the financial statements, and the
amount of the loss can be reasonably estimated. Accounting for contingencies,
such as legal settlements, workers’ compensation and medical malpractice
insurance matters, requires the Company to use judgment. While the Company
believes that the accruals for these matters are adequate, if the actual loss
from a loss contingency is significantly different than the estimated loss,
results of operations could be adversely affected.
Income Taxes. Income taxes
are accounted for under the asset and liability method. Deferred tax assets and
liabilities are recognized for the future tax consequences attributable to
differences between the financial statement carrying amounts of existing assets
and liabilities and their respective tax bases. Deferred tax assets and
liabilities are measured using enacted tax rates expected to apply to taxable
income in the years in which those temporary differences are expected to be
recovered or settled. The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in income in the period that includes the
enactment date. Deferred tax assets are reduced by a valuation
allowance if it is more likely than not that a portion of the deferred tax asset
will not be realized.
Revenue
Recognition. Revenues from contract assignments, net of sales
adjustments and discounts, are recognized when earned, based on hours worked by
the Company’s contract professionals on a weekly basis. Conversion and direct
hire fees are recognized when earned, upon conversion or direct hire of a
contract professional to a client’s regular employee. In addition, the Company
records a sales allowance against consolidated revenues, which is an estimate
based on historical billing adjustment experience. The sales allowance is
recorded as a reduction to revenues and an increase to the allowance for billing
adjustments. The billing adjustment reserve includes an allowance for fallouts.
Fallouts are direct hire and conversion fees that do not complete the
contingency period. The contingency period is typically 90 days or less. In
accordance with EITF 01-14, “Income Statement Characterization of Reimbursements
Received for ‘Out-of-Pocket’ Expenses Incurred,” the Company includes reimbursed
expenses, including those related to travel and out-of-pocket expenses, in
revenues and the associated amounts of reimbursable expenses in cost of
services.
Foreign Currency
Translation. The
functional currency of the Company’s foreign operations is their local currency,
and as such, their assets and liabilities are translated into U.S. dollars at
the rate of exchange in effect on the balance sheet date. Revenue and expenses
are translated at the average rates of exchange prevailing during each monthly
period. The related translation adjustments are recorded as cumulative foreign
currency translation adjustments in accumulated other comprehensive income as a
separate component of stockholders’ equity. Gains and losses resulting from
foreign currency transactions, which are not material, are included in SG&A
expenses in the Consolidated Statements of Operations and Comprehensive
Income.
Stock-Based Compensation.
Effective January 1, 2006, the Company adopted the provisions of SFAS No. 123
(revised 2004) “Share-Based Payment” (SFAS 123R) using the modified-prospective
transition method. Under this transition method, compensation expense recognized
includes: (a) compensation expense for all share-based awards granted prior to,
but not yet vested as of January 1, 2006, based on the grant date fair value
estimated in accordance with the original provisions of SFAS No. 123 “Accounting
for Stock-Based Compensation” (SFAS 123), recognized over the remaining vesting
period and (b) compensation expense for all share-based awards granted on or
after January 1, 2006, based on the grant date fair value estimated in
accordance with the provisions of SFAS 123R. In accordance with the
modified-prospective transition method, results for prior periods have not been
restated. The fair value of stock options and ESPP shares is
estimated using a Black-Scholes option valuation model. This
methodology requires the use of subjective assumptions including expected stock
price volatility and the estimated life of each award. The fair value
of equity-based compensation awards less the estimated forfeitures is amortized
over the vesting period of the award. The fair value of restricted
stock awards and stock units is calculated based upon the fair market value of
the Company’s common stock at the date of grant.
Use of Estimates. The
preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reporting period.
Actual results could differ from those estimates.
Concentration of Credit Risk.
Financial instruments that potentially subject the Company to credit risks
consist primarily of cash, cash equivalents and trade receivables. The Company
places its cash and cash equivalents in low risk investments with quality credit
institutions and limits the amount of credit exposure with any single
institution. For the Life Sciences, Physician and IT and Engineering segments
and the Allied Healthcare line of business, concentration of credit risk with
respect to accounts receivable are limited because of the large number of
geographically dispersed customers, thus spreading the trade credit risk. In
2008, the Company earned only 1.4 percent of consolidated revenues from several
customers operating under a single contract with Los Angeles County, compared
with 2.9 percent and 13.1 percent in 2007 and 2006, respectively. The revenues
from this contract are included in Healthcare segment revenues. The Company
performs ongoing credit evaluations to identify risks and maintains an allowance
to address these risks.
Fair Value of Financial
Instruments. The recorded values of cash and cash equivalents, restricted
cash, accounts receivable, accounts payable and accrued expenses approximate
their fair value based on their short-term nature. The amount of the
interest rate swap reflected on the Consolidated Balance Sheets in other accrued
expenses is equivalent to fair value as the Company marks the swap to market at
the end of each reporting period. See Note 12 for the related
disclosure for the interest rate swap.
The
following table presents the carrying amounts and the related estimated fair
values of the Company’s financial instruments not measured at fair value on a
recurring basis:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In
thousands)
|
ASSETS
|
|
|
Life
Insurance Policies
|
|
$ |
1,610 |
|
|
$ |
1,610 |
|
|
$ |
2,037 |
|
|
$ |
2,037 |
LIABILITIES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-Term
Debt
|
|
|
125,913 |
|
|
|
107,026 |
|
|
|
135,913 |
|
|
|
135,913 |
The
Company maintains life insurance policies for use as a funding source for its
deferred compensation arrangements. See Note 5 for the related disclosure of the
deferred compensation arrangements. These life insurance policies are recorded
at their cash surrender value as determined by the insurance broker. The fair
value of the long-term debt is based on the yields of comparable companies with
similar credit characteristics.
Advertising Costs.
Advertising costs, which are expensed as incurred, were $4.9 million, $4.3
million and $2.4 million for the years ended December 31, 2008, 2007,
and 2006, respectively.
Recent Accounting
Pronouncements. In September
2006, the Financial Accounting Standards Board (FASB) adopted SFAS No. 157,
“Fair Value Measurements” (SFAS 157). SFAS 157 defines fair value,
establishes a framework for measuring fair value in accordance with GAAP and
expands disclosures about fair value measurements. While SFAS 157 did not impact
the Company’s valuation methods, it expanded disclosures of assets and
liabilities that are recorded at fair value. SFAS 157 was effective for
financial statements issued for years beginning after November 15, 2007 and
interim periods within those years. The Company adopted this standard on January
1, 2008, and the adoption did not have a material impact on the results of
operations, financial position or cash flows. See Note 12 for the
related disclosure. The Company is in the process of evaluating the
previously-deferred provisions of SFAS 157, which was effective on January 1,
2009, for non-financial assets and liabilities recorded at fair value and the
impact on its consolidated financial position or results of
operations.
In
February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for
Financial Assets and Financial Liabilities.” This Statement permits entities to
choose to measure many financial instruments and certain other items at fair
value, with the objective of mitigating volatility in reported earnings caused
by measuring related assets and liabilities differently (without being required
to apply complex hedge accounting provisions). The Company was required to
make an election at the beginning of the year after November 15, 2007 to adopt
this standard. The Company did not elect the fair value option.
In
December 2007, the FASB issued SFAS No. 141(R), “Business Combinations” (SFAS
141R). SFAS 141R expanded the definition of a business, thus increasing the
number of transactions that qualify as business combinations. SFAS 141R requires
the acquirer to recognize 100 percent of an acquired business’ assets and
liabilities, including goodwill and certain contingent assets and liabilities,
at their fair values at the acquisition date. Contingent consideration is
recognized at fair value on the acquisition date, with changes in fair value
recognized in earnings until settled. Likewise, changes in acquired tax
contingencies, including those existing at the date of adoption, are recognized
in earnings if outside the maximum allocation period (generally one year).
Transaction-related expenses and restructuring costs are expensed as incurred,
and any adjustments to finalize the purchase accounting allocations, even within
the allocation period, are shown as revised in the future financial statements
to reflect the adjustments as if they had been recorded on the acquisition date.
Finally, a gain could result in the event of a bargain purchase (acquisition of
a business below the fair market value of the assets and liabilities), or a gain
or loss in the case of a change in the control of an existing investment. SFAS
141R is applied prospectively to business combinations with acquisition dates on
or after January 1, 2009. Adoption did not materially impact the Company’s
consolidated financial position or results of operations directly when it became
effective in 2009, as the only impact that the standard had on recorded amounts
at adoption was that related to disposition of uncertain tax positions
related to prior acquisitions. Following the date of adoption of the standard,
the resolution of such items at values that differ from recorded amounts will be
adjusted through earnings, rather than through goodwill. Adoption of this
statement will have a significant effect on how acquisition transactions
subsequent to January 1, 2009 are reflected in the financial
statements.
In March 2008, the FASB issued SFAS
No. 161, “Disclosures about Derivative Instruments and Hedging Activities, an
amendment of FASB Statement No. 133,” (SFAS 161), which requires additional
disclosures about the objectives of the derivative instruments and hedging
activities, the method of accounting for such instruments under SFAS No. 133 and
its related interpretations, and a tabular disclosure of the effects of such
instruments and related hedged items on the Company’s financial position,
financial performance, and cash flows. SFAS 161 was effective for the
Company beginning January 1, 2009. The Company is currently assessing the
potential impact that adoption of SFAS 161 may have on its financial
statements.
2.
Property and Equipment.
|
|
Property
and equipment at December 31, 2008 and 2007 consisted of the following (in
thousands):
|
|
|
|
|
|
Furniture
and fixtures
|
|
$ |
3,535 |
|
|
$ |
2,778 |
Computers
and related equipment
|
|
|
4,401 |
|
|
|
3,801 |
Computer
software
|
|
|
22,773 |
|
|
|
17,753 |
Machinery
and equipment
|
|
|
1,192 |
|
|
|
870 |
Leasehold
improvements
|
|
|
3,919 |
|
|
|
3,667 |
Work-in-progress
|
|
|
3,596 |
|
|
|
2,684 |
|
|
|
39,416 |
|
|
|
31,553 |
|
|
|
|
|
|
|
|
Less
accumulated depreciation and amortization
|
|
|
(21,921 |
) |
|
|
(17,655) |
|
|
|
|
|
|
|
|
Total
|
|
$ |
17,495 |
|
|
$ |
13,898 |
|
|
|
|
|
|
|
|
Depreciation
and amortization expense related to property and equipment for the years ended
December 31, 2008, 2007 and 2006 was $5.1 million, $6.2 million and $4.7
million respectively.
As
discussed in Note 1 under
Property and Equipment, the Company capitalizes costs associated with
customized internal-use software systems that have reached the application stage
and meet recoverability tests under the provisions of SOP 98-1. All software
costs capitalized under SOP 98-1 are depreciated over an estimated useful
life of three to five years.
The
Company has capitalized costs related to its various technology initiatives. The
net book value of the property and equipment related to software development was
$7.6 million and $4.1 million, as of December 31, 2008 and 2007, respectively,
which includes work-in-progress of $3.5 million and $2.2 million. The Company
has also capitalized website development costs of $0.3 million and $0.4 million
as of December 31, 2008 and 2007,respectively, of which no costs were
considered work-in-progress.
On
January 3, 2007, the Company acquired VSS Holding, Inc. and its subsidiaries,
which includes VISTA Staffing Solutions, Inc. (VISTA), a privately-owned leading
provider of physician staffing, known as locum tenens, and permanent physician
search services. VISTA is headquartered in Salt Lake City, Utah and works with
more than 1,000 physicians covering approximately thirty medical specialties.
The primary reasons for the VISTA acquisition were to diversify the Company’s
existing healthcare offerings, to complement its existing Nurse Travel business
line with cross-selling opportunities and to leverage its SG&A expenses,
including housing, travel and credentialing costs.
The total
purchase price of $48.5 million consisted of (i) an initial cash payment of
$41.1 million, which included a $4.1 million holdback for potential claims
indemnified by the selling shareholders, (ii) $0.9 million in direct acquisition
costs, (iii) $2.6 million payment in April of 2008 of the earn-out related to
the 2007 operating performance, and (iv) $5.3 million for the payment of
the earn-out related to the 2008 operating performance. Payment of the 2008
earn-out is tentatively scheduled for April 2009, pending the agreement of all
applicable parties to all terms and provisions related to such payments. The
earn-out payments have been included in the Consolidated Balance Sheets in
accrued earn-out payments. The $4.1 million holdback for potential claims
indemnifiable by the selling shareholders is held in escrow and has been
included as part of the purchase price allocation. The Company has filed for
claims indemnifiable by the selling shareholders of VISTA for $1.4 million,
which was recorded as a decrease to goodwill and an increase in other current
assets as of December 31, 2008. The holdback is estimated to be reduced for
the $1.4 million of claims indemnifiable by the selling shareholders and will be
released from escrow to the selling shareholders
when agreement
is achieved, which is expected to be in the second quarter of 2009.
The
Company recorded the acquisition using the purchase method of accounting, and
thus the results of operations from VISTA are included in the Company’s
consolidated financial statements (Physician segment) from the acquisition date.
Pursuant to SFAS No. 141, “Business Combinations” (SFAS 141), the purchase price
was allocated to the assets acquired and liabilities assumed based on their fair
values as of the date of the acquisition. Adjustments to the purchase
price will be reflected in subsequent periods, if and when conditions are
met. The purchase price was allocated as follows: $1.8 million to net tangible
assets acquired, $3.1 million to identified intangible assets with definite
lives, $6.5 million (trademarks) to identified intangible assets with indefinite
lives and $37.1 million to goodwill. The weighted average amortization period
for the identifiable intangible assets with definite lives is estimated to be
1.1 years. Intangible assets with definite lives include contractor relations of
$1.7 million (1.7 year weighted average amortization period), customer relations
of $1.4 million (3 month weighted average amortization period) and non-compete
agreements of $40,000 (3.0 year weighted average amortization period). Goodwill
is not deductible for tax purposes.
On
January 31, 2007, the Company acquired Oxford Global Resources, Inc. (Oxford), a
leading provider of high-end information technology and engineering staffing
services. The primary reasons for the Oxford acquisition were to enter the
markets for information technology and engineering staffing services and to
leverage the Company’s existing SG&A infrastructure.
The total
purchase price of $212.5 million consisted of (i) an initial price of $200.1
million, comprised of $190.1 million paid in cash and 795,292 shares of the
Company’s common stock valued at $10.0 million, (ii) $1.3 million in direct
acquisition costs, (iii) $6.3 million payment in April 2008 of the earn-out
related to the 2007 operating performance of Oxford, and (iv) $4.8 million for
the payment of the earn-out related to the 2008 operating performance of Oxford.
Payment of the 2008 earn-out is tentatively scheduled for April
2009, pending the agreement of all applicable parties to all terms and
provisions related to such payments. These costs have been included in the
Consolidated Balance Sheets in accrued earn-out payments. The initial price
includes a $20.0 million holdback for potential claims indemnifiable by the
Oxford shareholders, which was held in escrow and has been included as part of
the purchase price allocation. This holdback was released from escrow to the
selling shareholders on August 3, 2008.
The
Company recorded the acquisition using the purchase method of accounting, and
thus the results of operations from Oxford are included in the Company’s
consolidated financial statements (IT and Engineering segment) from the
acquisition date. Pursuant to SFAS 141, the purchase price was allocated to the
assets acquired and liabilities assumed based on their fair values as of the
date of the acquisition. Adjustments to the purchase price will be
reflected in subsequent periods, if and when conditions are met. The purchase
price was allocated as follows: $17.1 million to net tangible assets acquired,
$30.3 million to intangible assets with definite lives, $15.7 million to
identified intangible assets with indefinite lives (trademarks) and $149.6
million to goodwill. The weighted average amortization period for the
identifiable intangible assets with definite lives is estimated to be 2.1 years.
Intangible assets with definite lives include contractor relations of $20.8
million (1.7 year weighted average amortization period), customer relations of
$8.7 million (3.0 year weighted average amortization period), in-use software of
$0.5 million (2.0 year weighted average amortization period) and non-compete
agreements of $0.3 million (3.0 year weighted average amortization period). The
Company expects to reduce its federal and state income tax liability by
approximately $5.0 million per year over fifteen years as a result of an
election to classify the Oxford acquisition as an asset sale for tax purposes
under section 338(h)(10) of the Internal Revenue Code of 1986, as
amended.
The
Company utilized its existing cash and proceeds from the $165.0 million senior
secured credit facility to finance the acquisitions. See Note 4 for a discussion
of the credit facility.
The
summary below presents the amounts assigned to each major asset and liability
caption of VISTA and Oxford and presents pro-forma consolidated results of
operations for the years ended December 31, 2006 and 2007 as if the acquisition
of VISTA and Oxford described above had occurred at the beginning of each
period. The unaudited pro-forma financial information presented below gives
effect to certain adjustments, the amortization of intangible assets and
interest expense on acquisition related debt, other non-recurring expenses
related to VISTA and Oxford’s former owners and the shares issued as a result of
the shelf offering as if they had been issued at the beginning of 2006. The
pro-forma financial information is not necessarily indicative of the operating
results that would have occurred had the acquisition been consummated as of the
date indicated, nor are they necessarily indicative of future operating
results.
The
purchase price allocation as of December 31, 2008 was as follows (in
thousands):
|
|
|
|
|
|
|
|
|
Current
assets
|
|
$ |
12,840 |
|
|
$ |
24,938 |
Property
and equipment
|
|
|
2,221 |
|
|
|
3,433 |
Goodwill
|
|
|
37,143 |
|
|
|
149,556 |
Identifiable
intangible assets
|
|
|
9,640 |
|
|
|
45,900 |
Long-term
deposits and other long-term assets
|
|
|
58 |
|
|
|
644 |
Total
assets acquired
|
|
$ |
61,902 |
|
|
$ |
224,471 |
|
|
|
|
|
|
|
|
Current
liabilities
|
|
$ |
9,128 |
|
|
$ |
11,073 |
Long-term
liabilities
|
|
|
4,239 |
|
|
|
853 |
Total
liabilities assumed
|
|
|
13,367 |
|
|
|
11,926 |
Total
purchase price
|
|
$ |
48,535 |
|
|
$ |
212,545 |
The Pro-Forma
Consolidated Statement of Operations for the years ended December 31, 2007 and
2006 were as follows (in thousands):
|
|
Year
Ended December 31,
|
|
|
|
|
|
|
|
|
(unaudited)
|
Revenues
|
|
$ |
582,712 |
|
|
$ |
527,039 |
Cost
of service
|
|
|
397,528 |
|
|
|
365,704 |
Gross
profit
|
|
|
185,184 |
|
|
|
161,335 |
Selling,
general and administrative expenses
|
|
|
157,098 |
|
|
|
151,216 |
Operating
income
|
|
$ |
28,086 |
|
|
$ |
10,119 |
|
|
|
|
|
|
|
|
Net
income
|
|
$ |
8,951 |
|
|
$ |
3,907 |
|
|
|
|
|
|
|
|
Basic
earnings per share
|
|
$ |
0.25 |
|
|
$ |
0.11 |
Long-term
debt at December 31, 2008 and 2007 consisted of the following (in
thousands):
|
|
|
|
|
|
Senior
Secured Debt:
|
|
|
|
|
|
$20
million revolving credit facility, due January 2011
|
|
$ |
— |
|
|
$ |
— |
$145
million term loan facility, due January 2013
|
|
|
125,913 |
|
|
|
135,913 |
Total
|
|
$ |
125,913 |
|
|
$ |
135,913 |
|
|
|
|
|
|
|
|
Under terms
of the senior credit facility, the Company is required to maintain certain
financial covenants, including a minimum total leverage ratio, a minimum
interest coverage ratio and a limitation on capital expenditures. In addition,
the terms of the credit facility restrict the Company’s ability to pay dividends
of more than $2.0 million per year. As of December 31, 2008, the Company was in
compliance with all such covenants. The maximum total leverage ratio,
which measures total debt to our trailing twelve months consolidated earnings
before interest, taxes, depreciation and amortization of identifiable intangible
assets, as defined in the agreement, decreases to 1.25 from 2.0 for the twelve
months ended September 30, 2009. The credit facility is secured by
the assets of the Company.
The
payments made on the term loan were sufficient to cover the excess cash flow
payment required by the bank as well as all minimum quarterly
payments for the next four years through 2012. The revolving credit
facility requires a facility fee based on the average daily unused amount of the
commitment and the Company's total leverage ratio and is subject to the same
financial covenants and restrictions as the term loan facility.
On May 2,
2007, the Company entered into a transaction with a financial institution to fix
the underlying rate on $73.0 million of its outstanding bank loan for a period
of two years beginning June 30, 2007. This transaction, commonly known as an
interest rate swap, essentially fixes the Company’s base borrowing rate at
4.9425 percent as opposed to a floating rate, which resets at selected periods.
The current base rate on the loan balance in excess of $73.0 million, which will
be reset on March 31, 2009, is 2.25 percent plus LIBOR (0.47 percent at
December 31, 2008). On December 31, 2008 and December 31, 2007, the value of the
swap was marked-to-market, and the Company recorded a loss of $0.1 million
and $1.2 million, respectively, for the years then ended. The loss is shown in
interest expense in the Consolidated Statements of Operations and Comprehensive
Income, and the related liability of $1.3 million and $1.2 million,
respectively, as of December 31, 2008 and 2007 is included in the Consolidated
Balance Sheets in other accrued expenses.
5.
Goodwill and Other Identifiable Intangible Assets.
|
|
The
Company acquired VISTA and Oxford in the first quarter of 2007(see Note 3). In
December 2007, a small portion of the Oxford business (RMS) was sold for $1.0
million, reducing the acquired goodwill balance allocated to that respective
portion of the business.
The
changes in the carrying amount of goodwill for the years ended December 31, 2008
and 2007 are as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
as of December 31, 2008
|
|
$ |
1,197 |
|
|
$ |
15,912 |
|
|
$ |
37,143 |
|
|
$ |
148,525 |
|
|
$ |
202,777 |
Additional
consideration for earn-outs and escrow claim
|
|
|
― |
|
|
|
― |
|
|
|
4,299 |
|
|
|
4,952 |
|
|
|
9,251 |
Additional
consideration for RMS sale
|
|
|
― |
|
|
|
― |
|
|
|
― |
|
|
|
(26 |
) |
|
|
(26) |
Balance
as of December 31, 2007
|
|
$ |
1,197 |
|
|
$ |
15,912 |
|
|
$ |
32,844 |
|
|
$ |
143,599 |
|
|
$ |
193,552 |
Sale
of RMS business
|
|
|
― |
|
|
|
― |
|
|
|
― |
|
|
|
(1,035 |
) |
|
|
(1,035) |
Goodwill
related to Oxford acquisition
|
|
|
― |
|
|
|
― |
|
|
|
― |
|
|
|
144,634 |
|
|
|
144,634 |
Goodwill
related to VISTA acquisition
|
|
|
― |
|
|
|
― |
|
|
|
32,844 |
|
|
|
― |
|
|
|
32,844 |
Balance
as of December 31, 2006
|
|
$ |
1,197 |
|
|
$ |
15,912 |
|
|
$ |
― |
|
|
$ |
― |
|
|
$ |
17,109 |
As of
December 31, 2008 and December 31, 2007, the Company had the following
acquired identifiable intangible assets (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible
assets subject to amortization:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Customer
relations
|
3
months - 7 years
|
|
$ |
17,615 |
|
|
$ |
14,387 |
|
|
$ |
3,228 |
|
|
$ |
17,615 |
|
|
$ |
11,315 |
|
|
$ |
6,300 |
Contractor
relations
|
3 -
7 years
|
|
|
26,012 |
|
|
|
20,134 |
|
|
|
5,878 |
|
|
|
26,096 |
|
|
|
14,148 |
|
|
|
11,948 |
Non-compete agreements
|
2 -
3 years
|
|
|
390 |
|
|
|
268 |
|
|
|
122 |
|
|
|
390 |
|
|
|
145 |
|
|
|
245 |
In-use
software
|
2
years
|
|
|
500 |
|
|
|
500 |
|
|
|
― |
|
|
|
500 |
|
|
|
229 |
|
|
|
271 |
|
|
|
|
44,517 |
|
|
|
35,289 |
|
|
|
9,228 |
|
|
|
44,601 |
|
|
|
25,837 |
|
|
|
18,764 |
Intangible
assets not subject to amortization:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trademarks
|
|
|
|
22,200 |
|
|
|
— |
|
|
|
22,200 |
|
|
|
22,200 |
|
|
|
— |
|
|
|
22,200 |
Goodwill
|
|
|
|
202,777 |
|
|
|
— |
|
|
|
202,777 |
|
|
|
193,552 |
|
|
|
— |
|
|
|
193,552 |
Total
|
|
|
$ |
269,494 |
|
|
$ |
35,289 |
|
|
$ |
234,205 |
|
|
$ |
260,353 |
|
|
$ |
25,837 |
|
|
$ |
234,516 |
Amortization
expense for intangible assets subject to amortization with finite lives was $9.4
million, $15.3 million and $1.0 million for the years ended December 31,
2008, 2007 and 2006, respectively. Estimated amortization for each of the years
ended December 31, 2009 through December 31, 2013 is $6.1 million, $1.7 million, $0.7
million, $0.4 million and $0.3 million, respectively.
6.
401(k) Retirement Savings Plan, Deferred Compensation Plan and Change
in Control Severance Plan.
|
|
Under the
Company’s 401(k) Retirement Savings Plans, (which consist of a corporate 401(k)
Retirement Savings Plan for eligible employees of On Assignment and its
wholly-owned subsidiary, On Assignment Staffing Services, Inc., a separate
401(k) Retirement Savings Plan for eligible employees of VISTA and a separate
401(k) Retirement Savings Plan for eligible employees of Oxford), eligible
employees may elect to have a portion of their salary deferred and contributed
to the plans. The amount of salary deferred, up to certain limits set by the
IRS, is not subject to federal and state income tax at the time of deferral, but
will together with any earnings on deferred amounts, be subject to taxation upon
distribution. The plans cover all eligible employees and permit matching or
other discretionary contributions at the discretion of the Company’s Board of
Directors. Eligible employees under the corporate plan are must work 1,000 hours
prior to entering the Plan. Eligible employees under the VISTA plan are eligible
to enroll the first of the month following hire date and eligible employees
under the Oxford plan are eligible to enroll once they complete
three months of service prior to entering the plan. The Company made
contributions to the plans of $1.3 million, $1.1 million and $0.6 million
during the years ended December 31, 2008, 2007 and 2006, respectively.
These amounts are included in SG&A expenses in the Consolidated Statements
of Operations and Comprehensive Income.
Effective
January 1, 1998, the Company implemented the On Assignment, Inc.
Deferred Compensation Plan. The plan permits a select group of management or
highly compensated employees or directors that contribute materially to the
continued growth, development and future business success of the Company to
annually elect to defer up to 100 percent of their base salary, annual bonus,
stock option gain or fees on a pre-tax basis and earn tax-deferred returns on
these amounts. On September 4, 2008, effective as of January 1, 2008, the
Company amended the On Assignment Deferred Compensation Plan so that it applies
to deferrals made before January 1, 2005 only (hereinafter referred to as the
1998 Deferred Compensation Plan) and, also effective January 1, 2008, adopted a
new plan, called the On Assignment Deferred Compensation Plan – Effective
January 1, 2008, applicable to deferrals made on or after January 1, 2005
(referred to herein as the 2008 Deferred Compensation Plan). The
plans are not intended to be “qualified” within the meaning of IRS Code Section
401(a), rather, the plans are “unfunded and maintained by an employer primarily
for the purpose of providing deferred compensation for a select group of
management or highly compensated employees” within the meaning of
the Employee Retirement Income Security Act of 1974, as amended (ERISA),
Sections 201(2), 301(a)(3) and 401(a)(1).
Distributions
from the 1998 Deferred Compensation Plan are commenced within 60 days after the
participant’s retirement, death or termination of employment, in a lump sum, or
over five, ten or fifteen years, except that payments made upon termination
(other than due to death or retirement), are paid in a lump sum if the
participant’s account balance at the time of termination is less than
$25,000. Furthermore, if the Company determines in good faith prior
to a change in control that there is a reasonable likelihood that any
compensation paid to a participant for a taxable year of the Company would not
be deductible by the Company solely by reason of the limitation under IRS Code
Section 162(m), (“Section 162(m)”) then the Company may defer all or any portion
of a distribution until the earliest possible date, as determined by the Company
in good faith, on which the deductibility of compensation paid or payable to the
participant for the taxable year of the Company during which the distribution is
made will not be limited by Section 162(m), or if earlier, the effective date of
a change in control.
Distributions
from the 2008 Deferred Compensation Plan are commenced within 60 days following
the participant’s termination of employment, in a lump sum or in annual
installments of up to 15 years, except that if the participant’s account balance
is less than the applicable dollar amount specified in IRS Code Section
402(g)(1)(B), in effect for the year in which the distribution is to occur,
payment shall be made in a lump sum. Notwithstanding the foregoing,
in compliance with certain requirements of IRS Code Section 409A, plan
distributions to “specified employees” will commence the first day after the end
of the six month period immediately following the date on which the participant
experiences a termination of employment. Furthermore, if the Company
reasonably anticipates that the Company’s deduction with respect to any
distribution from the 2008 Deferred Compensation Plan would be limited or
eliminated by application of Section 162(m), then to the extent permitted by
applicable treasury regulations, payment shall be delayed until the earliest
date the Company reasonably anticipates that the deduction of the payment will
not be limited or eliminated by application of Section 162(m).
At
December 31, 2008 and 2007, the deferred compensation liability under the
1998 Deferred Compensation Plan was approximately $0.2 million and $0.3
million, respectively, and the liability under the 2005 Deferred Compensation
Plan for the same periods was approximately $1.4 million and $1.7 million,
respectively. Life insurance policies are maintained as a funding source to the
plans, under which the Company is the sole owner and beneficiary of such
insurance. The cash surrender value of these life insurance policies, which is
reflected in other assets in the accompanying Consolidated Balance Sheets, was
approximately $1.6 million and $2.0 million at December 31, 2008 and
2007, respectively.
The
Company adopted the On Assignment, Inc. Change in Control Severance Plan
(the CIC Plan) to provide severance benefits for officers and certain other
employees who are terminated following an acquisition of the Company. This CIC
Plan was adopted on February 12, 1998 and amended on
August 8, 2004, January 23, 2007, and December 11, 2008. Under the CIC
Plan, if an eligible employee is involuntarily terminated within eighteen months
after a change in control, as defined in the CIC Plan, then the employee will be
entitled to (i) a payment equal to the employee’s annual salary plus the
employee’s target bonus, payable in a lump sum, and (ii) a lump sum payment
representing the cost of continuation of health and welfare benefits, under the
Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”) for periods of
time ranging from nine months to eighteen months, for employees with titles of
vice president or higher. Severance benefits under the plan range from one month
to eighteen months of salary and target bonus, depending on the employee’s
length of service and position with the Company.
The
Company entered into an Amended and Restated Executive Change of Control
Agreements with the Chief Executive Officer and the Chief Financial Officer on
December 11, 2008, primarily for the purpose of causing their existing
agreements to meet the requirements of Code Section 409A. These
agreements supersede the CIC Plan with respect to these officers and
provide, in the event of an involuntary termination occurring within six
months and ten days following a change of control of the Company, for the
following benefits (i) a lump-sum payment equal to three times (for the Chief
Executive Officer’s salary plus target bonus) or two and a half times (for the
Chief Financial Officer) the sum of the officer’s, (ii) eighteen months
continuation of the officer’s health and welfare benefits and car allowance,
(subject to limitations in connection with subsequent employment), (iii) cash
payments equal to insurance premiums and retirement and deferred compensation
contributions that the Company would have paid (in each case, if any), over a
period of eighteen months following termination, and (iv) payment of up to
$15,000 of the cost of outplacement services. Additionally, under the
arrangements, immediately prior to a change of control, all outstanding Company
stock options, restricted stock and stock units held by the officer will become
fully vested (and, in the case of options, remain exercisable for an extended
period), subject, in the case of certain performance-vesting awards, to any
express limitations contained in the officer’s employment or other governing
agreement. In addition, the agreements entitle the executives to tax
gross-up payments in the event that any payments to the executives are subject
to “golden parachute” excise taxes under Code Section 280G.
7. Commitments and
Contingencies.
The
Company leases its facilities and certain office equipment under operating
leases, which expire at various dates through 2016. Certain leases contain rent
escalations and/or renewal options. Rent expense for all significant leases is
recognized on a straight-line basis. At December 31, 2008 and 2007, the
balance of deferred rent liability was $1.0 million and $0.7 million,
respectively, and is reflected in other current and long-term liabilities in the
accompanying Consolidated
Balance Sheets.
The following
is a summary of specified contractual cash obligation payments by the Company as
of December 31, 2008 (in thousands):
|
|
|
|
|
|
|
|
Accrued
Earn-Out Payments
|
|
|
|
2009
|
|
$ |
― |
|
|
$ |
6,426 |
|
|
$ |
10,168 |
|
|
$ |
16,594 |
2010
|
|
|
― |
|
|
|
5,456 |
|
|
|
― |
|
|
|
5,456 |
2011
|
|
|
― |
|
|
|
3,420 |
|
|
|
― |
|
|
|
3,420 |
2012
|
|
|
― |
|
|
|
2,011 |
|
|
|
― |
|
|
|
2,011 |
2013
|
|
|
125,913 |
|
|
|
1,512 |
|
|
|
― |
|
|
|
127,425 |
Thereafter
|
|
|
― |
|
|
|
3,757 |
|
|
|
― |
|
|
|
3,757 |
Total
|
|
$ |
125,913 |
|
|
$ |
22,582 |
|
|
$ |
10,168 |
|
|
$ |
158,663 |
Rent
expense for the years ended December 31, 2008, 2007, and 2006 was $9.5
million, $8.8 million and $5.1 million respectively. These amounts are included
in SG&A expenses in the Consolidated Statements of Operations and
Comprehensive Income.
As
discussed in Note 3, the Company has accrued $5.3 million and $4.8 million for
the payment of the earn-outs related to the 2008 operating performance of
VISTA and Oxford, respectively, and have been included in the Consolidated
Balance Sheets in accrued earn-out payments. We also filed for claims
indemnifiable by the selling shareholders of VISTA for $1.4 million, which was
recorded as a decrease to goodwill and an increase in other current assets as of
December 31, 2008. Payment of the earn-outs and claim
indemnification is tentatively scheduled for April 2009, pending the agreement
of all applicable parties to all terms and provisions related to such payments.
As discussed
in Note 1, the Company is partially self-insured for its workers’ compensation
liability related to the Life Sciences, Healthcare and IT and Engineering
segments as well as its medical malpractice liability in the Physician segment.
The Company accounts for claims incurred but not yet reported based on estimates
derived from historical claims experience and current trends of industry data.
Changes in estimates, differences in estimates and
actual
payments for claims are recognized in the period that the estimates changed or
the payments were made. The self-insurance claim liability was approximately
$9.8 million and $8.9 million at December 31, 2008 and 2007,
respectively. Additionally, the Company has letters of credit
outstanding to secure obligations for workers’ compensation claims
with various insurance carriers. The letters of credit outstanding at
December 31, 2008 and 2007 were $3.5 million and $4.4 million,
respectively.
As of
December 31, 2008 and 2007, the Company has an income tax reserve in other
long-term liabilities related to uncertain tax positions of $0.3
million.
Legal
Proceedings
The
Company is involved in various legal proceedings, claims and litigation arising
in the ordinary course of business. However, based on the facts currently
available, we do not believe that the disposition of matters that are pending or
asserted will have a material adverse effect on our financial position, results
of operations or cash flows.
|
|
|
|
|
|
|
|
|
|
|
|
United
States
|
|
$ |
32,085 |
|
|
$ |
14,435 |
|
|
$ |
9,858 |
Foreign
|
|
|
2,146 |
|
|
|
2,380 |
|
|
|
1,727 |
|
|
$ |
34,231 |
|
|
$ |
16,815 |
|
|
$ |
11,585 |
|
|
|
|
|
|
|
|
|
|
|
|
The
provision for income taxes consists of the following (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
Current:
|
|
|
|
|
|
|
|
|
Federal
|
|
$ |
13,319 |
|
|
$ |
9,804 |
|
|
$ |
3,763 |
State
|
|
|
2,314 |
|
|
|
1,125 |
|
|
|
216 |
Foreign
|
|
|
691 |
|
|
|
727 |
|
|
|
468 |
|
|
|
16,324 |
|
|
|
11,656 |
|
|
|
4,447 |
Deferred:
|
|
|
|
|
|
|
|
|
|
|
|
Federal
|
|
|
(1,292 |
) |
|
|
(4,536 |
) |
|
|
82 |
State
|
|
|
232 |
|
|
|
365 |
|
|
|
367 |
Foreign
|
|
|
(3 |
) |
|
|
8 |
|
|
|
(10) |
|
|
|
(1,063 |
) |
|
|
(4,163 |
) |
|
|
439 |
|
|
|
|
|
|
|
|
|
|
|
|
Change
in Valuation Allowance
|
|
|
― |
|
|
|
― |
|
|
|
(4,345) |
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$ |
15,261 |
|
|
$ |
7,493 |
|
|
$ |
541 |
|
|
|
|
|
|
|
|
|
|
|
|
As of
December 31, 2008, the Company had no federal net operating losses and
total combined state net operating losses of $10.7 million. The state net
operating losses can be carried forward for up to 20 years and begin expiring in
2013.
At
December 31, 2008, the Company had accumulated net foreign earnings of $7.5
million. The Company intends to reinvest the undistributed earnings of its
foreign subsidiaries and, therefore, no U.S. income tax has been provided on the
foreign earnings.
During the
quarter and year ended December 31, 2004, the Company established a
valuation allowance against its net domestic deferred income tax assets. The
valuation allowance was calculated pursuant to SFAS 109, which requires an
assessment of both positive and negative evidence when measuring the need for a
valuation allowance. Such evidence includes a company’s past and projected
future performance, the market environment in which the company operates, the
utilization of past tax credits and the length of carryback and carryforward
periods of net operating losses. At the end of 2006, the Company evaluated the
need for the valuation allowance in accordance with the Company’s valuation
allowance reversal methodology and in conjunction with SFAS 109. The Company
concluded that as a result of sustained profitability, which was evidenced by
consecutive quarters of net income along with projections of pre-tax income in
future years, that the criteria had been met for the full reversal of the
valuation allowance. Of the $4.9 million valuation allowance reversal, $4.3
million resulted in an income tax benefit and $0.6 million was recorded as an
increase to additional paid in capital resulting from stock option deductions
taken in 2006.
The
Company had gross deferred tax assets of $12.3 million and $9.3 million and
gross deferred tax liabilities of $5.0 million and $2.9 million at
December 31, 2008 and December 31, 2007, respectively. Foreign
deferred tax assets and liabilities were not material as of December 31,
2008 and 2007 and are included in the Federal balances in the table
below.
The
components of deferred tax assets (liabilities) are as follows (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred
income tax assets (liabilities):
|
|
|
|
|
|
|
|
|
|
|
|
Current:
|
|
|
|
|
|
|
|
|
|
|
|
Allowance for doubtful
accounts
|
|
$ |
836 |
|
|
$ |
103 |
|
|
$ |
770 |
|
|
$ |
101 |
Employee related
accruals
|
|
|
2,321 |
|
|
|
299 |
|
|
|
1,639 |
|
|
|
188 |
State taxes
|
|
|
776 |
|
|
|
— |
|
|
|
386 |
|
|
|
— |
Workers’ compensation loss
reserve
|
|
|
991 |
|
|
|
139 |
|
|
|
1,191 |
|
|
|
177 |
Medical malpractice loss
reserve
|
|
|
2,648 |
|
|
|
116 |
|
|
|
2,072 |
|
|
|
76 |
Net operating loss
carry-forwards
|
|
|
— |
|
|
|
138 |
|
|
|
— |
|
|
|
725 |
Other
|
|
|
850 |
|
|
|
130 |
|
|
|
599 |
|
|
|
94 |
Total
current deferred income tax assets
|
|
|
8,422 |
|
|
|
925 |
|
|
|
6,657 |
|
|
|
1,361 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-current:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net operating loss
carry-forwards
|
|
|
— |
|
|
|
453 |
|
|
|
— |
|
|
|
— |
Stock-based
compensation
|
|
|
2,259 |
|
|
|
147 |
|
|
|
1,040 |
|
|
|
110 |
Purchased intangibles,
net
|
|
|
(2,584 |
) |
|
|
(164 |
) |
|
|
(1,256 |
) |
|
|
59 |
Depreciation and amortization
expense
|
|
|
(1,833 |
) |
|
|
(152 |
) |
|
|
(1,454 |
) |
|
|
(109) |
Other
|
|
|
112 |
|
|
|
(235 |
) |
|
|
111 |
|
|
|
(165) |
Total
non-current deferred income tax (liabilities) assets
|
|
|
(2,046 |
) |
|
|
49 |
|
|
|
(1,559 |
) |
|
|
(105) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
deferred income tax assets
|
|
$ |
6,376 |
|
|
$ |
974 |
|
|
$ |
5,098 |
|
|
$ |
1,256 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The
reconciliation between the amount computed by applying the U.S. federal
statutory tax rate of 35 percent to income before income taxes and the actual
income taxes is as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
Income
tax provision at the statutory rate
|
|
$ |
11,981 |
|
|
$ |
5,885 |
|
|
$ |
3,939 |
|
|
|
|
|
|
|
|
|
|
|
|
State
income taxes, net of federal benefit
|
|
|
1,569 |
|
|
|
892 |
|
|
|
560 |
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
160 |
|
|
|
18 |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
Valuation
Allowance
|
|
|
— |
|
|
|
— |
|
|
|
(4,345) |
|
|
|
|
|
|
|
|
|
|
|
|
Income
tax contingency
|
|
|
32 |
|
|
|
(53 |
) |
|
|
350 |
|
|
|
|
|
|
|
|
|
|
|
|
Foreign
tax rate
|
|
|
(61 |
) |
|
|
(105 |
) |
|
|
(109) |
|
|
|
|
|
|
|
|
|
|
|
|
Permanent
differences
|
|
|
1,580 |
|
|
|
856 |
|
|
|
146 |
Total
|
|
$ |
15,261 |
|
|
$ |
7,493 |
|
|
$ |
541 |
|
|
|
|
|
|
|
|
|
|
|
|
The
Company receives a tax deduction for stock-based awards upon exercise of a
non-qualified stock option or as the result of disqualifying dispositions made
by directors, officers and employees. A disqualifying disposition occurs when
stock acquired through the exercise of incentive stock options or the Employee
Stock Purchase Plan is disposed of prior to the required holding period. In
addition, the Company receives a tax deduction upon the vesting of restricted
stock units or restricted stock awards. The Company received tax deductions
of $0.8 million from stock-based awards in 2008 and 2007.
The
Company adopted the provisions of FASB Interpretation No. 48 “Accounting for
Uncertainty in Income Taxes — an interpretation of FASB Statement No. 109” (FIN
48) on January 1, 2007. As a result of the implementation of FIN 48, the Company
made a comprehensive review of its portfolio of uncertain tax positions in
accordance with recognition standards established by FIN 48. In this regard, an
uncertain tax position represents the Company’s expected tax treatment of a tax
position taken in a filed tax return, or planned to be taken in a future return,
that has not been reflected in measuring income tax expense for financial
reporting purposes. As a result of this review, the Company adjusted the
estimated value of its uncertain tax positions by recognizing additional
liabilities totaling $0.2 million, including an accrual for interest and
penalties of $21,000, through a charge to retained earnings. Upon the adoption
of FIN 48, the estimated value of the Company’s uncertain tax positions was a
liability of $0.6 million, which includes penalties and interest, of which $0.2
million was carried in other long-term liabilities and $0.4 million was carried
as a reduction to non-current deferred tax assets in the consolidated condensed
statement of financial position as of March 31, 2007. As of December 31, 2008
and 2007, the estimated value of the Company’s uncertain tax positions is a
liability of $0.5 million, which includes penalties and interest, of which $0.3
million was carried in other long-term liabilities and $0.2 million was carried
as a reduction to non-current deferred tax assets. If the Company’s
positions are sustained by the taxing authority in favor of the Company, the
entire $0.5 million would reduce the Company’s effective tax rate. The Company
recognizes accrued interest and penalties related to uncertain tax positions in
income tax expense.
The
following is a reconciliation of the total amounts of unrecognized tax
benefits for the years ended December 31, 2008 and 2007 (in
thousands):
|
|
For
the year ended December 31,
|
|
|
2008
|
|
|
2007
|
Unrecognized
Tax Benefit beginning of year
|
|
$ |
832 |
|
|
$ |
841 |
Gross
Decreases - tax positions in prior year
|
|
|
(109 |
) |
|
|
(122) |
Gross
Decreases - tax positions in prior year
|
|
|
— |
|
|
|
(46) |
Gross
Increases - tax positions in current year
|
|
|
89 |
|
|
|
159 |
Unrecognized
Tax Benefit end of year
|
|
$ |
812 |
|
|
$ |
832 |
Related
to the unrecognized tax benefits noted above, the Company decreased accrued
penalties by $6,000 and gross interest by $12,000 during 2008 and in total, as
of December 31, 2008, had recognized a liability for penalties of $12,000 and
gross interest of $11,000. The Company
believes that there will be no significant increases or decreases to
unrecognized tax benefits within the next twelve
months.
The Company is
subject to taxation in the United States and various states and foreign
jurisdictions. The Internal Revenue Service (IRS) has examined and substantially
concluded all tax matters for years through 2006. Open tax years related to
federal, state and foreign jurisdictions remain subject to examination but are
not considered material.
9.
Earnings per Share.
Basic
earnings per share are computed based upon the weighted average number of shares
outstanding and diluted earnings per share are computed based upon the weighted
average number of shares and dilutive share equivalents (consisting of incentive
stock options, non-qualified stock options, restricted stock units and
restricted stock awards) outstanding during the periods using the treasury stock
method.
The
following is a reconciliation of the shares used to compute basic and diluted
earnings per share (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number of shares outstanding used to compute basic earnings per
share
|
|
|
35,487 |
|
|
|
35,138 |
|
|
|
27,155 |
Dilutive
effect of stock-based awards
|
|
|
371 |
|
|
|
633 |
|
|
|
897 |
Number
of shares used to compute diluted earnings per share
|
|
|
35,858 |
|
|
|
35,771 |
|
|
|
28,052 |
The
following table outlines the weighted average share equivalents outstanding
during each period that were excluded from the computation of diluted earnings
per share because the exercise price for these options was greater than the
average market price of the Company’s shares of common stock during the
respective periods. Also excluded from the computation of diluted earnings per
share were other share equivalents that became anti-dilutive when applying the
treasury stock method.
|
|
|
|
|
|
|
|
|
|
|
|
Anti-dilutive
common share equivalents outstanding (in thousands):
|
|
|
2,645 |
|
|
|
1,974 |
|
|
|
767 |
10.
Stock Option Plan and Employee Stock Purchase
Plan.
|
|
As of
December 31, 2008, the Company maintained its Restated 1987 Stock Option Plan
(as amended and restated through April 17, 2007) that was most recently approved
by shareholders on June 1, 2007 (the Plan). The
Company
issues stock options, restricted stock units (RSUs) and restricted stock awards
(RSAs) in accordance with the Plan and records compensation expense in
accordance with SFAS No. 123 (revised 2004), “Share-Based Payment,” (SFAS 123R).
Compensation expense charged against income related to stock-based compensation
was $6.3 million, $6.4 million and $3.0 million for the years ended December 31,
2008, 2007 and 2006, respectively, and is included in the Consolidated
Statements of Operations and Comprehensive Income in selling, general and
administrative expenses (SG&A). The Company has recognized an income tax
benefit of $2.2 million, $2.0 million, and $0.8 million in the income statement
for stock-based compensation arrangements for the years ended December 31, 2008,
2007 and 2006, respectively.
The Plan,
which is shareholder-approved, permits the grant of awards, including cash,
stock options, RSUs, RSAs, stock appreciation rights, unrestricted stock
units and dividend equivalent rights to its employees, officers, members of its
Board of Directors, consultants and advisors covering up to 13.9 million
shares of common stock, subject to per-recipient, annual and other periodic
caps. The Company believes that stock-based compensation better aligns the
interests of its employees and directors with those of its shareholders versus
exclusively providing cash-based compensation. Stock options are granted
with an exercise price equal to the closing market price of the Company’s stock
at the date of grant. Stock option awards generally vest over four years of
continuous service with the Company and generally have 10-year contractual terms
while RSUs and RSAs generally vest over a three year continuous
service period, however individual vesting and other terms may vary with respect
to all types of awards. Certain awards also provide for accelerated vesting in
the event of a change in control and/or upon certain qualifying
terminations of service.
The
preceding paragraph describes the general terms of most stock-based incentives
awarded by the Company. However, the Company issued a discrete set of
stock-based awards to its Chief Executive Officer that differs from those
generally stated terms. On January
2, 2008, the Chief Executive Officer was granted (1) 78,369 RSUs valued at
$0.5 million which vest on the third anniversary of the date of the grant, (2)
78,369 RSAs valued at $0.5 million, which vest December 31, 2009 contingent
upon meeting certain performance objectives approved by the Compensation
Committee (based on adjusted earnings before interest, taxes, depreciation and
amortization, or EBITDA) and (3) 78,369 RSUs valued at $0.5 million, which vest
December 31, 2010 contingent upon the Company meeting certain stock price
performance objectives relative to its peers over three years from the date of
grant. On January 2, 2007, the Chief Executive Officer was granted (1) 42,553
RSUs valued at $0.5 million, which vest on the third anniversary of the date of
the grant, (2) 42,553 shares of RSAs valued at $0.5 million, which vest December
31, 2009 contingent upon meeting certain performance objectives approved by the
Compensation Committee (based on adjusted earnings before interest, taxes,
depreciation and amortization, or EBITDA) and (3) 42,553 RSUs valued at $0.5
million, which vest December 31, 2009 contingent upon the Company meeting
certain stock price performance objectives relative to its peers over three
years from the date of grant. All awards are subject to the executive’s
continued employment through such vesting dates, however, the
vesting of certain awards will accelerate upon the occurrence of a change in
control of the Company and/or upon certain qualifying terminations of
employment. The grant-date fair-value of these awards, which was determined by
applying certain provisions of SFAS 123R relative to performance-based and
market-based awards, is generally being expensed over the vesting term. The
impact of these awards is reflected in the Restricted Stock Units and Restricted
Stock Awards section below.
On
September 6, 2007, the Company issued RSUs to certain officers. These awards
generally vest over three years and are forty percent contingent upon the
Company meeting certain performance objectives approved by the Compensation
Committee and are subject to the respective officer’s continued employment
through such vesting dates. The remaining sixty percent are subject solely to
the respective officer’s continued employment through such vesting
dates.
The fair
value of each option award is estimated on the date of grant using a
Black-Scholes option valuation model that incorporates assumptions disclosed in
the table below. Expected volatility is based on historical volatility of the
underlying stock for a period consistent with the expected lives of the stock
options as the Company believes this is a reasonable representation of future
volatility. Additionally, the stock option valuation model selected by the
Company uses historical data and management judgment to estimate stock option
exercise behavior and employee turnover rates to estimate the number of stock
option awards that will eventually vest. The expected life, or term, of options
granted is derived from historical exercise behavior and represents the period
of time that stock option awards are expected to be outstanding. The Company has
selected a risk-free rate based on the implied yield available on U.S. Treasury
Securities with a maturity equivalent to the options’ expected term. For RSUs
and RSAs, the Company records compensation expense based on the fair market
value of the awards on the grant date.
Stock
Options
The following table displays the
weighted average assumptions that have been applied to estimate the fair value
of stock option awards on the date of grant for the years ended December 31,
2008, 2007 and 2006:
|
|
|
|
|
|
Dividend
yield
|
—
|
—
|
—
|
Risk-free
interest rate
|
1.7%
|
4.6%
|
4.7%
|
Expected
volatility
|
51.5%
|
47.1%
|
51.7%
|
Expected
lives
|
3.4
years
|
3.4
years
|
4.0
years
|
The
following summarizes pricing and term information for options outstanding as of
December 31, 2008:
|
|
|
|
|
|
|
|
|
|
Number
Outstanding at December 31, 2008
|
|
Weighted
Average Remaining Contractual Life
|
|
Weighted
Average Exercise Price
|
|
|
Number
Exercisable at December 31, 2008
|
|
|
Weighted
Average Exercise Price
|
$ |
3.97 |
|
─
|
|
$ |
5.11 |
|
|
|
741,033 |
|
6.4
years
|
|
$ |
4.85 |
|
|
|
580,513 |
|
|
$ |
4.95 |
|
5.13 |
|
─
|
|
|
9.14 |
|
|
|
650,284 |
|
6.9
years
|
|
|
6.06 |
|
|
|
388,421 |
|
|
|
5.97 |
|
9.15 |
|
─
|
|
|
11.39 |
|
|
|
724,337 |
|
7.9
years
|
|
|
11.15 |
|
|
|
452,240 |
|
|
|
11.19 |
|
11.45 |
|
─
|
|
|
13.13 |
|
|
|
541,537 |
|
7.1
years
|
|
|
12.10 |
|
|
|
333,603 |
|
|
|
12.07 |
|
13.31 |
|
─
|
|
|
13.31 |
|
|
|
649,252 |
|
8.1
years
|
|
|
13.31 |
|
|
|
292,040 |
|
|
|
13.31 |
|
13.69 |
|
─
|
|
|
29.75 |
|
|
|
276,230 |
|
|
|
|
19.06 |
|
|
|
276,230 |
|
|
|
19.06 |
$ |
3.97 |
|
─
|
|
$ |
29.75 |
|
|
|
3,582,673 |
|
6.9
years
|
|
$ |
10.07 |
|
|
|
2,323,047 |
|
|
$ |
10.09 |
The
following table is a summary of stock option activity under the Plan as of
December 31, 2008 and changes for the year then ended:
|
|
|
|
|
Non-
Qualified Stock Options
|
|
|
Weighted
Average Exercise Price Per Share
|
|
|
Weighted
Average Remaining Contractual
Term
(Years)
|
|
|
Aggregate
Intrinsic Value
|
Outstanding
at January 1, 2008
|
|
|
851,761 |
|
|
|
2,860,726 |
|
|
$ |
10.40 |
|
|
|
7.4 |
|
|
$ |
2,174,000 |
Granted
|
|
|
― |
|
|
|
401,950 |
|
|
$ |
5.44 |
|
|
|
|
|
|
|
|
Exercised
|
|
|
(52,759 |
) |
|
|
(45,428 |
) |
|
$ |
4.87 |
|
|
|
|
|
|
|
|
Canceled
|
|
|
(116,694 |
) |
|
|
(316,883 |
) |
|
$ |
9.79 |
|
|
|
|
|
|
|
|
Outstanding
at December 31, 2008
|
|
|
682,308 |
|
|
|
2,900,365 |
|
|
$ |
10.07 |
|
|
|
6.9 |
|
|
$ |
782,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vested
or Expected to Vest at December 31, 2008
|
|
|
676,170 |
|
|
|
2,601,703 |
|
|
$ |
10.12 |
|
|
|
6.7 |
|
|
$ |
693,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable
at December 31, 2008
|
|
|
631,679 |
|
|
|
1,691,368 |
|
|
$ |
10.09 |
|
|
|
6.0 |
|
|
$ |
513,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The table
above includes 144,000 of non-employee director stock options outstanding as of
December 31, 2008 and 195,000 as of January 1, 2008.
The
weighted-average grant-date fair value of options granted during the years ended
December 31, 2008, 2007 and 2006 was $2.08, $4.05, and $5.05 per option,
respectively. The total intrinsic value of options exercised during
the years ended December 31, 2008, 2007 and 2006 was $0.2 million, $2.4 million,
and $1.4 million, respectively.
As of
December 31, 2008 there was unrecognized compensation expense of $2.3 million
related to unvested stock options based on options that are expected to vest.
The unrecognized compensation expense is expected to be recognized over a
weighted-average period of 2.6 years.
Restricted
Stock Units and Restricted Stock Awards
A summary of
the status of the Company’s unvested RSUs and RSAs as of December 31, 2008 and
changes during the year then ended are presented below:
|
|
Restricted
Stock Units / Awards
|
|
|
Weighted
Average Grant-Date Fair Value Per Unit / Award
|
Unvested
RSUs and RSAs outstanding at January 1, 2008
|
|
|
477,229 |
|
|
$ |
10.92 |
Granted
|
|
|
475,008 |
|
|
|
6.77 |
Vested
|
|
|
(186,409 |
) |
|
|
10.11 |
Forfeited
|
|
|
(6,111 |
) |
|
|
8.66 |
Unvested
RSUs and RSAs outstanding at December 31, 2008
|
|
|
759,717 |
|
|
$ |
8.54 |
Unvested
and expected to vest RSUs and RSAs outstanding at December 31,
2008
|
|
|
702,121 |
|
|
$ |
8.46 |
|
|
|
|
|
|
|
|
The table
above includes 23,068 RSUs that were awarded to non-employee directors on
August 1, 2008, of which 11,536 shares vested immediately upon issuance and
the remaining shares will vest on August 1, 2009 and 11,532 shares are
outstanding as of December 31, 2008. The weighted average grant-date fair value
of these awards was $8.67. In accordance with SFAS 123R, the Company
records compensation expense based on the fair market value of the awards on the
grant date. There was unrecognized compensation of $58,000 as of December 31,
2008 related to these RSUs that will be recorded over the remaining term of
approximately seven months.
The
Company has approved certain awards in which a variable number of shares are to
be granted to the employees based on a fixed monetary amount. As such, the
provisions of SFAS 123R and SFAS No. 150, “Accounting for Certain Financial
Instruments with Characteristics of both Liabilities and Equity” (SFAS 150)
require the Company to classify and account for these awards as liability awards
until the number of shares is determined. The expense related to these awards
for the years ended December 31, 2008 and 2007 was $0.2 million and $0.3
million, respectively, and is included in SG&A in the Consolidated
Statements of Operations and Comprehensive Income, and the associated liability
of $0.2 million and $0.3 million, respectively, is included in the Consolidated
Balance Sheets in other current liabilities.
The
weighted-average grant-date fair value of RSUs and RSAs granted during the years
ended December 31, 2008, 2007 and 2006 was $6.77, $11.98 and $11.06 per award,
respectively. The total intrinsic value of RSUs and RSAs vested
during years ended December 31, 2008, 2007 and 2006 was $1.3 million, $1.7
million and $1.5 million, respectively.
As of
December 31, 2008, there was unrecognized compensation expense of $3.7 million
related to unvested RSUs and RSAs based on awards that are expected to vest. The
unrecognized compensation expense is expected to be recognized over a
weighted-average period of 1.9 years.
The
Company approved stock-based awards for its Chief Executive Officer with terms
as follows: On January 2, 2009, the Chief Executive Officer, pending
continued employment through such grant dates, will be granted (1) RSAs valued
at $0.5 million, which vest December 31, 2009, contingent upon meeting certain
performance objectives, which will be set and approved annually by the
Compensation Committee in the first quarter of 2009 (based on adjusted EBITDA)
and (2) RSUs valued at $0.5 million, which vest December 31, 2011, contingent
upon the Company meeting certain stock price performance objectives relative to
its peers over three years from the date of grant, which will be set within 90
days of the first trading day of the day they are granted. All awards are
subject to the executive’s continued employment through such vesting dates, however, the
vesting of certain awards will accelerate upon the occurrence of a change in
control of the Company and/or upon certain qualifying terminations of
employment. These awards are not included in the disclosures above and there is
no related expense in the current period as the conditions for these awards have
not been set.
Employee
Stock Purchase Plan
The
Employee Stock Purchase Plan (ESPP) allows eligible employees to purchase common
stock of the Company, through payroll deductions, at eighty-five percent of the
lower of the market price on the first day or the last day of semi-annual
purchase periods. The ESPP is intended to qualify as an “employee stock purchase
plan” under IRS Code Section 423. Eligible employees may contribute multiples of
one percent of their eligible earnings toward the purchase of the stock (subject
to certain IRS limitations). Under this plan, 315,827, 126,484 and 78,632 shares
of common stock were issued to employees for the years ended December 31, 2008,
2007 and 2006, respectively.
In
accordance with the ESPP, shares of common stock are transferred to
participating employees at the conclusion of each six month enrollment period,
which end on the last business day of the month in February and August each
year. The weighted average fair value of stock purchased under the
Company’s ESPP was $2.21, $3.02 and $2.58 per share for the years ended December
31, 2008, 2007 and 2006, respectively. Compensation expense of shares purchased
under the ESPP is measured based on a Black-Scholes option-pricing model. The
model accounts for the discount from market value and applies an expected life
in line with each six month purchase period. The amounts recognized as
stock-based compensation expense related to the ESPP were $0.6 million, $0.5
million and $0.2 million for the years ended December 31, 2008, 2007 and 2006,
respectively.
The
Company has four reportable segments: Life Sciences, Healthcare, Physician
and IT and Engineering. The Life Sciences (formerly Lab Support) segment
provides contract, contract-to-permanent and direct placement services of
laboratory and scientific professionals to the biotechnology, pharmaceutical,
food and beverage, medical device, personal care, chemical and environmental
industries. These contract staffing specialties include chemists, clinical
research associates, clinical lab assistants, engineers, biologists,
biochemists, microbiologists, molecular biologists, food scientists, regulatory
affairs specialists, lab assistants and other skilled scientific
professionals.
The
Healthcare segment includes the combined results of the Nurse Travel and Allied
Healthcare (formerly Medical Financial and Allied, or MF&A) lines of
business. The lines of business have been aggregated into the Healthcare segment
based on similar economic characteristics, end-market customers and management
personnel. The Healthcare segment provides contract, contract-to-permanent and
direct placement of professionals from more than ten healthcare, medical
financial and allied occupations. These contract staffing specialties include
nurses, specialty nurses, respiratory therapists, surgical technicians, imaging
technicians, x-ray technicians, medical technologists, phlebotomists, coders,
billers, claims processors and collections staff.
The
Physician segment, comprised of VISTA Staffing Solutions, Inc., provides
contract and direct placement physicians to healthcare organizations. The
Physician segment works with nearly all medical specialties, placing them
in hospitals, community-based practices, and federal, state and local
facilities.
The IT
and Engineering segment, comprised of Oxford Global Resources, Inc., provides
high-end contract placement services of information technology and engineering
professionals with expertise in specialized information technology; software and
hardware engineering; and mechanical, electrical, validation and
telecommunications engineering fields.
The
Company’s management evaluates the performance of each segment primarily based
on revenues, gross profit and operating income. The information in the following
table is derived directly from the segments’ internal financial reporting used
for corporate management purposes.
All
revenues, gross profit and operating income disclosed in the tables below
include activity for the Physician and IT and Engineering segments from January
3, 2007 and January 31, 2007, respectively.
The following
table represents revenues, gross profit and operating income by reportable
segment (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
Revenues:
|
|
|
|
|
|
|
|
|
Life Sciences
|
|
$ |
129,483 |
|
|
$ |
134,622 |
|
|
$ |
117,462 |
Healthcare
|
|
|
180,671 |
|
|
|
175,079 |
|
|
|
170,104 |
Physician
|
|
|
89,217 |
|
|
|
74,599 |
|
|
|
— |
IT and Engineering
|
|
|
218,687 |
|
|
|
182,880 |
|
|
|
— |
Total Revenues
|
|
$ |
618,058 |
|
|
$ |
567,180 |
|
|
$ |
287,566 |
|
|
|
|
|
|
|
|
|
|
|
|
Gross
Profit:
|
|
|
|
|
|
|
|
|
|
|
|
Life Sciences
|
|
$ |
43,502 |
|
|
$ |
45,024 |
|
|
$ |
38,143 |
Healthcare
|
|
|
46,265 |
|
|
|
44,269 |
|
|
|
39,698 |
Physician
|
|
|
27,369 |
|
|
|
21,808 |
|
|
|
— |
IT and Engineering
|
|
|
82,320 |
|
|
|
68,436 |
|
|
|
— |
Total Gross
Profit
|
|
$ |
199,456 |
|
|
$ |
179,537 |
|
|
$ |
77,841 |
|
|
|
|
|
|
|
|
|
|
|
|
Operating
Income:
|
|
|
|
|
|
|
|
|
|
|
|
Life Sciences
|
|
$ |
13,048 |
|
|
$ |
14,731 |
|
|
$ |
5,206 |
Healthcare
|
|
|
6,285 |
|
|
|
3,099 |
|
|
|
4,735 |
Physician
|
|
|
5,869 |
|
|
|
1,447 |
|
|
|
— |
IT and Engineering
|
|
|
18,312 |
|
|
|
8,318 |
|
|
|
— |
Total Operating
Income
|
|
$ |
43,514 |
|
|
$ |
27,595 |
|
|
$ |
9,941 |
|
|
|
|
|
|
|
|
|
|
|
|
The
Company does not report Life Sciences and Healthcare segments’ total assets
separately as the operations are largely centralized. The following table
represents total assets as allocated by reportable segment (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Assets:
|
|
|
|
|
|
|
|
Life
Sciences and Healthcare
|
|
|
$ |
115,458 |
|
|
$ |
107,253 |
|
Physician
|
|
|
|
72,940 |
|
|
|
59,204 |
|
IT
and Engineering
|
|
|
|
213,452 |
|
|
|
218,223 |
|
Total Assets
|
|
|
$ |
401,850 |
|
|
$ |
384,680 |
|
|
|
|
|
|
|
|
|
|
|
|
The
Company does not report all assets by segment for all reportable segments. The
following table represents certain identifiable assets by reportable segment
that are regularly reviewed by management (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
Accounts Receivable:
|
|
|
|
|
|
|
|
Life
Sciences
|
|
|
$ |
15,418 |
|
|
$ |
18,380 |
|
Healthcare
|
|
|
|
25,108 |
|
|
|
22,440 |
|
Physician
|
|
|
|
14,978 |
|
|
|
12,427 |
|
IT
and Engineering
|
|
|
|
25,309 |
|
|
|
27,847 |
|
Total Gross Accounts
Receivable
|
|
|
$ |
80,813 |
|
|
$ |
81,094 |
|
|
|
|
|
|
|
|
|
|
|
|
The Company
operates internationally, with operations in the United States, Europe, Canada,
Australia and New Zealand. The following table represents revenues by geographic
location (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
Revenues:
|
|
|
|
|
|
|
|
|
Domestic
|
|
$ |
584,316 |
|
|
$ |
539,776 |
|
|
$ |
269,602 |
Foreign
|
|
|
33,742 |
|
|
|
27,404 |
|
|
|
17,964 |
Total Revenues
|
|
$ |
618,058 |
|
|
$ |
567,180 |
|
|
$ |
287,566 |
|
|
|
|
|
|
|
|
|
|
|
|
The
following table represents long-lived assets by geographic location (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
Long-Lived
Assets:
|
|
|
|
|
|
|
|
|
Domestic
|
|
$ |
22,300 |
|
|
$ |
19,479 |
|
|
$ |
11,964 |
Foreign
|
|
|
622 |
|
|
|
833 |
|
|
|
465 |
Total Long-Lived
Assets
|
|
$ |
22,922 |
|
|
$ |
20,312 |
|
|
$ |
12,429 |
|
|
|
|
|
|
|
|
|
|
|
|
12.
Fair Value of Financial Instruments.
The
Company adopted SFAS No. 157, “Fair Value Measurements,” (SFAS 157) on January
1, 2008 and there was no material impact to its consolidated financial
statements. SFAS 157 applies to all assets and liabilities that
are being measured and reported on a fair value basis. SFAS 157 requires a new
disclosure that establishes a framework for measuring fair value in accordance
with generally accepted accounting principles (GAAP), and expands disclosure
about fair value measurements. This statement enables the reader of the
financial statements to assess the inputs used to develop those measurements by
establishing a hierarchy for ranking the quality and reliability of the
information used to determine fair values. The statement requires that assets
and liabilities carried at fair value will be classified and disclosed in one of
the following three categories:
Level 1:
Quoted market prices in active markets for identical assets or
liabilities.
Level 2:
Observable market based inputs or unobservable inputs that are corroborated by
market data.
Level 3:
Unobservable inputs that are not corroborated by market data.
The fair
value of the interest rate swap (used for purposes other than trading) is the
estimated amount the Company would receive to terminate the swap agreements at
the reporting date, taking into account current interest rates and the
creditworthiness of the Company and the swap counterparty depending on whether
the swap is in an asset or liability position, referred to as a credit valuation
adjustment. The credit valuation adjustment at December 31, 2008 was
not significant. The Company’s fair value measurement as of December
31, 2008 using significant other observable inputs (Level 2) for the interest
rate swap was a $1.3 million liability. The Company’s derivative instrument is a
pay-fixed, receive-variable interest rate swap based on a LIBOR swap rate. The
LIBOR swap rate is observable at commonly quoted intervals for the full term of
the swap and therefore is considered a Level 2 item.
13.
Unaudited Quarterly Results.
|
|
The
following table presents unaudited quarterly financial information for each of
the four quarters ended December 31, 2008 and December 31, 2007. In
the opinion of the Company’s management, the quarterly information contains all
adjustments, consisting only of normal recurring accruals, necessary for a fair
presentation thereof. The operating results for any quarter are not necessarily
indicative of the results for any future period.
|
|
(in
thousands, except per share data)
Quarter
Ended
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
$ |
147,616 |
|
|
$ |
161,947 |
|
|
$ |
156,082 |
|
|
$ |
152,413 |
|
|
$ |
152,040 |
|
|
$ |
148,657 |
|
|
$ |
143,854 |
|
|
$ |
122,629 |
Cost of services
|
|
|
99,061 |
|
|
|
109,138 |
|
|
|
105,418 |
|
|
|
104,985 |
|
|
|
103,731 |
|
|
|
101,130 |
|
|
|
97,613 |
|
|
|
85,169 |
Gross
profit
|
|
|
48,555 |
|
|
|
52,809 |
|
|
|
50,664 |
|
|
|
47,428 |
|
|
|
48,309 |
|
|
|
47,527 |
|
|
|
46,241 |
|
|
|
37,460 |
Selling,
general and
administrative
expenses
|
|
|
38,229 |
|
|
|
39,190 |
|
|
|
38,826 |
|
|
|
39,697 |
|
|
|
40,363 |
|
|
|
38,326 |
|
|
|
38,992 |
|
|
|
34,261 |
Operating
income
|
|
|
10,326 |
|
|
|
13,619 |
|
|
|
11,838 |
|
|
|
7,731 |
|
|
|
7,946 |
|
|
|
9,201 |
|
|
|
7,249 |
|
|
|
3,199 |
Interest expense
|
|
|
(2,999 |
) |
|
|
(1,863 |
) |
|
|
(1,252 |
) |
|
|
(3,884 |
) |
|
|
(3,626 |
) |
|
|
(3,855 |
) |
|
|
(2,557 |
) |
|
|
(2,136) |
Interest income
|
|
|
126 |
|
|
|
158 |
|
|
|
158 |
|
|
|
273 |
|
|
|
412 |
|
|
|
344 |
|
|
|
220 |
|
|
|
418 |
Earnings
before income taxes
|
|
|
7,453 |
|
|
|
11,914 |
|
|
|
10,744 |
|
|
|
4,120 |
|
|
|
4,732 |
|
|
|
5,690 |
|
|
|
4,912 |
|
|
|
1,481 |
Provision for income
taxes
|
|
|
3,915 |
|
|
|
4,977 |
|
|
|
4,652 |
|
|
|
1,717 |
|
|
|
2,514 |
|
|
|
2,435 |
|
|
|
1,974 |
|
|
|
570 |
Net
income
|
|
$ |
3,538 |
|
|
$ |
6,937 |
|
|
$ |
6,092 |
|
|
$ |
2,403 |
|
|
$ |
2,218 |
|
|
$ |
3,255 |
|
|
$ |
2,938 |
|
|
$ |
911 |
Earnings
per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$ |
0.10 |
|
|
$ |
0.20 |
|
|
$ |
0.17 |
|
|
$ |
0.07 |
|
|
$ |
0.06 |
|
|
$ |
0.09 |
|
|
$ |
0.08 |
|
|
$ |
0.03 |
Diluted
|
|
$ |
0.10 |
|
|
$ |
0.19 |
|
|
$ |
0.17 |
|
|
$ |
0.07 |
|
|
$ |
0.06 |
|
|
$ |
0.09 |
|
|
$ |
0.08 |
|
|
$ |
0.03 |
Weighted
average number of shares outstanding
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
35,707 |
|
|
|
35,546 |
|
|
|
35,426 |
|
|
|
35,266 |
|
|
|
35,387 |
|
|
|
35,313 |
|
|
|
35,176 |
|
|
|
34,667 |
Dilutive
|
|
|
35,985 |
|
|
|
36,071 |
|
|
|
35,838 |
|
|
|
35,375 |
|
|
|
35,759 |
|
|
|
35,886 |
|
|
|
35,813 |
|
|
|
35,629 |
Item
9. Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure
|
|
Not
applicable.
|
Evaluation
of Disclosure Controls and
Procedures
|
As of the
end of the period covered by this report, the Company’s management carried out
an evaluation, under the supervision and with the participation of our Principal
Executive Officer and Principal Financial Officer, of the effectiveness of our
disclosure controls and procedures (as defined in Rule 13a-15(e) of the
Securities Exchange Act of 1934). Based on this evaluation, our Principal
Executive Officer and Principal Financial Officer have concluded that our
disclosure controls and procedures are effective as of the end of the period
covered by this report. The term “disclosure controls and procedures”
means controls and other procedures of the Company that are designed to ensure
that information required to be disclosed by the Company in the reports that it
files or submits under the Securities Exchange Act of 1934 is recorded,
processed, summarized and reported within the time periods specified in the
Securities and Exchange Commission’s rules and forms. “Disclosure
controls and procedures” include, without limitation, controls and procedures
designed to ensure that information required to be disclosed by the Company in
the reports that it files or submits under the Securities Exchange Act of 1934
is accumulated and communicated to the Company’s management, including its
principal executive and principal financial officers, or persons performing
similar functions, as appropriate to allow timely decisions regarding required
disclosure.
|
Management’s
Report on Internal Control Over Financial
Reporting
|
Management
is responsible for establishing and maintaining adequate internal control over
financial reporting (as defined in Rule 13a-15(f) of the Securities Exchange Act
of 1934) for the Company. The term “internal control over financial reporting”
is defined as a process designed by, or under the supervision of, the Company’s
principal executive and principal financial officers, or persons performing
similar functions, and effected by the Company’s board of directors, management
and other personnel, to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles and
includes those policies and procedures that:
·
|
Pertain
to the maintenance of records that, in reasonable detail, accurately and
fairly reflect the transactions and dispositions of the assets of the
Company;
|
·
|
Provide
reasonable assurance that the transactions are recorded as necessary to
permit preparation of financial statements in accordance with generally
accepted accounting principles, and that receipts and expenditures of the
Company are being made only in accordance with authorizations of
management and directors of the Company;
and
|
·
|
Provide
reasonable assurance regarding prevention of timely detection of
unauthorized acquisition, use, or disposition of the Company’s assets that
could have a material effect on the financial
statements.
|
Because
of its inherent limitations, internal control over financial reporting may not
prevent or detect misstatements. Also, projections of any evaluation of
effectiveness to future periods are subject to risk that controls may become
inadequate because of changes in conditions, or that the degree of compliance
with policies or procedures may deteriorate.
Management,
under the supervision and with the participation of our Principal Executive
Officer and Principal Financial Officer, assessed the effectiveness of the
Company’s internal control over financial reporting as of December 31,
2008. In making this assessment, management used the criteria set forth by the
Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated
Framework. Based on our assessment and those criteria, management
believes that the Company maintained effective internal control over financial
reporting as of December 31, 2008. Our independent registered public
accounting firm, Deloitte & Touche LLP, has included an attestation
report on our internal control over financial reporting, which is included
below.
Changes
in Internal Controls
There
were no changes in the Company’s internal control over financial reporting that
occurred during the Company’s fourth quarter that have materially affected, or
are reasonably likely to materially affect, the Company’s internal control over
financial reporting.
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the
Board of Directors and Stockholders of On Assignment, Inc.
Calabasas,
California
We have
audited the internal control over financial reporting of On Assignment, Inc. and
subsidiaries (the "Company") as of December 31, 2008, based on criteria
established in Internal
Control — Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission. The Company's management is
responsible for maintaining effective internal control over financial reporting
and for its assessment of the effectiveness of internal control over financial
reporting, included in the accompanying Management's Report on Internal Control
Over Financial Reporting. Our responsibility is to express an opinion on the
Company's internal control over financial reporting based on our
audit.
We
conducted our audit in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether effective
internal control over financial reporting was maintained in all material
respects. Our audit included obtaining an understanding of internal control over
financial reporting, assessing the risk that a material weakness exists, testing
and evaluating the design and operating effectiveness of internal control based
on the assessed risk, and performing such other procedures as we considered
necessary in the circumstances. We believe that our audit provides a reasonable
basis for our opinion.
A
company's internal control over financial reporting is a process designed by, or
under the supervision of, the company's principal executive and principal
financial officers, or persons performing similar functions, and effected by the
company's board of directors, management, and other personnel to provide
reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with
generally accepted accounting principles. A company's internal control over
financial reporting includes those policies and procedures that (1) pertain to
the maintenance of records that, in reasonable detail, accurately and fairly
reflect the transactions and dispositions of the assets of the company; (2)
provide reasonable assurance that transactions are recorded as necessary to
permit preparation of financial statements in accordance with generally accepted
accounting principles, and that receipts and expenditures of the company are
being made only in accordance with authorizations of management and directors of
the company; and (3) provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use, or disposition of the company's
assets that could have a material effect on the financial
statements.
Because
of the inherent limitations of internal control over financial reporting,
including the possibility of collusion or improper management override of
controls, material misstatements due to error or fraud may not be prevented or
detected on a timely basis. Also, projections of any evaluation of the
effectiveness of the internal control over financial reporting to future periods
are subject to the risk that the controls may become inadequate because of
changes in conditions, or that the degree of compliance with the policies or
procedures may deteriorate.
In our
opinion, the Company maintained, in all material respects, effective internal
control over financial reporting as of December 31, 2008, based on the criteria
established in Internal
Control — Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission.
We have
also audited, in accordance with the standards of the Public Company Accounting
Oversight Board (United States), the consolidated financial statements and
financial statement schedule as of and for the year ended December 31, 2008 of
the Company and our report dated March 16, 2009 expressed an unqualified opinion
on those financial statements and financial statement schedule.
/s/ Deloitte & Touche
LLP
Los
Angeles, California
March 16,
2009
Item
9B. Other Information
|
|
None.
Item 10. Directors and
Executive Officers of the Registrant
|
|
Information
responsive to this item will be set forth under the captions “Proposal One—Election of Directors,”
“Continuing Directors,” “Section 16(a) Beneficial Ownership Reporting
Compliance,” “Ethics” and “Board Committee Meetings” in the Company’s proxy
statement for use in connection with its 2009 Annual Meeting of Stockholders
(the “2009 Proxy Statement”) and is incorporated herein by reference. The 2009
Proxy Statement will be filed with the SEC within 120 days after the end of the
Company’s year. The information under the heading “Executive Officers of the
Registrant” in Item 1 of this Form 10-K is also incorporated by reference
in this section.
Item 11. Executive
Compensation
|
|
Information
responsive to this item will be set forth under the captions “Compensation
Discussion and Analysis,” “Summary of Executive Compensation,” “Summary of
Grants of Plan Based Awards,” “Employment Contracts and Change in Control
Arrangements” “Summary of Outstanding Equity Awards,” “Summary of Option
Exercises and Stock Vested,” “Deferred Compensation” and “Board Committees and
Meetings” in the 2009 Proxy Statement to be filed with the SEC within 120 days
after the end of the Company’s year and is incorporated herein by reference.
Item 12. Security Ownership of
Certain Beneficial Owners and Management and Related Stockholder
Matters
|
|
Information
responsive to this item will be set forth under the captions “Security Ownership
of Certain Beneficial Owners and Management” and “Equity Compensation Plan
Information” in the 2009 Proxy Statement to be filed with the SEC within 120
days after the end of the Company’s year and is incorporated herein by
reference.
Item 13. Certain Relationships
and Related Transactions
|
|
Information
responsive to this Item will be set forth under the caption “Certain
Relationships and Related Transactions” and “Independent Directors” in the 2009
Proxy Statement to be filed with the SEC within 120 days after the end of the
Company’s year and is incorporated herein by reference.
Item
14. Principal Accountant Fees and Services
|
|
Information
responsive to this Item will be set forth under the caption “Report of the Audit
Committee” and “Principal Accountant Fees and Services” in the 2009 Proxy
Statement, to be filed with the SEC within 120 days after the end of the
Company’s year and is incorporated herein by reference.
Item 15. Exhibits and Financial
Statement Schedule
|
|
(a)
List of documents filed as part of this report
1.
Financial Statements:
Report of
Independent Registered Public Accounting Firm
Consolidated
Balance Sheets at December 31, 2008 and 2007
Consolidated
Statements of Operations and Comprehensive Income (Loss) for the Years Ended
December 31, 2008, 2007 and 2006
Consolidated
Statements of Stockholders’ Equity for the Years Ended December 31, 2008,
2007 and 2006
Consolidated
Statements of Cash Flows for the Years Ended December 31, 2008, 2007 and
2006
Notes to
Consolidated Financial Statements
|
2. Financial Statement
Schedule:
|
Schedule
II—Valuation and Qualifying Accounts
Schedules
other than those referred to above have been omitted because they are not
applicable or not required under the instructions contained in Regulation S-X or
because the information is included elsewhere in the financial statements or
notes thereto.
(b)
Exhibits
See
Index to Exhibits.
Pursuant
to the requirements of the Section 13 or 15(d) of the Securities and
Exchange Act of 1934, the registrant has duly caused this to report to be signed
on its behalf by the undersigned, thereunto duly authorized, on this 16th day of
March 2009.
|
ON
ASSIGNMENT, INC.
|
|
|
|
Peter
T. Dameris
|
|
Chief
Executive Officer and President
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been
signed below by the following persons on behalf of the registrant and in the
capacities indicated and on the dates indicated.
|
|
|
|
|
|
|
Chief
Executive Officer, President and Director
|
|
March
16, 2009
|
Peter
T. Dameris
|
|
(Principal
Executive Officer)
|
|
|
|
|
Senior
Vice President, Finance and Chief Financial Officer
|
|
March
16, 2009
|
James
L. Brill
|
|
(Principal
Financial and Accounting Officer)
|
|
|
/s/
William E. Brock
|
|
Director
|
|
March
16, 2009
|
William
E. Brock
|
|
|
|
|
/s/
Jonathan S. Holman
|
|
Director
|
|
March
16, 2009
|
Jonathan
S. Holman
|
|
|
|
|
/s/
Edward L. Pierce
|
|
Director
|
|
March
16, 2009
|
Edward
L. Pierce
|
|
|
|
|
/s/
Jeremy M. Jones
|
|
Director
|
|
March
16, 2009
|
Jeremy
M. Jones
|
|
|
|
|
SCHEDULE
II—VALUATION AND QUALIFYING ACCOUNTS
Year
Ended December 31, 2008, 2007 and 2006
(In
thousands)
|
|
Balance
at beginning of year
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year
ended December 31, 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allowance
for doubtful accounts and billing adjustments
|
|
$ |
2,254 |
|
|
|
— |
|
|
|
641 |
|
|
|
(452 |
) |
|
$ |
2,443 |
Workers’
compensation and medical malpractice loss reserves
|
|
$ |
8,921 |
|
|
|
— |
|
|
|
5,384 |
|
|
|
(4,551 |
) |
|
$ |
9,754 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year
ended December 31, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allowance
for doubtful accounts and billing adjustments
|
|
$ |
1,380 |
|
|
|
805 |
|
|
|
680 |
|
|
|
(611 |
) |
|
$ |
2,254 |
Workers’
compensation and medical malpractice loss reserves
|
|
$ |
3,551 |
|
|
|
4,596 |
|
|
|
4,095 |
|
|
|
(3,321 |
) |
|
$ |
8,921 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year
ended December 31, 2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allowance
for doubtful accounts and billing adjustments
|
|
$ |
1,581 |
|
|
|
— |
|
|
|
60 |
|
|
|
(261 |
) |
|
$ |
1,380 |
Workers’
compensation loss reserves
|
|
$ |
3,488 |
|
|
|
— |
|
|
|
2,224 |
|
|
|
(2,161 |
) |
|
$ |
3,551 |
Income
tax valuation allowance
|
|
$ |
4,928 |
|
|
|
— |
|
|
|
— |
|
|
|
(4,928 |
) |
|
$ |
— |
INDEX
TO EXHIBITS
|
|
|
|
|
2.1
|
|
(14)
|
|
Agreement
and Plan of Merger, dated as of January 3, 2007, by and among On
Assignment, Inc., On Assignment 2007 Acquisition Corp. and Oxford Global
Resources, Inc. and Thomas F. Ryan, as Indemnification
Representative.
|
2.2
|
|
(15)
|
|
Stock
Purchase Agreement, dated as of December 20, 2006, by and among On
Assignment, Inc., VSS Holding, Inc., the stockholders of VSS Holding, Inc.
and the optionholders of VSS Holding, Inc.
|
3.1
|
|
(1)
|
|
Certificate
of Amendment of Restated Certificate of Incorporation of On Assignment,
Inc.
|
3.2
|
|
(2)
|
|
Restated
Certificate of Incorporation of On Assignment, Inc., as
amended.
|
3.3
|
|
(3)
|
|
Amended
and Restated Bylaws of On Assignment, Inc.
|
4.1
|
|
(4)
|
|
Specimen
Common Stock Certificate.
|
4.2
|
|
(9)
|
|
Rights
Agreement, dated June 4, 2003, between On Assignment, Inc. and U.S. Stock
Transfer Corporation as Rights Agent, which includes the Certificate of
Designation, Preferences and Rights of Series A Junior Participating
Preferred Stock as Exhibit A, the Summary of Rights to Purchase Series A
Junior Participating Preferred Stock as Exhibit B and the Form of Rights
Certificate as Exhibit C.
|
10.1
|
|
(13)
|
|
Form
of Indemnification Agreements.
†
|
10.2
|
|
(12)
|
|
Restated
1987 Stock Option Plan, as amended and restated April 7, 2006.
†
|
10.3
|
|
(13)
|
|
First
Amendment to Restated 1987 Stock Option Plan, dated January 23, 2007.
†
|
10.4
|
|
(12)
|
|
Second
Amendment to the Restated 1987 Stock Option Plan, dated April 17,
2007.
†
|
10.5
|
|
(18)
|
|
Third
Amendment to the Restated 1987 Stock Option Plan, dated December 11,
2008.
†
|
10.6
|
|
(12)
|
|
Employee
Stock Purchase Plan, as amended and restated June 18, 2002.
†
|
10.7
|
|
(12)
|
|
First
Amendment to the Employee Stock Purchase Plan, dated January 23,
2007.
†
|
10.8
|
|
(5)
|
|
Office
Lease, dated December 7, 1993, by and between On Assignment, Inc. and
Malibu Canyon Office Partners, LP.
|
10.9
|
|
(6)
|
|
Seventh
Amendment to Office Lease, dated August 20, 2002.
|
10.10*
|
|
|
|
Amended
and Restated Change in Control Severance Plan and Summary Plan
Description, dated December 11, 2008.
†
|
10.11
|
|
(8)
|
|
On
Assignment, Inc. Amended and Restated Deferred Compensation Plan,
effective February 1, 1999.
†
|
10.12
|
|
(16)
|
|
Amendment
No. 1 to the On Assignment, Inc. Amended and Restated Deferred
Compensation Plan, dated September 4, 2008. †
|
10.13
|
|
(8)
|
|
Master
Trust Agreement for On Assignment, Inc. Amended and Restated Deferred
Compensation Plan.
|
10.14
|
|
(16)
|
|
On
Assignment, Inc. Deferred Compensation Plan, effective January 1, 2008.
†
|
10.15
|
|
(17)
|
|
Separation
Agreement between On Assignment, Inc. and Shawn Mohr, dated January 14,
2008. †
|
10.16*
|
|
|
|
Amended
and Restated Senior Executive Agreement between On Assignment, Inc. and
Peter Dameris, dated December 11, 2008.
†
|
10.17*
|
|
|
|
Amended
and Restated Employment Agreement between Oxford Global Resources, Inc.,
On Assignment, Inc. and Michael J. McGowan dated December 30, 2008.
†
|
10.18*
|
|
|
|
Amended
and Restated Employment Agreement between On Assignment, Inc. and James
Brill, dated December 11, 2008.
†
|
10.19*
|
|
|
|
Amended
and Restated Employment Agreement between VISTA Staffing Solutions, Inc.,
On Assignment, Inc. and Mark S. Brouse, dated December 11, 2008.
†
|
|
|
|
|
10.20*
|
|
|
|
Amended
and Restated Senior Executive Agreement between On Assignment, Inc. and
Emmett McGrath, dated December 11, 2008.
†
|
|
|
|
|
10.21*
|
|
|
|
Amended
and Restated Executive Change in Control Agreement between On Assignment
and Peter T. Dameris, dated December 11, 2008.
†
|
|
|
|
|
10.22*
|
|
|
|
Amended
and Restated Executive Change in Control Agreement between On Assignment,
Inc. and James L. Brill, dated December 11, 2008.
†
|
|
|
|
|
10.23
|
|
(13)
|
|
Separation
Agreement between On Assignment, Inc. and Michael J. Holtzman, dated
December 8, 2006.
†
|
|
|
|
|
10.24
|
|
(7)
|
|
Form
of Option Agreements.
|
|
|
|
|
10.25
|
|
(10)
|
|
Executive
Incentive Compensation Plan.
†
|
|
|
|
|
10.26
|
|
(11)
|
|
Form
of Restricted Stock Unit Agreements.
|
|
|
|
|
10.27
|
|
(13)
|
|
Credit
Agreement among On Assignment, Inc., UBS Securities, LLC, UBS AG, Stamford
Branch, UBS Loan Finance, LLC and other parties thereto, dated January 31,
2007.
|
|
|
|
|
21.1*
|
|
|
|
Subsidiaries
of the Registrant.
|
|
|
|
|
23.1*
|
|
|
|
Consent
of Independent Registered Public Accounting Firm.
|
|
|
|
|
31.1*
|
|
|
|
Certification
of Peter T. Dameris, Chief Executive Officer and President pursuant to
Rule 13a-14(a) or 15d-14(a).
|
|
|
|
|
31.2*
|
|
|
|
Certification
of James L. Brill, Senior Vice President, Finance and Chief Financial
Officer pursuant to Rule 13a-14(a) or 15d-14(a).
|
|
|
|
|
32.1*
|
|
|
|
Certification
of Peter T. Dameris, Chief Executive Officer and President, and James L.
Brill, Senior Vice President, Finance and Chief Financial Officer pursuant
to 18 U.S.C. Section 1350.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
†
|
These
exhibits relate to management contracts or compensatory plans, contracts
or arrangements in which directors and/or executive officers of the
Registrant may participate.
|
(1)
|
Incorporated
by reference from an exhibit filed with our Current Report on Form 8-K
(File No. 0-20540) filed with the Securities and Exchange Commission on
October 5, 2000.
|
(2)
|
Incorporated
by reference from an exhibit filed with our Annual Report on Form 10-K
(File No. 0-20540) filed with the Securities and Exchange Commission on
March 30, 1993.
|
(3)
|
Incorporated
by reference from an exhibit filed with our Current Report on Form 8-K
(File No. 0-20540) filed with the Securities and Exchange Commission on
May 3, 2002.
|
(4)
|
Incorporated
by reference from an exhibit filed with our Registration Statement on Form
S-1 (File No. 33-50646) declared effective by the Securities and Exchange
Commission on September 21, 1992.
|
(5)
|
Incorporated
by reference from an exhibit filed with our Annual Report on Form 10-K
(File No. 0-20540) filed with the Securities and Exchange Commission on
March 24, 1994.
|
(6)
|
Incorporated
by reference from an exhibit filed with our Quarterly Report on Form 10-Q
(File No. 0-20540) filed with the Securities and Exchange Commission on
November 14, 2002.
|
(7)
|
Incorporated
by reference from an exhibit filed with our Annual Report on Form 10-K
(File No. 0-20540) filed with the Securities and Exchange Commission on
March 16, 2005.
|
(8)
|
Incorporated
by reference from an exhibit filed with our Quarterly Report on Form 10-Q
(File No. 0-20540) filed with the Securities and Exchange Commission on
May 15, 1998.
|
(9)
|
Incorporated
by reference from an exhibit filed with our Current Report on Form 8-K
(File No. 0-20540) filed with the Securities and Exchange Commission on
June 5, 2003.
|
(10)
|
Incorporated
by reference from an exhibit filed with our Current Report on Form 8-K
(File No. 0-20540) filed with the Securities and Exchange Commission on
April 1, 2005.
|
(11)
|
Incorporated
by reference from an exhibit filed with our Current Report on Form 8-K
(File No. 0-20540) filed with the Securities and Exchange Commission on
August 8, 2005.
|
(12)
|
Incorporated
by reference from an exhibit filed with our Registration Statement on Form
S−8 (File No. 333−143907) filed with the Securities and Exchange
Commission on June 20, 2007.
|
(13)
|
Incorporated
by reference from an exhibit filed with our Annual Report on Form 10-K
(File No. 0-20540) filed with the Securities and Exchange Commission on
March 16, 2007.
|
(14)
|
Incorporated
by reference from an exhibit filed with our Current Report on Form 8-K
(File No. 0-20540) filed with the Securities and Exchange Commission on
January 9, 2007.
|
(15)
|
Incorporated
by reference from an exhibit filed with our Current Report on Form 8-K
(File No. 0-20540) filed with the Securities and Exchange Commission on
December 22, 2006.
|
(16) |
Incorporated
by reference from an exhibit filed with our Current Report on Form 8-K
(File No. 0-20540) filed with the Securities and Exchange Commission on
September 9, 2008. |
|
|
(17)
|
Incorporated by reference from an exhibit filed
with our Quarterly Report on Form 10-Q (File No. 0-20540) filed with the
Securities and Exchange Commission on May 12, 2008.
|
(18)
|
Incorporated by reference from an exhibit filed
with our Current Report on Form 8-K (File No. 0-20540) filed with the
Securities and Exchange Commission on December 16, 2008.
|